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Drug discovery & development 
The quest for treatments against disease and for symptom 
relief goes back at least several millennia. Around 1700 BC, 
the Mesopotamians described the use of drugs for 
medicinal purposes in a series of 40 tablets collectively 
known as “Treatise of medical diagnosis and prognosis”1. It 
was not until the beginning of the twentieth century that 
Paul Ehrlich (1854-1915) hypothesized that chemicals can 
exert specific biological effects due to the existence of 
‘chemoreceptors’ on cells. With his notion that differential 
‘chemoreceptors’, e.g. in infectious organisms or cancer 
cells, could be exploited for therapeutic benefit and that the 
chemical structure of a compound is linked to its specific 
pharmacological activity, he unknowingly provided the 
foundation for modern drug discovery2. 
The drug discovery and development process covers all 
steps from the discovery of a therapeutically relevant 
biological target (Paul Ehrlich’s ‘chemoreceptors’) to the 
approval and launch of a drug (Figure 1). The drug discovery 
process generally starts with target discovery, which aims to 
identify biological targets in the pathology of interest that 
can be modified by chemical intervention. Once a target is 
validated (e.g. using genetically modified animal models), 











high-throughput screens of chemical libraries. After evaluation and limited optimization, 
hits can be identified as lead compounds, which show proof-of-principle in an animal 
model. Analogs with improved potency, reduced off-target activity and optimal 
physicochemical and metabolic properties are synthesized during lead optimization. The 
most promising compounds are assessed on pharmacodynamic, pharmacokinetic and 
toxicological properties. The main goal of the preclinical phase is to successfully 
demonstrate in vivo efficacy in a suitable animal model and to determine the safe dose 
for first-in-human studies. The investigational new drug then proceeds to the drug 
development stage, consisting of several clinical testing phases. During clinical phase I 
the dosage and safety is assessed in a small group of healthy volunteers. Phase II focuses 
on preliminary efficacy and side effects in a small patient group, whereas during phase 
III efficacy and adverse reactions are monitored in a large patient group. Roughly 10 
percent of the investigational new drugs passes all clinical tests and can be launched as 
novel drug application after their approval by regulatory bodies3–5. 
 
Figure 1 | The drug discovery and drug development process. Schematic representation of the stages in drug 
discovery and drug development, with their estimated duration and number of compounds/studies required 
for the development of a single approved drug (modified from literature 3–5).  
Drug discovery and development is a time- and resource-demanding process. On 
average, it takes more than 13 years to progress from hit to launch and the estimated 
costs currently exceed $ 2.5 billion5–7 for each new drug that enters the market. Despite 
technological advances, the introduction rate of new drugs is at a low, while 
development costs are rising substantially (mainly due to late-stage clinical failures 
caused by limited efficacy or unexpected toxicology)4,8,9. Although the target-based drug 
discovery process described above is effective in early stages of drug development, it 
often fails to predict pharmacological properties and clinical efficacy. The alternative 
phenotypic drug discovery approach is postulated to have more predictive power on 
pharmacological success in later stages10,11. In phenotypic screens compounds are 
directly screened in a relevant cellular or animal model for desirable phenotypic effects 
and responsible target(s) are identified in later stages of the drug discovery process12. In 
either drug discovery approach target identification is a crucial step, because the clinical 
success of a drug-candidate is highly dependent on understanding the relevance of its 
biological target(s) in the intended disease. The target identification process is 
challenging, but advancements are made due to continuous development of novel tools, 
methods and strategies, e.g. patient-derived induced pluripotent stem cells (iPSCs)13 and 
zebrafish14 as alternative models in phenotypic screening, single-cell analysis 
techniques15 like RNA-seq16, and computational approaches17. In the last decades, 
activity-based protein profiling (ABPP) has emerged as a powerful chemical biology 
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Activity-based protein profiling  
ABPP is a chemical proteomic method that uses active-site directed probes to assess the 
functional state of an entire enzyme class in complex biological samples18–20. These 
probes covalently interact with their target enzyme and report on the abundance of 
active protein, hence the term activity-based probe (ABP). An ABP typically consists of 
three main parts (Figure 2A): a reactive group or ‘warhead’ that covalently interacts with 
the enzyme’s active site, a chemical linker or spacer element, and a reporter tag that 
enables detection of the probe targets19. The reporter tag can be incorporated in the 
ABP itself (direct probes, Figure 2B) or can be introduced at a later stage by 
bio-orthogonal chemistry (two-step probe, Figure 2C). Copper(I)-catalyzed azide-alkyne 
cycloaddition (“click” chemistry) is one of the most common bio-orthogonal reactions 
to introduce a reporter group21. Although the workflow of direct probes is more 
efficient, a large reporter tag may alter the probe’s affinity and selectivity and may affect 
cell permeability22. 
 
Figure 2 | Activity-based protein profiling. (A) An activity-based probe consists of a reactive group coupled to a 
reporter tag (a fluorophore for gel-based analysis by SDS-PAGE or an affinity tag for purification and analysis by 
LC-MS) by a chemical linker element. (B, C) Schematic representation of (B) direct ABPP in which a complex 
proteome is incubated with a probe containing a reporter tag and (C) two-step ABPP which requires 
bio-orthogonal chemistry (“click” chemistry) to introduce a reporter tag to a two-step probe.  
Complex protein samples can be labeled with ABPs in different experimental 
settings, including in cell or tissue lysates (in vitro), live cells (in situ), and living organisms 
(in vivo)23. The readout of the experiment is generally dependent on the type of reporter 
tag that is used. Fluorescent reporter tags enable rapid analysis in a gel-based assay. The 
labeled proteome is separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). In-gel fluorescence scanning provides a rapid readout, but 
sensitivity is limited and target identification heavily relies on specific inhibitors. Affinity 
tags, like biotin, enable target enrichment e.g. by avidin chromatography (pull-down). 
After tryptic digestion of the enriched targets, the resulting peptides can be identified 
by liquid chromatography-mass spectrometry (LC-MS) (Figure 2B, C)19,24. This MS-based 
ABPP method (also called chemical proteomics) is much lower throughput, but the high 
sensitivity and high information content make the technique very attractive 
nonetheless. 


















Comparative and competitive ABPP  
Two types of experimental setups are commonly used in ABPP: comparative and 
competitive ABPP (Figure 3). The comparative ABPP approach enables comparison of 
the activity landscapes of two or more biologically distinct samples19,25, e.g. healthy 
versus diseased26,27 (Figure 3A). Altered enzyme activities can provide insight in (the 
regulation of) biological pathways and can serve as a starting point in target discovery. 
An important advantage of ABPP over gene expression studies, is that ABPP provides a 
direct readout of the enzymatic state of the protein and thus also accounts for the 
effects post-translational modifications. 
 
Figure 3 | Competitive and comparative ABPP. (A) In comparative ABPP two proteomes from different biological 
states, e.g. healthy versus diseased or different cell types, are compared by gel- or MS-based analysis of probe 
treated samples. (B) Competitive ABPP enables target-engagement assessment and off-target profiling. 
Inhibitor treatment can be done in vitro (cell or tissue lysate), in situ (live cells), or in vivo (living organisms), 
followed by in vitro probe incubation and gel- or MS-based analysis. 
Competitive ABPP, the second major application, is particularly suitable for inhibitor 
profiling (Figure 3B)19,23,24. It enables simultaneous assessment of inhibitor potency and 
selectivity and is a powerful tool for target engagement studies. In the drug discovery 
process, competitive ABPP can guide the lead identification, optimization, and the pre-
clinical testing phase. Prior to labeling with an ABP, the proteome is incubated in vitro, 
in situ, or in vivo with inhibitor. Targets are identified as those with reduced probe 
labeling after inhibitor pre-incubation. Target identification is restricted to the enzymes 
identified by the probe, therefore broad-spectrum ABPs are especially suitable for 
competitive ABPP. Alternatively, introduction of a ligation handle in the inhibitor 
enables identification of all covalent interaction partners with two-step ABPP 
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(Figure 2C). Since the ligation handle can affect potency and selectivity, it is important 
to cross-check with the original inhibitor28.  
Finally, ABPP can serve as a tool for the characterization of unannoted proteins. 
Interaction between an ABP and an uncharacterized protein can facilitate the 
assignment of the protein to a specific enzymatic class or family19.  
Activity-based probes 
A variety of enzyme classes can be targeted with ABPs19,24, including the serine 
hydrolases18,29, cysteine and threonine proteases30,31, kinases32, phosphatases, 
cytochrome P450s33, and glycosidases34,35. Photoaffinity probes provide an alternative 
labeling method for enzymes (e.g. metallohydrolases) or other druggable targets (e.g. 
receptors) that otherwise cannot interact covalently with a probe. The photoreactive 
group in these probes can form a covalent bond with the associated protein after 
UV- irradiation36. 
 
Figure 4 | Activity-based probes. Broad-spectrum serine-hydrolase probes fluorophosphonate (FP)-TAMRA, 
FP-BODIPY and FP-biotin. Tailored lipase probes MB064 and MB108, targeting e.g. DAGLα/β. Two-step DAGL-
probe DH376, containing an alkyne ligation handle, and its derived direct probe DH379. Reactive-lysine 
targeting kinase probe XO44. 
The work in this thesis focuses on activity-profiling of the serine hydrolases, which 
represent ~ 1 % of all proteins in mammals. The serine hydrolases are characterized by 
a well conserved GXSXG amino acid motif and are involved in a broad spectrum of 
physiological and pathological processes37,38. The active-site serine can interact 
covalently with fluorophosphonate (FP)-based probes, such as FP-rhodamine 
(FP-TAMRA)18 and FP-BODIPY22, which are especially suitable for broad-spectrum 










probes like DH376 and DH37941 enable assessment of specific hydrolases such as the 
diacylglycerol lipases (Figure 4) (see The endocannabinoid system).  
In addition, the kinase-targeting probe XO44 is used (Figure 4)32. The kinases, a large 
protein family comprising over 500 members, are known for their pivotal roles in cell 
signaling processes, differentiation, proliferation, and disease42,43. A conserved lysine in 
the kinase active-site offers a reactive group for XO4432. Of note, in contrast to the serine 
hydrolase probes, XO44 labels available kinase active-sites dependent on their affinity, 
but not necessarily on their active state. 
The endocannabinoid system 
The endocannabinoid system (ECS, Figure 5) plays a central role in the work described 
in this thesis. The ECS mediates the physiological effects of Δ9-tetrahydrocannabinol 
(THC), the psychoactive compound in Cannabis sativa, to which the ECS owes its 
name44,45. The ECS is comprised of the cannabinoid receptors type 1 and 2 (CB1R, CB2R), 
their endogenous ligands, also known as the endocannabinoids, and the enzymes for 
ligand biosynthesis and degradation. CB1R and CB2R are G protein-coupled receptors 
and are activated by the endocannabinoids, as well as by plant-derived cannabinoids 
(phytocannabinoids) like THC46. The CB1R is most abundant in the central nervous 
system47, while CB2R is mainly expressed in cells of the immune system48. The ECS 
mediates numerous physiological processes, including appetite and metabolism, 
learning and memory, pain sensation and anxiety, and inflammation45,49–51.  
 
Figure 5 | The endocannabinoid system. The endocannabinoid system is involved in multiple physiological 
processes and is comprised of the cannabinoid receptors 1 and 2 (CB1R, CB2R), their endogenous ligands 
(endocannabinoids) and their metabolic enzymes. Ligands & metabolites (grey): DAG: diacylglycerol, 2-AG: 
2-arachidonoylglycerol, AA: arachidonic acid, THC: Δ9-tetrahydrocannabinol, AEA: anandamide, NAPE: 
N-acylphosphatidylethanolamine. Endocannabinoid metabolic enzymes (blue): DAGLα/β: diacylglycerol lipase 
α and β. MGLL: monoacylglycerol lipase. ABHD4/6/12: α,β-hydrolase domain containing proteins 4, 6 and 12. 
FAAH: fatty acid amide hydrolase. NAPE-PLD: N-acylphosphatidylethanolamine phospholipase D, PLA2: 
phospholipase A2, GDE1/4: glycerophosphodiesterase 1 and 4, Lyso-PLD: unidentified lysophospolipase D, PLC: 
unidentified phospholipase C, PTPN22: tyrosine-protein phosphatase non-receptor type 22, SHIP1: 
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In the early 90s N-arachidonoylethanolamide (anandamide, AEA) was identified as 
the first endocannabinoid52. In the following years, 2-arachidonoylglycerol (2-AG)53,54 as 
well as several other endocannabinoids were identified. However, AEA and 2-AG are 
considered to be the two main endocannabinoids45. In the brain the endocannabinoids 
are synthesized on-demand at the membrane, in contrast to classical neurotransmitters 
which are stored in presynaptic vesicles. The endocannabinoids activate the presynaptic 
CB1R in a retrograde fashion and signaling is terminated by their hydrolysis. This 
mechanism implies that endocannabinoid levels at the synapse must be tightly 
controlled by their metabolic enzymes46.  
Several metabolic pathways control the endocannabinoid levels (Figure 5). 
Diacylglycerol lipase α and β (DAGLα, DAGLβ) are the two main enzymes producing 
2-AG, by catalyzing the hydrolysis of diacylglycerol (DAG) to 2-AG 55. The majority of 2-AG 
is hydrolyzed to arachidonic acid (AA) by monoacylglycerol lipase (MGLL)56,57, but 
α,β-hydrolase domain containing proteins 6 and 12 (ABHD6, ABHD12) can also catalyze 
this reaction57–59. The biosynthesis of AEA is less straightforward, due to the existence 
of multiple N-acylethanolamine (NAE) biosynthetic pathways. Direct hydrolysis of 
N-acylphospatidylethanolamines (NAPEs) to NAEs (including AEA) by NAPE 
phospholipase D (NAPE-PLD) is considered to be the canonical pathway60. The NAEs are 
hydrolyzed to ethanolamine and free fatty acid by fatty acid amide hydrolase (FAAH)61,62. 
Of note, three alternative multistep pathways exist for the biosynthesis of AEA from 
NAPEs: (I) phospholipase A2 (PLA2) and ABHD4 mediated conversion of NAPE to 
lyso-NAPE, followed by conversion to AEA by an unknown lysophopholipase D 
(Lyso-PLD); (II) conversion of lyso-NAPE to glycerophospho-AEA by ABHD4 and 
subsequent hydrolysis to AEA by glycerophosphodiseterase 1 or 4 (GDE1, GDE4); or (III) 
conversion of NAPE to phospho-AEA by an unidentified phospholipase C and cleavage 
to AEA by tyrosine-protein phosphatase non-receptor type 22 (PTPN22) or 
phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 (SHIP1)60. 
The ECS as a therapeutic target 
The role of the ECS in various pathological conditions, including neurological63 and 
cardiovascular64 disorders, makes it a promising target for therapeutic 
intervention51,65,66. At the same time, its involvement in multiple physiological processes 
makes drug discovery challenging and requires accurate balancing of activation and 
inhibition to achieve only the desired effects. Several synthetic CB1R and CB2R ligands 
have been developed, but thus far their clinical success was limited. Rimonabant, a CB1R 
antagonist, was an efficacious anorectic drug for the treatment of obesity, but two years 
after its launch in 2006 it was withdrawn from the market due to severe psychiatric side 
effects67,68. Several CB2R agonists were effective in the treatment of (inflammatory) pain 
in preclinical animal models, but their development has been discontinued due to a lack 





Regulating endogenous ligand levels may provide a more controlled modulation of 
cannabinoid receptor signaling than direct modulation by synthetic ligands. Therefore, 
targeting the endocannabinoid metabolic enzymes is a promising avenue for the 
development of ECS-directed therapeutics. Recently, positive results have been 
obtained in a phase Ib clinical trial using selective MGLL inhibitor ABX-1431 for the 
treatment of Tourette syndrome70–72. ABPP played a central part in the development of 
ABX-1431. This technique had previously been used for selectivity profiling of 
PF04457845, a FAAH inhibitor73. Although PF04457845 was effective in increasing 
plasma levels of NAEs in a first-in-human study74, the drug exerted no analgesic effects 
in clinical trials75. Several clinical trials for other indications are, however, still on-going76. 
BIA 10-2474, another FAAH inhibitor, produced mild-to-severe neurological symptoms 
and resulted in the death of a healthy volunteer in a recent phase I clinical trial77,78. Given 
the clinical safety profile of PF04457845, off-target activities of BIA 10-2474 are likely to 
have contributed to its clinical neurotoxicity. Competitive ABPP may provide insight in 
the BIA 10-2474 interaction profile.  
A better understanding of the ECS in (patho)physiological processes will provide 
insight in how to regulate cannabinoid receptor signaling and will guide its therapeutic 
exploitation. Most endocannabinoid metabolic enzymes (including DAGLα, DAGLβ, 
MGLL, FAAH, ABHD4, ABHD6, ABHD12) belong to the serine hydrolases family and can 
thus be studied by ABPP using the probes described in Figure 4. ABPP is anticipated to 
provide new insights in the regulation of the ECS by mapping the endocannabinoid 
metabolic enzymes in biological processes and facilitate ECS-related drug discovery.  
Aim and outline 
The aim of the research described in this thesis is to explore activity-based protein 
profiling (ABPP) as a versatile tool in drug discovery and cell biology.  
Chapter 2 describes comparative ABPP as a tool for mapping the serine hydrolase 
activity profile in clinical samples from patients with terminal-stage heart failure (due to 
previous ischemic pathology). In Chapter 3, the comparative ABPP is method optimized 
for broad-spectrum profiling of serine hydrolases and kinases in zebrafish larvae during 
early zebrafish development. In addition, this chapter reports the use of zebrafish larvae 
as a pre-clinical animal model for in vivo target engagement and selectivity screening 
using FAAH inhibitor PF04457845 in a competitive ABPP setup. In Chapter 4, competitive 
ABPP is employed to investigate the in vitro and in situ interaction landscape of 
BIA 10-2474, the FAAH inhibitor that caused severe neurological adverse effects in a 
recent clinical trial77,78. In Chapter 5, the enzymes involved in 2-AG biosynthesis during 
neuronal differentiation are identified using retinoic acid (RA)-induced differentiation of 
Neuro-2a cells as a model system. A combined strategy of ABPP, CRISPR/Cas9 gene 
editing, biochemistry and lipidomics identifies ABHD6 as a 2-AG biosynthetic 
diacylglycerol lipase. Chapter 6 summarizes the work described in this thesis and 
discusses the future perspective for ABPP in drug discovery and cellular biology.  
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profiling of the human 
ischemic heart 
ABSTRACT | Acute myocardial infarction and subsequent 
post-infarction heart failure are among the leading causes 
of mortality worldwide. Recently, the endocannabinoid 
system (ECS) has emerged as a critical modulator of 
cardiovascular disease, but the role of endocannabinoid 
metabolic enzymes had not been investigated thus far. 
Here, targeted lipidomics and activity-based protein 
profiling (ABPP) enabled investigation of the 
endocannabinoids and their metabolic enzymes in 
ischemic end-stage failing human hearts and non-failing 
controls. Based on lipidomics analysis, two subgroups 
were identified within the ischemic group; the first similar 
to control hearts and the second with decreased levels of 
the endocannabinoid 2-arachidonoyl-glycerol (2-AG) and 
drastically increased levels of the endocannabinoid 
anandamide (AEA), other N-acylethanolamines (NAEs) 
and free fatty acids. The altered lipid profile was 
accompanied by strong reductions in the activity of 13 
hydrolases, including the 2-AG hydrolytic enzyme 
monoacylglycerol lipase (MGLL). These data suggest the 
presence of different biological states within the ischemic 
group, despite the lack of a clinical characteristic clearly 
distinguishing the patients. In addition, this study 
demonstrates ABPP as a tool to rapidly analyze enzyme 
activity in clinical samples, which may be valuable for 






Ischemic heart disease, involving acute myocardial infarction and subsequent heart 
failure development, was responsible for 12.7% of the total global mortality (2008), 
thereby making it the leading cause of mortality worldwide1. Recently, the 
endocannabinoid system (ECS) has emerged as a modulator of the cardiovascular 
system, especially under diseased conditions2–4. The ECS is comprised of the cannabinoid 
receptor type 1 and 2 (CB1R, CB2R), their endogenous ligands, the endocannabinoids 
2-arachidonoylglycerol (2-AG) and anandamide (AEA), and their metabolic enzymes 
(Figure 1)5. Diacylglycerol lipase α and β (DAGLα, DAGLβ) are the two main 2-AG 
biosynthetic enzymes6. The majority of 2-AG is hydrolyzed to arachidonic acid (AA) by 
monoacylglycerol lipase (MGLL)7,8, but α,β-hydrolase domain containing proteins 6 and 
12 (ABHD6, ABHD12) hydrolyze 2-AG as well8–10. The existence of multiple 
N-acylethanolamine (NAE) metabolic pathways makes AEA biosynthesis more complex. 
Direct hydrolysis of N-acylphospatidylethanolamines (NAPEs) to NAEs by NAPE 
phosholipase D (NAPE-PLD), is considered the canonical pathway11, but alternative 
multi-step pathways exist as well11. The NAEs are hydrolyzed to ethanolamines and free 
fatty acids by fatty acid amide hydrolase (FAAH)12,13. Of note, several other NAE species 
have been reported as bioactive lipids, suggesting an important modulatory role for this 
lipid class. For example, oleoylethanolamide (OEA) and stearoylethanolamide (SEA) 
have anorexic effects in the periphery14,15 and palmitoylethanolamide (PEA) was 
reported to enhance antinociception16,17. 
 
Figure 1 | The endocanabinoid system. The endocannabinoid system comprises of cannabinoid receptors type 
1 and 2 (CB1R, CB2R), their endogenous ligands 2-arachidonoylglycerol (2-AG) and anandamide (AEA) and their 
metabolic enzymes: diacylglycerol lipase α and β (DAGLα, DAGLβ), monoacylglycerol lipase (MGLL), 
α,β-hydrolase domain containing proteins 6 and 12 (ABHD6, ABHD12), N-acylphosphatidylethanolamine 
phospholipase D (NAPE-PLD), and fatty acid amide hydrolase (FAAH). Alternative multi-step pathways for AEA 
biosynthesis are not shown. 
The ECS regulates a broad spectrum of physiological and pathological processes, 
including energy balance, obesity, pain, inflammation, neurological and immunological 
disorders18–20. In the cardiovascular system, the endocannabinoids are implicated in 
various contexts in receptor dependent and independent cardiac and vascular effects, 
including vasodilation and vasoconstriction, cardiac protection against atherogenic 
inflammation, depression of cardiac function, and cell death of cardiomyocytes and 
endothelial cells3,21–23. In vivo cardiovascular effects of the endocannabinoids may be 
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effects on the myocardium and vasculature24,25. The two cannabinoid receptors have 
been shown to have opposing effects, e.g. CB1R facilitates the development of 
cardiometabolic disease and cardiac dysfunction3,26, whereas CB2R mainly exerts anti-
inflammatory effects3,27,28.  
CB1R-mediated endocannabinoid signaling has been implicated in the pathogenesis 
of shock, atherosclerosis, and numerous forms of cardiomyopathies (ischemic, diabetic, 
doxorubicin-induced)3,20. The beneficial in vivo effects of CB2R agonists in rodent models 
of myocardial infarction have primarily been attributed to limiting inflammatory cell 
infiltration27. FAAH knockout mice, having a threefold increase in myocardial AEA, 
displayed increased mortality, myocardial injury and neutrophil infiltration in 
experimental models of cardiomyopathy in a CB1R-dependent manner29 and FAAH 
deficiency also enhanced intra-plaque neutrophil recruitment in atherosclerotic mice30. 
In obese humans, increased plasma levels of AEA and 2‐AG strongly correlated with 
impaired coronary endothelial function and adverse cardiovascular events31,32. In 
epicardial fat from ischemic human hearts, CB1R was upregulated, accompanied by 
down‐regulation of CB2R and FAAH33. Similar upregulation of CB1R was observed in 
atherosclerotic coronary artery sections from patients with unstable angina and in obese 
human subjects34. In the Chinese Han population, a G1359A polymorphism in the CB1R 
gene was also linked to coronary artery disease35. These findings strongly suggest that 
the primary cardiovascular effects of endocannabinoids are deleterious and 
CB1R-mediated. Nonetheless, endocannabinoids have also been shown to exert 
protective effects in the heart via CB1R/CB2R-independent mechanisms, mostly based 
on ex vivo and indirect studies27. 
Despite extensive investigation on the endocannabinoids and their receptors in 
cardiac (dys)function, only little is known about the endocannabinoid metabolic 
enzymes. Most endocannabinoid metabolic enzymes, with the exception of NAPE-PLD, 
belong to the serine hydrolase family. This protein class can be targeted by 
activity-based probes covalently interacting with their catalytic serine residue. 
Activity-based probes are used in chemical proteomics to  assess the functional state of 
an entire enzyme classes in complex biological samples36–38.  In this study, the 
endocannabinoid metabolic enzymes were evaluated in ischemic end-stage failing 





Results & Discussion 
To investigate the involvement of the ECS in cardiac ischemia, tissue from the left 
ventricle was obtained from patients with terminal-stage heart failure (due to previous 
ischemic pathology) indicated for heart transplantation, as well as from non-failing 
control hearts (n=6, Table 1). The expression levels of ECS-related proteins in control 
and ischemic failing hearts were determined by quantitative real-time polymerase chain 
reaction (qRT-PCR) (Figure 2). CB1R (CNR1) expression strongly increased in half of the 
ischemic samples, however the overall increase was not significant (p=0.08). Reduced 
expression of the 2-AG biosynthetic enzyme DAGLβ and the 2-AG hydrolytic enzymes 
MGLL and ABHD6 was observed in the ischemic tissue. The AEA metabolic enzymes were 
not significantly altered, nor was CB2R (CNR2) expression. 
 
Figure 2 | Quantitative PCR on ECS-related genes in cardiac ischemia. mRNA levels of endocannabinoid related 
genes were normalized to house-keeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT) 
expression and expressed relative to control (mean ± SEM, two-tailed t-test: ** p < 0.01). 
In light of the altered mRNA expression of ECS-related enzymes, the 
endocannabinoid levels in control and ischemic failing cardiac tissues were compared. 
Lipids were extracted from a second set of cardiac tissues (n=9, Table 1) and were 
analyzed by liquid chromatography coupled to mass spectrometry (LC-MS) (Figure 3, 
Supplementary Figure S1A). NAEs, free fatty acids (FFA) and cortisol (COR) were included 
in the assay. The NAEs and their related FFA levels had strongly increased in the ischemic 
failing tissues (Figure 3, Supplementary Figure S1B). However, based on their lipid 
profile, the ischemic samples could be categorized into two separate subgroups. The 
first (Ischemic 1: I1-I3, I8-I9) had a lipid profile similar to control for most lipids including 
the endocannabinoids. Only several lipids were increased, including N-docosahexa-
enoylethanolamide (DHEA), eicosapentaenoyl-ethanolamide (EPEA), α- and γ- linoleic 
acid (α-LA and γ-LA) (maximum fold-change: 2.8). In contrast, all NAE and FFA levels 
were increased with a fold change ranging from 4 to 120 in the second subgroup 
(Ischemic 2: I4-I7) as compared to controls. In addition, the endocannabinoid AEA was 
increased by a 31 ± 13-fold, while 2-AG was significantly reduced by a 5-fold in this 
subgroup.  
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Table 1 | Clinical characteristics of study populations. Values are given as mean ± SEM. Set A: Figure 2. Set B: 
Figures 3-5. NYHA: New York Heart Association (3.5 is included in class IV), LVED: left ventricular end-diastolic 
diameter, LVSD: left ventricular end-systolic diameter, PW: posterior wall-thickness, IVS: interventricular 
septum thickness; SVR: systemic vascular resistance, CO: cardiac output, BMI: body mass index, n.a.: not 

















Samples (n) 6 6 9 9 5 4 
Gender (female/male) 1 / 5 1 / 5 2 / 7 9 5 4 
Age (year) 34.7 ± 4.5 56.2 ± 4.1 37.8 ± 3.8 58.0 ± 2.7 60.4 ± 2.5 55.0 ± 5.5  
BMI (kg/m2) 26.0 ± 5.0 26.1 ± 2.3 25.2 ± 1.3 26.6 ± 1.1 28.7 ± 1.2 24.0 ± 1.0 * 
NYHA functional  
class I/II/III/IV (n) 
n.a. 0/1/2/3 n.a. 0/1/5/3 0/1/2/2 0/0/3/1 
CO (L/min) n.a. 3.9 ± 0.6 n.a. 4.0 ± 0.21 4.5 ± 0.1 3.4 ± 0.2 *** 
LVED (mm) n.a. 69.2 ± 2.5 n.a. 75.0 ± 3.2 70.2 ± 3.6 81.0 ± 4.4 
LVSD (mm) n.a. 63.0 ± 3.2 n.a. 67.8 ± 4.5 62.3 ± 6.7 73.3 ± 5.5 
PW (mm) n.a. 9.1 ± 0.7 n.a. 8.4 ± 0.8 9.8 ± 1.0 6.7 ± 0.5 * 
IVS (mm) n.a. 8.4 ± 1.1 n.a. 9.5 ± 0.7 10.2 ± 1.2 8.7 ± 0.6 
SVR (mmHg·min/L) n.a. 18.3 ± 1.8 n.a. 19.0 ± 2.2 15.1 ± 2.5 23.8 ± 2.2 * 
Increased AEA levels have been reported in the past e.g. due to various forms of 
ischemia/reperfusion (I/R) (e.g. hepatic, brain). In the liver, I/R increased 2-AG and AEA 
levels positively correlated with tissue damage markers such as tumor necrosis factor α 
(TNF-α), but inflammatory stimuli per se only increased AEA levels39. NAE levels have 
also been shown to drastically increase post-mortem40 and in infarcted myocardium41-44, 
thus suggesting the observed effects may be related to the extent of tissue injury. Of 
note, there were no obvious differences in clinical characteristics (gender, age, co-
morbidity, recent ischemic events, etc.) between the two ischemic subgroups. 
Nonetheless, cardiac function in the second subgroup was more severely affected based 
on significantly decreased cardiac output (CO) and increased systemic vascular 
resistance (SVR) (Table 2). In addition, the body mass index (BMI) of the second 
subgroup was significantly lower than that of the first subgroup; however, it was not 
significantly different from controls. 
Next, the activity of the ECS metabolic enzymes was investigated by activity-based 
protein profiling (ABPP). The tissue was lysed by dounce homogenization and clear 
lysates were labeled with fluorescent activity-based probes (Figure 4), which enabled 
visualization of probe targets by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and in-gel fluorescence scanning. FP-TAMRA, a broad 
spectrum serine hydrolase probe fluorophosphonate-rhodamine (FP-TAMRA), labels 
ABHD6, MGLL, and FAAH amongst many other hydrolases36,38. The tailored lipase probe 
MB064 preferentially reacts with the DAGLα, DAGLβ, ABHD6, and ABHD1237,45. Probes 







Figure 3 | Ischemic heart tissues can be categorized into subgroups based on divergent lipid profiles. Heatmap 
summary of lipid analysis of healthy (control) and ischemic cardiac tissue. Lipid levels were normalized to tissue 
weight and are expressed as mean response ratio of controls (grayscale, log10) or relative to mean control (red-
blue scale, log10 ratio). Detailed lipid characteristics in Table 3.  
In total, more than 20 hydrolases were labeled, including MGLL (33 and 35 kDa) 
(Figure 4). The overall hydrolase activity in ischemic samples I4-I7 (*, subgroup 2 based 
on lipid profile) was reduced as compared to the remaining ischemic samples and 
controls for which only limited deviations in labeling were observed. In addition, MGLL 
activity and expression were nearly abolished in I4-7 (Figure 4B, D, F). However, there 
were no obvious differences in the overall protein staining (Figure 4E) and general post-
mortem degradation by autolysis thus appears unlikely. Interestingly, an additional band 
was observed in the activity profile of samples I4-I7 (Figure 4B, indicated with #). Of 
note, the other ECS metabolic hydrolases, including DAGLα (~120 kDa), DAGLβ (~70 
kDa), ABHD6 (~35 kDa), and FAAH (~60 kDa) were not detected (Figure 4A, C), even 
though ABHD6 activity was detected in murine myocardium in the past47. 









































































































Figure 4 | Activity-based protein profiling of healthy and ischemic human hearts. (A-D) Gel-based ABPP analysis 
of healthy (control) and ischemic cardiac tissue. Whole lysates were labeled with activity-based probes (20 min, 
rt), resolved by SDS-PAGE and in-gel fluorescence was detected. Coomassie served as a protein loading control. 
(A) β-lactone probe MB064 (2 µM). (B) Broad-spectrum hydrolase probe FP-TAMRA (500 nM). (C) DAGL-probe 
DH379 (1 µM). (D) MAGL-probe DH459 (1 µM). (E) Coomassie staining. (F) Western-blot using anti-MGLL (1:200, 
O/N, 4 °C) verified MGLL expression. * Denotes samples with overall reduced serine hydrolase labeling. 
The biotinylated counterparts of FP-TAMRA and MB064, FP-biotin and MB108 
respectively, were then used for target identification by mass spectrometry-based 
chemical proteomics (Figure 5). In total, 31 hydrolases were identified, including MGLL 
as the only ECS-related hydrolase (Figure 5A, Supplementary Table S1). A slight, but 
non-significant, upregulation of CES1, NCEH1, and DPP4 was observed in the ischemic 
group, as well as downregulation of several hydrolases, including MGLL (Figure 5B). 
Strikingly, separation of the ischemic samples into two subgroups (based on lipid profile, 
Figure 3) revealed that 13 hydrolase activities, including MGLL, were drastically and 
significantly reduced in the subgroup with an altered lipid profile (Ischemic 2, Figure 5C). 
Hydrolase activities from the first subgroup, however, were not significantly altered. 
Notably, not all hydrolase activities were affected in the second subgroup and the extent 
of activity reduction is different between the altered hydrolases. This reinforces the 
hypothesis that the observed alterations in these samples are indeed not artefacts 
resulting from a general process such as post-mortem autolysis. 
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Sample C1 I1 C2 I2 C3 I3 C4 I4 C5 I5 C6 I6 C7 I7 C8 I8 C9 I9
Ischemic - + - + - + - + - + - + - + - + - +
DH463 (1 µM)
Sample C1 I1 C2 I2 C3 I3 C4 I4 C5 I5 C6 I6 C7 I7 C8 I8 C9 I9
Ischemic - + - + - + - + - + - + - + - + - +
DH379 (1 µM)
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Sample C1 I1 C2 I2 C3 I3 C4 I4 C5 I5 C6 I6 C7 I7 C8 I8 C9 I9
Ischemic - + - + - + - + - + - + - + - + - +
Blot anti-MAGL
Sample C1 I1 C2 I2 C3 I3 C4 I4 C5 I5 C6 I6 C7 I7 C8 I8 C9 I9
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Figure 5 | Activity-based proteomics on healthy and ischemic heart tissues. (A-C) Lysates from healthy (control) 
and ischemic cardiac tissues were labeled with MB108 and FP-biotin (10 µM each, 30 min, 37 °C) and analyzed 
by mass-spectrometry. A pre-boiled sample (10% SDS, 100 °C, 5 min) served as negative control. (A) Heatmap 
summary of mean abundance of hydrolases from control tissues. (B) Hydrolase activity relative to mean control. 
Data is expressed as mean ± SEM (n=9), t-test with Benjamini-Hochberg correction: * q < 0.05. (C) Hydrolase 
activity relative to mean control, ischemic samples categorized in subgroups. Data is expressed as mean ± SEM 
(control n=9, ischemic 1 n=5, ischemic 2 n=4), t-test with Benjamini-Hochberg correction. Control versus 
ischemic 1: not significant; control versus ischemic 2: # q < 0.05, ## q < 0.01. 
Taken together, lipidomics and ABPP enabled the identification of a subgroup within 
the ischemic sample set, which showed drastic increases in NAE and FFA levels, whereas 
many hydrolase activities had decreased. Aside from MGLL, no endocannabinoid 
metabolic enzymes were detected, possibly due to instability or inactivity as a result of 
tissue preparation. Despite accurate sample handling, differences in the sample 
collection procedure cannot be excluded as a potential cause for the observed 
subgroups. In addition, therapeutic interventions or unknown clinical factors may 
separate the ischemic tissues from one another. Nonetheless these data demonstrated 
that ABPP can be used for the rapid analysis of serine hydrolases in clinical samples. In 
the future, this technique may aid in the discovery of drug targets or biomarkers. 
Conclusion 
In summary, an MS-based approach was used to investigate the endocannabinoids and 
their metabolic enzymes in cardiac ischemia using ischemic end-stage failing hearts and 
non-failing controls. Targeted lipidomics analysis revealed the existence of two 
subgroups within the ischemic samples; the first largely similar to controls and the 
second with decreased 2-AG and increased AEA, NAE and FFA levels. The altered lipid 
profile was accompanied by a strong reduction in the activity of multiple hydrolases, 
including the 2-AG hydrolytic enzyme MGLL. These data suggested the presence of 
different biological states within the ischemic group, possibly the extent of tissue injury, 
despite the lack of a clinical characteristic separating the patients other than cardiac 
damage. In addition, this study demonstrated ABPP as a tool to rapidly assess clinical 
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Materials and probes 
Activity-based fluorophosphonate-based probes FP-TAMRA and FP-biotin were purchased from 
ThermoFisher and Santa Cruz biotechnology respectively. MB064 and MB108 were synthesized 
in-house as previously described45. All synthesized compounds were at least 95% pure and were 
analyzed by LC-MS, NMR and HRMS. Other chemicals, reagents, and primers were purchased from 
Sigma Aldrich unless indicated otherwise. 
Ethical statement 
All experimental procedures were done in accordance with the ethical standards of the 
responsible institutional and national committee on human experimentation, adhering to the 
Helsinki Declaration (1975). Written informed consent was obtained from all patients involved in 
the study according to the protocol approved by the Local Ethics Committees of the Institute of 
Cardiology, Warszawa, Poland (IK-NP-0021-24/1426/14).  
Sample collection and preparation 
Healthy (control) human hearts were obtained from organ donor patients (n=6/9) whose hearts 
were not used for transplantation due to technical reasons (e.g. donor/recipient incompatibility). 
The donors did not have any relevant previous cardiological history or any abnormalities in ECG 
and echocardiography (left ventricle dimensions/contractility within normal ranges). Explanted 
failing hearts were obtained from patients suffering from end-stage advanced heart failure of 
ischemic etiology (n=6/9).  
Sample collection was performed as previously described48. In brief, human tissue samples 
were taken at the time of heart explanation (avoiding scarred, fibrotic, or adipose tissue, 
endocardium, epicardium, or coronary vessels). The samples were rinsed immediately in saline, 
blotted dry, frozen in liquid nitrogen, powdered with a pestle and mortar in liquid nitrogen and 
stored in cryovials at -80 °C until further analysis. 
Quantitative real-time PCR 
RNA isolation 
Total RNA was isolated from left ventricular samples (n = 6) with a chloroform/isopropanol 
precipitation method. In brief, Qiazol® (Qiagen) was added to each sample and homogenized with 
TissueLyser (Qiagen). Homogenates were centrifuged and DNA and protein were precipitated 
from the clean upper phase with chloroform. Total RNA was precipitated with isopropanol and 
pellets were washed twice with ethanol (VWR). Finally, total RNA was resuspended in 
nuclease-free water, and RNA concentration was determined by spectrophotometry (NanoDrop, 
Thermo Fischer Scientific). 
cDNA synthesis 
cDNA was synthesized from 1 µg total RNA by Sensifast cDNA synthesis kit (Bioline) according to 
the manufacturers protocol. cDNA was diluted 20 times with RNAse-free water. qRT-PCR reactions 
were performed on a LightCycler® 480 II instrument (Roche) by using SensiFAST SYBR Green 
master mix (Bioline). Polymerase was heat-activated for 2 min at 95 °C and targets were amplified 
and quantified in 40 cycles (denaturation: 5 s at 93 °C; annealing: 10 s at 60 °C; synthesis:  20 s at 
72 °C). Forward and reverse primers for the fatty acid amide hydrolase (FAAH), cannabinoid 
receptor 1 (CNR1), cannabinoid receptor 2 (CNR2), diacylglycerol lipase α (DAGLα), diacylglycerol 




phospholipase D (NAPEPLD), α/β-hydrolase domain-containing 6 (ABHD6), α/β-hydrolase domain-
containing 12 (Abhd12) were used for analysis. Hypoxanthine-guanine phosphoribosyltransferase 
(HPRT) was used as a housekeeping gene. Results were calculated with 2‐ΔΔCp evaluation method. 
Primer sequences are shown in Table 2. 
Table 2 | qPCR primers. 
Gene Accession number Product (bp) Primer Primer Sequence 




















































Lipid extraction was performed as previously described49, with minor adaptations. In brief, ~50 mg 
tissue was weighed into a pre-cooled 1.5 mL Eppendorf tube and reconstituted in ice-cold 
ammonium acetate buffer (0.1 M, pH 4) (4 μL/mg tissue). The tissue was finely cut using chirurgical 
scissors and subsequently homogenized by probe sonication (3 cycles, 10 s, 30% amplitude) while 
kept on ice. Samples were spiked with 10 μL of deuterated internal standard mix (Table 1). After 
extraction with 1000 μL methyl tert-butyl ether (MTBE), the tubes were thoroughly mixed for 
5 min using a bullet blender (Next Advance) at medium speed, followed by a centrifugation step 
(16,000 g, 5 min, 4 °C). Next, 850 μL of the upper MTBE layer was transferred to clean 1.5 mL 
Eppendorf tube. Samples were dried in a speedvac (Eppendorf) followed by reconstitution in 
acetonitrile:water (50 μL, 90:10, v/v). The reconstituted samples were centrifuged (16,000 g, 
5 min, 4 °C) before transferring into LC-MS vials. 5 μL of each sample was injected into the 
LC-MS/MS system. 
LC-MS/MS analysis 
LC-MS/MS analysis was performed as previously described49, with minor adaptations. A targeted 
analysis of 31 compounds, including endocannabinoids and related N-acylethanolamines 
(NAEs) along with the fatty acids (Table 2), was measured using an Acquity UPLC I class Binary 
solvent manager pump (Waters) in conjugation with AB SCIEX 6500 quadrupole-ion trap (AB 
Sciex). The separation was performed with an Acquity HSS T3 column (1.2 × 100 mm, 1.8 μm) 
maintained at 45 °C. The aqueous mobile phase A consisted of 2 mM ammonium formate and 
10 mM formic acid, and the organic mobile phase B was acetonitrile. The flow rate was set 
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to 0.55 mL/min; initial gradient conditions were 55% B held for 2 min and linearly ramped to 100% 
B over 6 min and held for 2 min; after 10 s the system returned to initial conditions and held 2 min 
next injection. Electrospray ionization-MS and a selective Multiple Reaction Mode (MRM) was 
used for endocannabinoid quantification. Individually optimized MRM transitions using their 
synthetic standards for target compounds and internal standards are described in Table 3. 
Table 3 | LC-MS Standards and internal standards for lipidomics analysis. 
Standards 
Abbreviation Metabolite Q1 Q3 Polarity 
1&2-AG 2&1-Arachidonoylglycerol (20:4) 379 287 + 
AEA Anandamide (20:4) 348 62 + 
DHEA N-docosahexaenoylethanolamide (22:6) 372 62 + 
LEA  N-linoleoylethanolamide (18:2) 324 62 + 
NADA N-arachidonoyl dopamine (28:4) 440 137 + 
OEA N-oleoylethanolamide (18:1) 326 62 + 
PEA N-palmitoylethanolamide (16:0) 300 62 + 
SEA N-stearoylethanolamide (18:0) 328 62 + 
2-AGE 2-arachidonyl glycerol ether (20:4) 365 273 + 
DEA N-docosatetraenoylethanolamide (22:4) 376 62 + 
DGLEA  Dihomo-γ-linolenoylethanolamide (18:3) 350 62 + 
O-AEA O-arachidonoyleethanolamine (20:4) 348 62 + 
2-LG    2-Linoleoyl glycerol (18:2) 355 263 + 
1-LG     1-Linoleoyl glycerol (18:2) 355 263 + 
2-OG     2-Oleoyl glycerol (18:1) 357 265 + 
EPEA Eicosapentaenoyl ethanolamide (20:5) 346 62 + 
POEA  N-palmitoleoylethanolamide (16:1) 298 62 + 
ETAEA Eicosatrienoic acid ethanolamide (20:3) 350 62 + 
PDEA   N-pentadecanoylethanolamide (15:0) 286 62 + 
α-LEA  N-α-linolenylethanolamide (18:2) 322 62 + 
OA Oleic acid (18:1) 281 263 - 
LA Linoleic acid (18:2-ω6) 279 261 - 
α-LA α-linolenic acid (18:3-ω3) 277 233 - 
γ-LA γ-linolenic acid (18:3-ω6) 277 233 - 
DGLA Dihomo-γ-linolenic acid (20:3-ω6) 305 261 - 
MA Mead acid (20:3-ω9) 305 261 - 
AA Arachidonic acid (20:4-ω6) 303 259 - 
EPA Eicosapentaenoic acid (20:5-ω3) 301 257 - 
DTA Docosatetraenoic acid (22:4-ω6) 332 288 - 
DHA Docosahexaenoic acid (22:6-ω3) 327 283 - 
Internal Standards 
Abbreviation Metabolite  Q1 Q3 Polarity 
2-AG  (20:4)-d8 2-Arachidonoylglycerol-d8 387 294 + 
PEA    (16:0)-d4 Palmitoyl ethanolamide-d4 304 62 + 
SEA    (18:0)-d3 Stearoyl ethanolamide-d3 331 62 + 
OEA   (18:1)-d4 Oleoyl ethanolamide-d4 330 66 + 
LEA    (18:2)-d4 Linoleoyl ethanolamide-d4 328 66 + 
AEA   (20:4)-d8 Arachidonoyl ethanolamide-d8 356 62 + 
DHEA (22:6)-d4 Docosahexaenoyl ethanolamide-d4 376 66 + 






Activity-based protein profiling 
Sample preparation 
Cardiac tissue was dounce homogenized in ice-cold lysis buffer (250 mM sucrose, 20 mM HEPES 
pH 7.2, 2 mM DTT, 1 mM MgCl2, 2 U/mL benzonase) and incubated on ice (15 min). Clear lysate 
was obtained as the supernatant fraction after two low-speed centrifugation steps (2500 g, 5 min, 
4 °C). After dilution to 2 mg/mL in storage buffer (20 mM HEPES pH 7.2, 2 mM DTT), samples were 
used or flash frozen in liquid nitrogen and stored at -80 ⁰C until further use. 
Gel-based ABPP 
Clear lysates (2 mg/mL) were incubated with activity-based probes MB064 (2 µM), FP-TAMRA 
(500 nM), DH379 (1 µM) or DH463 (1 µM) (20 min, rt). The reaction was quenched with Laemmli 
buffer (30 min, rt) and 20 μg protein was resolved by SDS-PAGE (10% acrylamide gel, ~80 min, 180 
V) along with protein marker (PageRulerTM Plus, Thermo Fisher). In-gel fluorescence was 
measured in the Cy2, Cy3 and Cy5 channels (ChemiDocTM MP, Bio-Rad) and gels were stained with 
Coomassie after scanning. Fluorescence was quantified and normalized to Coomassie staining 
using ImageLabTM software (Bio-Rad).  
Chemical proteomics with label-free quantification  
The chemical proteomics workflow was modified from a previously published protocol50. In short, 
for general profiling of the serine hydrolases the clear lysates (250 µg protein, 1 mg/mL) were 
incubated with serine hydrolase probe cocktail (10 µM MB108, 10 µM FP-Biotin, 30 min, 37 ˚C, 
300 rpm). A denatured protein sample (1% SDS, 5 min, 100 ˚C) was taken along as a negative 
control. Precipitation, alkylation, avidin enrichment, on-bead digestion and sample preparation 
was performed according to protocol. Dried peptides were stored at -20 °C until LC-MS analysis. 
Prior to measurement, samples were reconstituted in 50 µL LC-MS solution and transferred to 
LC-MS vials. LC-MS data was analyzed by ProteinLynx Global SERVERTM (PLGS, Waters) and 
IsoQuant software51 (www.proteomeumb.org/MZw.html) minimal peptide score 6, false 
discovery rate 1%). Excel was used for further analysis, with the following cut-offs: false discovery 
rate 1%, unique peptides ≥ 1, identified peptides ≥ 2, ratio positive over negative control ≥ 2, part 
of putative hydrolase target list. Graphs were created using GraphPad Prism 7 (GraphPad). 
Western blot 
Clear lysates (2 mg/mL) were denatured with Laemmli buffer (5 min, 100 ˚C) and 45 μg lysate was 
resolved by SDS-PAGE (10% acrylamide gel, 65 min, 200V) along with PageRulerTM Plus Protein 
Marker (Thermo Scientific). Proteins were transferred to 0.2 μm polyvinylidene difluoride 
membranes by Trans-Blot Turbo™ Transfer system (Bio-Rad). Membranes were washed with TBS 
(50 mM Tris, 150 mM NaCl) and blocked with 5% milk in TBS-T (50 mM Tris, 150 mM NaCl, 0.05% 
Tween 20) (1 h, rt). Membranes were then incubated with primary antibody rabbit-anti-MAGL 
(ab24701, Abcam, 1:200 in 5% milk in TBS-T, O/N, 4 °C) washed with TBS-T, incubated with 
secondary donkey-anti-rabbit Alexa647 (A-31573, Thermo Fisher; 1:10000 in 5% milk TBS-T, 1 h, 
rt), and washed with TBS-T and TBS. Fluorescence was detected on the ChemiDocTM MP (Bio-Rad) 
in the Alexa647 channel, and Cy3/Cy5 channels for the protein marker.  
Statistical methods 
Statistical significance was determined by a Student’s t-test (two-tailed, unpaired)(p-values) with 
Benjamini-Hochberg false discovery rate (FDR 10%, q-values) for lipidomics and proteomics data 
using GraphPad Prism 7 (GraphPad) software. Samples were compared to (mean) healthy controls 
and significance is indicated as * < 0.05, ** < 0.01, *** < 0.001. 
  





Figure S1 | Targeted lipidomics of healthy and ischemic heart tissues reveals subgroups in ischemic samples. Lipids 
were extracted from control and ischemic cardiac tissue, followed by targeted lipidomics analysis. Lipid levels 
were normalized to tissue weight and are expressed relative to mean control. (A) Lipid levels relative to mean 
control. Data is expressed as mean ± SEM (n=9), t-test with Benjamini-Hochberg correction for 
multicomparison: not significant. (B) Lipid levels relative to mean control, ischemic samples categorized in 
subgroups. Data is expressed as mean ± SEM (control: n=9, ischemic 1: n=5, ischemic 2: n=4), t-test with 
Benjamini-Hochberg correction for multicomparison. * q < 0.05, *** q < 0.001 (control vs. ischemic 1), # q < 









































































































































































































































































Table S1 | Identified hydrolase targets in human cardiac tissue. Abbreviations and descriptions as annotated on 
uniprot.org. 
Protein  Description 
ABHD10 Mycophenolic acid acyl-glucuronide esterase, mitochondrial  
(α,β-hydrolase domain containing protein 10) 
ABHD11 Protein ABHD11 (α,β-hydrolase domain containing protein 11) 
ABHD14b Protein ABHD14b (α,β-hydrolase domain containing protein 14b) 
ABHD16a Protein ABHD16a (α,β-hydrolase domain containing protein 16a) 
ACOT1 Acyl-coenzyme A thioesterase 1 
APEH Acylamino-acid-releasing enzyme (acyl-peptide hydrolase) 
BTD Biotinidase 
CES1 Liver carboxylesterase 1 (carboxylesterase 1) 
CES2 Cocaine esterase (carboxylesterase 2) 
CMBL Carboxymethylenebutenolidase homolog 
CPVL Probable serine carboxypeptidase CPVL (Carboxypeptidase, vitellogenic-like) 
CTSA Lysosomal protective protein (cathepsin A) 
DDHD2 Phospholipase DDHD2 (DDHD domain-containing protein 2) 
DPP4 Dipeptidyl peptidase 4 
ESD S-formylglutathione hydrolase 
IAH1 Isoamyl acetate-hydrolyzing esterase 1 homolog 
LPL Lipoprotein lipase 
LYPLA1 Acyl-protein thioesterase 1 (Lysophospholipase 1) 
LYPLA2 Acyl-protein thioesterase 2 (Lysophospholipase 2) 
LYPLAL1 Lysophospholipase-like protein 1 
MGLL Monoglyceride lipase (monoacylglycerol lipase) 
NCEH1 Neutral cholesterol ester hydrolase 1 
NIT2 Omega-amidase NIT2 
PAFAH1b2 Platelet-activating factor acetylhydrolase IB subunit beta 
PAFAH1b3 Platelet-activating factor acetylhydrolase IB subunit gamma 
PARK7 Protein DJ-1 (Protein/nucleic acid deglycase DJ-1, parkinson disease protein 7) 
PLA2G15 Group XV phospholipase A2 
PPME1 Protein phosphatase methylesterase 1 
PREP Prolyl endopeptidase 
PREPL Propyl endopeptidase-like 
SCPEP1 Retinoid-inducible serine carboxypeptidase (Serine carboxypeptidase 1) 
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Applications of activity-
based protein profiling 
in developing zebrafish 
ABSTRACT | The zebrafish (Danio rerio) is increasingly 
used as a pre-clinical vertebrate model in drug discovery 
and development. Here, an activity-based protein 
profiling (ABPP) method for broad-spectrum profiling of 
serine hydrolases and kinases in zebrafish larvae is 
presented. ABPP coupled to mass spectrometry analysis 
enabled the identification and mapping of 45 hydrolases 
and 51 kinases throughout early zebrafish development 
(0-5 days post fertilization), showing a variety of activity 
profiles. As an application, fatty acid amide hydrolase 
(FAAH) inhibitor PF04457845 was used in a competitive 
ABPP setup. FAAH2a was the only inhibited hydrolase 
among the hydrolases detected by chemical proteomics 
and downstream inhibition effects were confirmed by 
lipidomics analysis. With the increasing popularity of 
zebrafish as a vertebrate animal model and their use in 
phenotypic drug discovery, the combined approach of 
comparative and competitive ABPP may serve as a 
valuable tool in the drug discovery process, 






The zebrafish (Danio rerio) is a popular model system for embryonic development1,2 and 
is increasingly used as a pre-clinical vertebrate model in drug discovery3,4. The zebrafish 
is evolutionary more distinct from humans than rodents are. Nonetheless, 71% of all 
human proteins and 82% of all disease-causing proteins have zebrafish orthologues5. 
Pharmacological effects of compounds are often conserved, as active sites or ligand 
binding domains tend to be more homologous3. A variety of genetic modification 
strategies in zebrafish has facilitated the generation of disease models, closely 
mimicking human diseases. Combined with several other advantages, including small 
size, rapid development, optical transparency and cost-effective use, the zebrafish is 
considered an attractive model organism, which is complementary to existing rodent 
models6. Its use has paved the way to whole-animal (semi-)high-throughput screening 
in phenotypic target discovery and toxicological screening6–8. However, target 
identification and target engagement studies remain challenging. Most biochemical 
zebrafish studies, especially in embryonic development, rely on protein9,10 and gene 
expression11,12 profiles. Despite the fact that gene and protein expression do not directly 
translate to protein activity, the activity profile is often not taken into account and the 
enzymatic state of a protein is not considered. 
Activity-based protein profiling (ABPP) may aid in gaining a more complete view on 
the early development of the zebrafish and may help establish its validity as a model 
organism in the drug discovery process. ABPP uses active-site directed probes to assess 
the functional state of an entire enzyme class in a complex protein sample. Fluorescent 
reporter tags enable rapid sample analysis by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and in-gel fluorescence scanning, whereas affinity tags can 
be used for target enrichment and subsequent identification by mass spectrometry 
(MS)13,14. The method can be used for inhibitor profiling in a competitive setup. It 
enables target engagement studies and provides information on the selectivity profile 
of small molecule modulators within the investigated protein class15,16. Alternatively, a 
comparative setup can be used to map the activity landscape of different biological 
samples or states17, e.g. different stages of development, which may enable discovery 
of biological markers and drug targets15.  
Two important protein classes, the serine hydrolases and kinases, can be targeted 
by activity-based probes. The serine hydrolases represent approximately 1% of all 
proteins in mammals and are characterized by a well conserved GXSXG amino acid motif 
and are involved in a broad spectrum of physiological processes, including signaling and 
metabolism14. Their active-site serine can interact covalently with fluorophosphonate 
(FP)-based and β-lactone-based probes, such as FP-rhodamine (FP-TAMRA)14,15 and 
MB06418,19. The kinases, a large protein family with over 500 members, are known for 
their pivotal roles in cell signaling processes, differentiation, proliferation, and 
disease20,21. A conserved lysine in the kinase active-site offers a reactive group for 
kinase-targeting probes such as XO4422. This probe contains an alkyne moiety which 
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serves as a ligation handle to introduce a reporter group via a copper(I)-catalyzed azide-
alkyne cycloaddition (“click” chemistry)23. Serine hydrolases and kinases have been 
demonstrated as drug targets by successful development of inhibitors and their 
therapeutic use in various diseases, including cancer , inflammation and Alzheimer’s24,25. 
For example, PF04457845, a fatty acid amide hydrolase inhibitor (FAAH), has entered 
clinical trials for the treatment of neurological disorders26,27 and kinase inhibitors such 
as Imatinib and Dasatinib are powerful drugs in cancer treatment28. 
In this study, a comparative ABPP assay was developed to map the serine hydrolase 
and kinase activity landscape during early zebrafish development (0-5 days post 
fertilization (dpf)). The assay was subsequently used in a competitive ABPP setup, using 
PF04457845 as a model drug. PF04457845 targets FAAH27,29, a membrane-bound serine 
hydrolase that degrades the endocannabinoid anandamide (AEA) and related amidated 
lipids30–33. Treatment of zebrafish larvae with PF04457845 enabled rapid mapping of the 
in vivo inhibitor interaction profile in a similar fashion as was reported for in vitro and in 
situ model systems16.  
Results & Discussion 
Comparative ABPP: Mapping zebrafish development 
ABPP has previously been used to map the serine hydrolase landscape e.g. in mouse 
tissue17. Here, an ABPP assay was developed to facilitate the use of zebrafish larvae. It 
was anticipated that the number of proteins expressed would increase over the course 
of development. Therefore, clear lysate, membrane, and cytosol fractions were 
prepared from a large batch of 5 dpf larvae and fractions were analyzed by gel-based 
ABPP using hydrolase probes MB064 and FP-TAMRA (Figure 1A). Extensive labeling was 
observed, but band overlap impeded band identification by competitive ABPP (data not 
shown). Chemical proteomics with their biotinylated counterparts, MB108 and FP-biotin 
respectively, resulted in the identification of 61 different hydrolases (Figure 1B, 
Supplementary Table S1), of which 46, 33, and 48 were found in the lysate, cytosol, and 
membrane fractions respectively. Targets were identified as those having ≥ 2-fold 
enrichment as compared to heat-inactivated controls and a peptide count ≥ 2 with at 
least 1 unique peptide. In addition, targets were filtered against a putative probe-target 
list developed for human/mouse-based experiments34 and zebrafish gene homologues 
were included. Several of the enriched targets contained a serine hydrolase motif 
(GXSXG)35, but were not part of the putative hydrolase target list. These hydrolases are 
indicated as additional zebrafish targets (Supplementary Table S1).  
Several members of the α,β-hydrolase domain containing protein (ABHD) family 
were detected, as well as a variety of carboxylic ester hydrolases (CEL, CES), and 
members of the endocannabinoid metabolic pathways such as monoacylglycerol lipase 
(MGLL) and the fatty acid amide hydrolases (FAAH, FAAH2a, FAAH2b). Of note, even 




activity profile, poorly abundant proteins or tissue-specific activities may be lost in the 
proteomic analysis. 
To increase sample throughput and improve experimental ease, the profiling process 
was streamlined by reducing sample size and simplifying sample preparation. Whole 
lysates were prepared from samples containing a varying number of larvae per replicate. 
Inconsistent labeling was observed in the gel-based assay when a single larva was used, 
whereas using 5 larvae was sufficient to obtain a reproducible labeling pattern between 
biological replicates (data not shown). The optimized assay conditions were employed 
in a comparative ABPP setup and enabled assessment of the hydrolase activity 
landscape throughout development. Larvae were obtained immediately after 
fertilization at 1, 2, 3, 4 or 5 dpf (5 larvae/replicate). Gel-based analysis of whole lysates 
labeled with MB064 and FP-TAMRA revealed that both the number of hydrolases and 
the activity of most hydrolases increased over time (Figure 2). Similarly, coomassie 
staining showed an overall increase in the number of proteins from 1 dpf onwards. 
Vitellogenin, one of the main constituents of the yolk sac, was observed as two thick 
bands at 70 and 120 kDa that decreased over time, in accordance with the use of the 
yolk as nutrient source1.  
 
Figure 1 | The serine hydrolase activity profile in zebrafish larvae (5 dpf). Clear lysate (lys), membrane (mem) and 
cytosol (cyt) fractions from zebrafish larvae (5 dpf) were analyzed by gel-based ABPP and chemical proteomics. 
(A) Proteins were labeled with MB064 (2 µM) or FP-TAMRA (500 nM) (20 min, 28 °C) and 10 µg protein was 
resolved by SDS-PAGE. Coomassie served as a protein loading control. (B) Samples (200 µg protein) were labeled 
with FP-Biotin and MB108 (10 µM each, 30 min, 28 °C) and analyzed by chemical proteomics. Absolute 
abundance is summarized in a heat map (blue scale), proteins that were not detected are depicted in grey (n=3). 
Targets with a non-serine nucleophile are indicated with *, additional zebrafish targets contain a GXSXG motif 








































































































































































































































































































































































































































































































































































































Figure 2 | Comparative ABPP analysis of serine hydrolases during embryonic development. Whole lysate of 
zebrafish larvae from different development stages (0-5 dpf, 5 larvae/sample) was labeled with FP-TAMRA 
(500 nM) or MB064 (2 µM) (20 min, 28 °C) and resolved by SDS-PAGE. Coomassie served as a protein loading 
control. 
Next, chemical proteomics was used to identify the hydrolase targets. Whole lysates 
(5 larvae/replicate, 0-5 dpf) were labeled with probes MB108 and FP-biotin and analyzed 
by LC-MS after affinity purification and trypsin-digestion (Figure 3A, Supplementary 
Figure S1, Supplementary Table S1). In total, 45 hydrolases were identified. In line with 
the gel-based data, the number of hydrolases detected increased over time, as well as 
their activity. 
The activity of several hydrolases coincided with development of the organs in which 
they are generally highly expressed. For example, a rapid increase in carboxylic esterase 
2 and 3 (CES2, CES3) and arylacetamide deacetylase (AADAC) abundance was observed 
from day 3 on (Figure 3). ces2, ces3 and aadac are generally highly expressed in the 
liver36,37, of which the growth phase (> 2 dpf)38 coincides with the increase in CES and 
AADAC activity as observed by ABPP. Similarly, activity of the pancreatic enzymes 
chymotrypsin (zgc:92041)36,37 and carboxylic ester hydrolase 1 and 2 (CEL.1, CEL.2) 36,37 
appeared at the end of pancreatic development (> 3 dpf)39.  
Several other hydrolases (including acylaminoacyl-peptide hydrolase (APEH), 
S-formylgluthatione hydrolase (ESD), OVCA2 esterase (OVCA2) and platelet-activating 
factor acetylhydrolase isoform 1b gamma subunit (PAFAH1b3) had a more constant 
activity. Their reported (gene) expression is more uniform across different tissue 
types36,37, thus making their activity profiles less sensitive to development of a specific 
tissue type.  
FAAH2b showed the most outstanding activity profile, as it was the only hydrolase 
which had a reduction in activity during development. FAAH2b is one of the metabolic 
enzymes in the endocannabinoid system. This system is responsible for the physiological 
effects of cannabis and is involved in a number of biological processes. In an mRNA-
based study, faah2b expression was detected directly after fertilization, followed by a 
FP-TAMRA MB064 
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rapid reduction and recovery at 4-5 dpf40. High FAAH2b activity levels during fertilization 
may be required for the hydrolysis of the endocannabinoid AEA and other 
N-acylethanolamines (NAEs). Functional cannabinoid receptors present in the sperm can 
be activated upon AEA release from female follicle fluids or eggs, thereby hampering 
fertilization41,42. Therefore, rapid degradation of AEA may be beneficial in the 
fertilization process. 
 
Figure 3 | Serine hydrolase and kinase activity landscape during zebrafish development (0-5 dpf). Heatmap 
summary of activity-based proteomics of (serine) hydrolases (A) and kinases (B). (A) Zebrafish whole lysates 
from different development stages (0-5 dpf, 5 larvae/sample) were treated with MB108 and FP-Biotin (10 µM 
each, 30 min, 28 °C), followed by chemical proteomics analysis. * Indicates targets with a non-serine 
nucleophile, ** indicates additional zebrafish targets containing a GXSXG motif, which were not included in the 
putative hydrolase target list. (B) Zebrafish whole lysates from different development stages (0-5 dpf, 
5 larvae/sample) were treated with XO44 (10 µM, 60 min, 28 °C) and conjugated to biotin-azide (40 µM, 60 min, 
28 °C), followed by chemical proteomics analysis. (A-B) Data is represented as absolute abundance at the time 
point with maximum abundance (blue scale) (individual data points in Supplementary Figure S1-2). Relative 
abundance is expressed as a percentage of maximum abundance per protein (green-red scale) or as not 
detected (grey) (mean, n=6). Outliers as determined by ROUT’s outlier test (5%) have been excluded from 
calculations. 
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Several other endocannabinoid metabolic enzymes were also detected including the 
2-arachidonoyl glycerol (2-AG) hydrolytic enzymes MGLL, ABHD12 and ABHD6a, starting 
at 1, 2 and 3 dpf, respectively, and increased over time. A similar increase in mRNA 
expression has been observed for abhd6a43. In contradiction with the chemical 
proteomics data, mgll expression peaked at 8 hpf, but was stably expressed from 1 dpf 
onward, while abhd12 expression decreased from 2 dpf onwards in the same study43. 
Thus, gene expression and protein activity are not always directly correlated. 
The ABPP assay was extended with kinase targeting probe XO4422, which interacts 
with a well-conserved reactive lysine in the kinase active site (Figure 3B, Supplementary 
Figure S2, Supplementary Table S2). Lysates were incubated with the probe, which was 
subsequently conjugated to a biotin reporter to enable enrichment and proteomic 
analysis. In total, 51 kinases were identified, having ≥ 2-fold enrichment as compared to 
vehicle-treated controls, a peptide count ≥ 2 and at least 1 unique peptide. In addition, 
targets (or their human orthologues) had to be annotated as kinases in the Uniprot 
protein database. Of note, in contrast to the hydrolase probes, XO44 labels available 
kinase active-sites dependent on their affinity, but not necessarily on their active state. 
The number of detected kinases increased throughout development and in general 
their abundance increased time dependently. For example, cyclin dependent kinase 5 
(CDK5), serine/threonine kinase 38a (STK38A) and mitogen-activated protein kinase 1 
and 3 (MAPK1, MAPK3) abundance steadily increased over time from fertilization 
onward. However, also different labeling profiles were observed. STK25B and MAPK14, 
for example, were detected at later stages and increased from there on, while STK24B 
remained stable once expressed. In contrast, STK25A decreased time dependently from 
0 dpf onwards and CDK1 was stably expressed until 3 dpf and subsequently reduced.  
A more distinct labeling profile was observed for p21 protein (CDC42/rac)-activated 
kinase 2b (PAK2b) and CDK2 which peaked at 3-4 dpf and 2 dpf respectively.  Brain-
subtype creatine kinase (CKBB) was abundant after fertilization, followed by a strong 
decrease at 1 dpf and a subsequent recovery and increase. These profiles suggest tight 
regulation of activity throughout the embryonic phase and may be related to important 
developmental processes. In human embryonic stem cells CDK2 plays a crucial role in 
balancing cell proliferation and cell death. Its downregulation induces a loss of 
pluripotency as well as differentiation toward extraembryonic lineages44. The function 
of PAK2b, or its human homologue PAK2, in development has not yet been described. 
Several kinases also showed a steady abundance over time, which may indicate a 
more general role or a less tight regulation. For example, the metabolic kinase 
phosphoglycerate kinase (PGK), an ATP-generating enzyme in the glycolytic pathway45, 
is present at a very constant level, which corresponds with its house-keeping character. 
Similarly, v-akt murine thymoma viral oncogene homolog 2 (AKT2) is stably active from 




cause developmental deficits and increase lethality in zebrafish larvae, thereby stressing 
its importance throughout development46. 
Competitive ABPP: PF04457845 profiling  
Having established the activity profile of serine hydrolases, a competitive ABPP assay 
was developed to enable rapid in vivo target engagement assessment and off-target 
profiling. Zebrafish larvae (5 dpf) were exposed to vehicle (DMSO, 0.1%) or FAAH 
inhibitor PF04457845 (1 µM, 8 h) in their swimming medium. The bioavailability of the 
inhibitor was assessed by measuring the drug concentration in the blood using LC-MS 
analysis. PF04457845 was detected at a concentration of 0.5 µM (n=1), thereby 
validating internal drug exposure in the treated larvae. After treatment, lysates were 
analyzed by gel-based ABPP using fluorescent probes MB064 and FP-TAMRA (Figure 
4A-B) or chemical proteomics using their biotinylated counterparts MB108 and FP-biotin 
respectively (Figure 4C). PF04457845 inhibited fatty acid amide hydrolase 2a (FAAH2a), 
a FAAH analogue, without affecting the other 58 detected hydrolases. This is in line with 
human in vitro and in situ studies in which PF04457845 only targeted FAAH and FAAH216. 
Of note, PF04457845’s intended target FAAH falls below the detection limit in whole 
lysate fractions and inhibition could thus not be determined. 
 
Figure 4 | Competitive ABPP of zebrafish larvae in vivo treated with FAAH-inhibitor PF04457845. (A-B) Gel-based 
activity profiling of zebrafish larvae (5 dpf) treated in vivo with vehicle or PF04457845 (1 µM, 8 h, 28 °C). Clear 
lysate was labeled with (A) MB064 (1 µM) or (B) FP-TAMRA (500 nM) (20 min, 28 °C) and 12.5 µg protein was 
resolved by SDS-PAGE. Coomassie is shown as a loading control. (C) Heatmap summary of chemical proteomics 
analysis of zebrafish larvae (5 dpf, 300 µg protein) treated in vivo with vehicle or PF04457845 (1 µM, 8 h, 28 °C) 
with probes MB108 and FP-biotin (10 µM each, 30 min, 28 °C). Data is expressed relative to vehicle treated 
(mean, n=4). Targets with a non-serine nucleophile are indicated with *, additional zebrafish targets contain a 
GXSXG motif but were not included in the putative hydrolase target list.  
FAAH30,32 and FAAH2a47,48 both hydrolyze the endocannabinoid AEA49 as well as 
other N-acylethanolamines (NAEs). To assess the functional effect of PF04457845 on 
FAAH(2), endocannabinoid levels were investigated by LC-MS (Figure 5A). The larvae 
were exposed to the drug in their swimming medium (1 µM PF04457845, 2-24 h). The 
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levels of FAAH substrate AEA increased after 2 hours of treatment and reached a steady 
state after 5 hours, thus indicating that PF04457845 uptake was sufficient to inhibit 
FAAH/FAAH2 in vivo. The levels of a second endocannabinoid 2-AG were not affected by 
the drug (Figure 5A). Semi-targeted lipidomics was performed to assess the effects of 
PF04457845 on the overall lipid profile. In total, 223 lipids from 15 different lipid classes 
were detected in 5 dpf zebrafish larvae (Figure 5B). PF04457845 exposure (8 h) 
increased NAE levels, while other lipid classes remained unchanged. These data 
correspond with the clean interaction profile of PF04457845 as determined by ABPP. 
 
Figure 5 |Lipidomics analysis of zebrafish larvae in vivo treated with FAAH inhibitor PF04457845. (A) Time 
response curve of endocannabinoids (AEA, 2-AG) and metabolite arachidonic acid (AA). Zebrafish larvae (5 dpf) 
were treated in vivo with vehicle or PF04457845 (1 µM, 2-24 h). Endocannabinoid levels were measured by LC-
MS and expressed relative to vehicle-treated controls at the corresponding time point (mean ± SEM, n=3). (B-C) 
Zebrafish larvae (5 dpf) were treated with vehicle or PF04457845 (1 µM, 8 h) and lipid levels were analyzed by 
LC-MS. (B) Total number of lipid species detected in zebrafish larvae sorted by lipid class. (C) Volcano plot 
summary of lipidomics data. Lipids with a fold change (FC) threshold of ≥ 1.20 or ≤ 0.80 and Benjamini-Hochberg 
false discovery rate (FDR) ≤ 25%, circles colored by lipid class (mean fold change, n=3). 
Conclusion 
In summary, a proteomics-based ABPP method was developed and enabled rapid 
mapping of the activity landscape of two large protein families in zebrafish larvae. Over 
50 serine hydrolases were targeted using broad-spectrum probes FP-biotin and MB108, 
as well as 51 kinases using the reactive-lysine targeting probe XO44. This enabled 
mapping of the hydrolase activity and kinase landscape throughout early zebrafish 
development (0-5 dpf). In addition, FAAH inhibitor PF04457845 was used to showcase 
zebrafish larvae as a simple in vivo model for drug discovery.  
Phenotypic (semi-high throughput) drug screening is gaining popularity as it enables 
discovery of therapeutic drugs, even without having a validated drug-target4,50. The 
comparative chemical proteomics workflow may aid the discovery of potential serine 
hydrolase or kinase drug targets by enabling activity profile assessment between 
observed phenotypes. The competitive setup extends the assay, as it enables target 
identification and off-target screening. In addition, the comparative assay serves as a 
complementary tool to study developmental processes at the protein activity level, 
circumventing current limitations such as poor antibody availability for zebrafish 
proteins and limited translatability of mRNA levels to protein expression and activity.  






























































































Materials, probes and inhibitors 
Fluorophosphonate-TAMRA (FP-TAMRA) and MB064, were synthesized in house as previously 
described18,51. XO44 was synthesized according to literature procedures22. All synthesized 
compounds were at least 95% pure and were analyzed by LC-MS, NMR, and HRMS. Stocks are 
prepared in DMSO. Other chemicals were purchased from Sigma Aldrich, unless indicated 
otherwise.  
Zebrafish sample collection 
Zebrafish husbandry 
Wildtype zebrafish were housed at Leiden University, the Netherlands in compliance with the local 
animal welfare regulations and were maintained according to standard protocols (zfin.org). 
Embryos were collected from family crosses of AB/TL wild-type strain (license number 10612, 
Leiden University) and were grown at 28.5 °C in embryo medium (60 µg/mL Instant Ocean sea 
salts (Sera Marin), methylene blue) in the dark. All experiments were performed using zebrafish 
embryos and larvae before the feeding stage, as specified by the EU animal protection Directive 
2010/63/EU. 
Sample collection development stages 
Fertilized embryos were transferred to a petri dish in embryo medium and were maintained at 
28.5 °C in the dark until 5 dpf. At 0, 1, 2, 3, 4, or 5 dpf embryos/larvae were collected. Emrbyos/ 
larvae were washed three times with embryo medium. For each replicate, five embryos/larvae 
were transferred to a 1.5 mL Eppendorf tube using a Pasteur pipet. Alternatively, a large number 
of zebrafish larvae (> 100) was washed and transferred to a 1.5 mL Eppendorf tube. In either case, 
excess liquid  was removed and the embryos/larvae were flash frozen in liquid nitrogen and stored 
at -80 °C until further use. 
PF04457845 in vivo treatment  
Embryos were raised in an incubator at 28.5 °C. At 5 dpf, larvae were treated with vehicle (0.05% 
DMSO) or PF04457845 (1 µM, 2-24 h, as indicated). For lipid extraction, three replicates of 20 
larvae each were collected, washed three times with 80/20 embryo medium/methanol (v/v). For 
ABPP four replicates of ~60 larvae each were collected, without additional washing. Excess liquid 
was removed and the larvae were flash frozen in liquid nitrogen and stored at -80 °C until further 
use.  
Activity-based protein profiling 
Sample preparation 
Zebrafish larvae were thawed on ice and homogenized in a sufficient amount of sucrose lysis 
buffer (250 mM sucrose, 20 mM HEPES pH 7.2, 2 mM DTT, 1 mM MgCl2, 2 U/mL benzonase) or 
kinase lysis buffer (100 mM HEPES pH 8.0, 1.5 mM MgCl2, 1 mM EGTA pH 8.0, 150 mM NaCl, 1 mM 
Na3VO4, 0.1% (v/v) NP-40, 10 mM NaF, 1x mammalian protease inhibitor (M250, Amresco), 
2 U/mL benzonase) with a pestle motor (whole lysate). Clear lysate was obtained as the 
supernatant fraction after two low-speed centrifugation steps (5 min, 1000 g, 4 °C) in which the 
cell debris was removed. Clear lysate was separated into cytosol and membrane fractions by 
ultracentrifugation (30,000 g, 60-90 min, 4 °C). The membrane pellet was resuspended in sucrose 
or kinase lysis buffer. Protein concentration of clear lysate, membrane, and cytosol fractions was 
determined by Bradford assay and samples were diluted (1-2 mg/mL) in their according buffers. 
Samples were flash frozen in liquid nitrogen and stored at -80 °C until further use.  
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For time-course experiments, the larvae (five per replicate) were homogenized in 100 µL 
sucrose or kinase lysis buffer using a pestle motor. The entire sample (± 100 µL whole lysate) was 
used for proteomics experiments. For the gel-based assay, 20 µL lysate was used per 
activity-based probe.  
Gel-based ABPP 
Protein samples were incubated with activity-based probes MB064 (2 µM) or FP-TAMRA (500 nM). 
The reaction was quenched with Laemmli buffer (15 min, 50 °C) and samples were resolved by 
SDS-PAGE (10% acrylamide gel, ± 80 min, 180 V) along with protein marker (PageRulerTM Plus, 
Thermo Fisher). In-gel fluorescence was measured in the Cy3- and Cy5-channel (ChemiDocTM MP, 
Bio-Rad) and gels were stained with Coomassie after scanning. Fluorescence was quantified and 
normalized to Coomassie staining using ImageLabTM software (Bio-Rad).  
Label-free proteomics  
The label-free chemical proteomics workflow was modified from Van Rooden et al.34. For serine 
hydrolase activity profiling, the lysates were incubated with serine hydrolase probe cocktail 
(10 µM MB108, 10 µM FP-biotin, 30 min, 28 °C, 300 rpm) and as a negative control a denatured 
protein sample (1% SDS, 5 min, 100 °C) was taken along. For kinase profiling, the lysates were 
incubated with kinase-probe XO44 (10 µM, 30 min, 28 °C, 300 rpm). Treatment with vehicle (2% 
DMSO) was taken along as a negative control. Subsequently, the probe was conjugated to biotin-
azide by addition of click mix (final concentration: 1 mM CuSO4·(H2O)5, 0.56 mM sodium ascorbate, 
0.2 mM THPTA, 40 µM biotin-azide) and subsequent incubation (60 min, 28 °C, 300 rpm). 
Precipitation, alkylation and avidin enrichment were performed according to protocol34. 
Avidin beads were washed twice with SDS/PBS, followed by three PBS washes. On-bead digestion 
was performed overnight according to protocol and after sample preparation the dried peptides 
were stored at -20 °C until LC-MS analysis. Prior to measurement, samples were reconstituted in 
40 μL LC-MS sample solution and transferred to LC-MS vials. LC-MS data was analyzed by 
ProteinLynx Global SERVERTM (PLGS, Waters) and IsoQuant software52 (www.proteomeumb.org/ 
MZw.html) (settings: minimal peptide score 5.5/6.0, false discovery rate 1%). Excel was used for 
further analysis, with the following cut-offs: unique peptides ≥ 1, identified peptides ≥ 2, ratio 
positive over negative control ≥ 2, part of hydrolase target list and/or containing a GXSXG serine 
hydrolase motif (additional zebrafish targets) (probe cocktail), or having the annotation kinase in 
the Uniprot database (XO44). Graphs were created using GraphPad Prism 7 (GraphPad). 
Lipidomics analysis: Endocannabinoids 
Lipid extraction 
Endocannabinoids and their congeners were quantified using LC-MS/MS analysis. The lipid 
extraction was performed on ice. In brief, 20 zebrafish larvae at 5 dpf were transferred to 1.5 mL 
Eppendorf tubes, spiked with deuterated internal standard mix for endocannabinoids 
(N-arachidonoylethanolamine (AEA)-d8, N-arachidonoyldopamine (NADA)-d8, N-docosahexa-
enoyl-ethanolamide (DHEA)-d4, 2-arachidonoylglycerol (2-AG)-d8, N-stearoylethanolamine 
(SEA)-d3, N-palmitoylethanolamine (PEA)-d4, N-linoleoylethanolamine (LEA)-d3 and 
N-oleoylethanolamine (OEA)-d4), followed by the addition of ammonium acetate buffer (100 µL, 
0.1 M, pH 4). After extraction with methyl tert-butyl ether (800 µL), the tubes were thoroughly 
sonicated until the sample was homogenous. The samples were mixed for 6 min using a bullet 
blender at medium speed (Next Advance Inc.), followed by a centrifugation step (5,000 g, 12 min, 
4 °C). Then 750 μL of the upper methyl tert-butyl ether layer was transferred into a clean 1.5 mL 
Eppendorf tube. Samples were dried in a speed-vac (Eppendorf) followed by reconstitution in 
acetonitrile/H2O (30 µL, 90/10, v/v). The reconstituted samples were centrifuged (14,000 g, 3 min, 





A targeted analysis of 21 endocannabinoids and related NAEs was measured using an Acquity 
UPLC I class Binary solvent manager pump (Waters) in conjugation with AB SCIEX 6500 
quadrupole-ion trap (QTRAP) (AB Sciex). Separation was performed with an Acquity HSS T3 
column (1.2 x 100 mm, 1.8 µm) maintained at 45 °C. The aqueous mobile phase A consisted of 
2 mM ammonium formate and 10 mM formic acid, and the organic mobile phase B was 
acetonitrile. The flow rate was set to 0.4 mL/min; initial gradient conditions were 55% B held for 
2 min and linearly ramped to 100% B over 6 min and held for 2 min; after 10 s, the system returned 
to initial conditions and held 2 min before next injection. Electrospray ionization-MS was operated 
in positive mode for measurement of 21 endocannabinoids and NAEs, and a selective Multiple 
Reaction Mode (sMRM) was used for quantification. Peak area integration was performed with 
MultiQuant (AB Sciex, Version 3.0.2) data analysis software. The obtained peak areas of targets 
were corrected by appropriate internal standards. Calculated response ratios, determined as the 
peak area ratios of the target analytes to the respective internal standards, were used to obtain 
absolute concentrations from their respective calibration curves. 
Table 1 | Target list of endocannabinoids and N-acylethanolamines and their validation parameters. The method 
is validated in terms of linearity sensitivity (LOQ), process efficiency (matrix effect with recovery) and precision. 
Endogenous concentrations are expressed as mean ± SEM. 










2&1AG (20:4) Arachidonoylglycerol 78 0.998 5 2270 ± 59 
AEA (20:4) Anandamide 85 0.999 12 0.5 ± 0.02 
DHEA (22:6) N-Docosahexaenoyl ethanolamide 49 0.999 4 42 ± 1.6 
LEA (18:2) N-Linoleoylethanolamide 79 0.999 3 0.38 ± 0.11 
OEA (18:1) N-Oleoylethanolamide 84 0.999 6 1.2 ± 0.28 
PEA (16:0) N-Palmitoylethanolamide 87 0.999 3 21.6 ± 0.9 
SEA (18:0) N-Stearoylethanolamide 91 0.999 2 11.7 ± 0.6 
DEA (22:4) N-Docosatetraenoyl ethanolamide 48 0.998 19 0.4 ± 0.02 
DGLEA (18:3) Dihomo-γ-Linolenoyl ethanolamide 65 0.999 35 0.1 ± 0.01 
2-LG (18:2) 2-Linoleoyl glycerol 63 0.999 8 6153 ± 493 
1-LG (18:2) 1-Linoleoyl glycerol 74 0.981 7 773 ± 66 
2-OG (18:1) 2-Oleoyl glycerol 73 0.999 3 17999 ± 1740 
1-OG (18:1) 1-Oleoyl glycerol N/A 0.986 3 2564 ± 191 
EPEA (20:5) N-Eicosapentaenoyl ethanolamide 65 0.999 5 7.3 ± 0.44 
POEA (16:1) N-Palmitoleoylethanolamide 99 0.999 4 0.8 ± 0.04 
PDEA (15:0) N-Pentadecanoylethanolamide 82 0.999 7 0.2 ± 0.01 
AA (20:4) Arachidonic Acid 122 0.998 7 80167 ± 5530 
Lipidomics analysis: Targeted lipidomics 
Sample extraction 
The endocannabinoid extraction protocol was followed, with the following adjustment. In 
addition to the endocannabinoid internal standards, non-endogenous lipid internal standards 
were added (lysophosphatidylcholine (LPC) 17:0, phosphatidylethanolamine (PE) 17:0/17:0, 
phosphatidylcholine (PC) 17:0/17:0, sphingomyelin (SM) d18:1/17:0, triglyceride (TG) 
17:0/17:0/17:0, ceramide (Cer) d18:1/17:0 and fatty acid (FA) 17:0-d33). Each sample was injected 
on three different lipidomics platforms: endocannabinoids (5 µL), positive lipids (2 µL) and 
negative lipids (8 µL). 
LC-MS/MS analysis 
The endocannabinoid analysis was followed as described above. Both lipidomics methods 
(positive and negative lipids) are adapted and modified from previously published work16. In brief, 
these methods are measured on an Acquity UPLC Binary solvent manager pump (Waters) coupled 
to a Synapt G2 electrospray ionization quadrupole time-of-flight (ESI-Q-TOF, Waters) high 
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resolution mass spectrometer using reference mass correction. The chromatographic separation 
was achieved on an Acquity HSS T3 column (1.2 x 100 mm, 1.8 µm) maintained at 40 °C for both 
methods. The positive lipid run includes targets from different lipid classes including 
(lyso)phosphatidylcholines, triglycerides, ceramides. (Lyso)phosphatidylethanolamines and 
sphingomyelins were separated using a flow of 0.4 mL/min over a 16 min gradient. In positive 
mode, the mobile phase A consisted of 60/40 (v/v) acetonitrile/H2O with 10 mM ammonium 
formate, and the mobile phase B consisted of 10/90 (v/v) acetonitrile/isopropanol with 10 mM 
ammonium formate. The negative lipids constitute mainly free fatty acids and 
(lyso)phosphatidylcholines were separated with a flow of 0.4 mL/min over a 15 min gradient. In 
negative mode, the aqueous mobile phase A consisted of 5/95 (v/v) acetonitrile/H2O with 10 mM 
ammonium formate, and the organic mobile phase B consisted of 99% (v/v) methanol with 10 mM 
ammonium formate. The targets in both lipid methods were detected full scan (100-1000 m/z) in 
their respective ion charge mode. 
PF04457845 quantification 
Sample extraction 
PF04457845 was quantified using LC-MS/MS analysis in blood samples pooled from 20-25 treated 
zebrafish larvae at 5 dpf (1 µM PF04457845, 8 h). The blood sample (total ~83 nL) was collected 
from anatomical locations of the larval circulation using a pulled needle (borosilicate glass 
capillary, original diameter: 0.5 mm, Sutter Instruments) in a micromanipulator, connected to a 
manual CellTram pump (Eppendorf) under 20x microscopic magnification (Leica). For 
determination of sample volume, an image was taken of each sample’s blood content within the 
needle. To prevent coagulation, needles and collection tubes were coated with heparin. The 
sample extraction was performed on ice. 200 µL of acetonitrile was added to the blood samples. 
The samples were vortexed and then centrifuged (13,000 g, 10 min). 150 µL of supernatant was 
evaporated to dryness using a speedvac (Eppendorf) and reconstituted in 10 µL of acetonitrile.   
LC-MS/MS analysis 
PF04457845 was measured using an Acquity UPLC I class Binary solvent manager pump (Waters) 
in conjugation with AB SCIEX 6500 quadrupole-ion trap (QTRAP) (AB Sciex). Separation was 
performed with Acquity HSS T3 column (1.2 x 100 mm, 1.8 µm) maintained at 45 °C. The aqueous 
mobile phase A consisted of 2 mM ammonium formate and 10 mM formic acid, and the organic 
mobile phase B was acetonitrile. The flow rate was set to 0.5 mL/min; initial gradient conditions 
were 60% B held for 0.5 min and linearly ramped to 100% B over 2.5 min and held for 0.5 min; 
after 10 s the system returned to initial conditions and held 1.5 min before next injection. 
Electrospray ionization-MS was operated in positive mode for measurement of PF04457845 and 
a selective Multiple Reaction Mode (sMRM) was used for quantification. The ion masses 
monitored were Q1/Q3 456/335 (m/z). Peak area integration was performed with MultiQuant (AB 
Sciex, Version 3.0.2) data analysis software. The limit of detection (LOD) was 1 pM and the linear 
range used was from 1 to 1000 pM. 
Statistical methods 
All statistical measures and methods are included in the respective Figure or Table captions. In 
brief, all data are shown as the mean ± SEM where applicable. A Student’s t-test (unpaired, two-
tailed) was used to determine differences between two groups. All statistical analyses were 
conducted using Excel (Microsoft) or GraphPad Prism 7 (GraphPad), and a p-value < 0.05 was 
considered significant throughout unless indicated otherwise. For the lipidomics analysis a 
Benjamini-Hochberg correction was applied to obtain multicomparison corrected p-values and a 





Table S1 | Identified hydrolase targets in zebrafish. Abbreviations and descriptions as annotated on uniprot.org. 
* Indicates targets with a GXSXG-domain that are not annotated, their molecular function is based on gene 
ontology. 
Protein  Description Protein Description 
AADAC Arylacetamide deacetylase MGLL Monoglyceride lipase 
ABHD10a α-β hydrolase domain containing 10a NCEH1B,1 
Neutral cholesterol ester hydrolase 1b, 
tandem duplicate 1 
ABHD10b α-β hydrolase domain containing 10b NCEH1B,2 
Neutral cholesterol ester hydrolase 1b, 
tandem duplicate 2 
ABHD12 
si:ch211-117n7.7i 
α-β hydrolase domain containing 12 NIT2 Omega-amidase NIT2 
ABHD14b α-β hydrolase domain containing 14b OLAH Oleoyl-ACP hydrolase 
ABHD16a α-β hydrolase domain containing 16a OVCA2 Esterase OVCA2 
ABHD4 α-β hydrolase domain containing 4 PAFAH1B3 
Platelet-activating factor acetylhydrolase  
isoform 1b γ subunit 
ABHD6a α-β hydrolase domain containing 6a PLA2G15 Phospholipase A2  group XV 
ACHE Acetylcholinesterase PLA2G7 Platelet-activating factor acetylhydrolase 
ACOT18 Acyl-CoA thioesterase 18 PNPLA6 
Patatin-like phospholipase  
domain-containing 6 
AFMID Kynurenine formamidase PNPLA7a 
Patatin-like phospholipase  
domain-containing 7a 
APEH Acylaminoacyl-peptide hydrolase PNPLA7b 
Patatin-like phospholipase  
domain-containing 7b 
CEL,1 Carboxylic ester hydrolase PPT1 Palmitoyl-protein thioesterase 1 
CEL,2 Carboxylic ester hydrolase PPT2 Palmitoyl-protein thioesterase 2 
CES2 Carboxylic ester hydrolase PRCP Prolylcarboxypeptidase  
CES3 Carboxylic ester hydrolase PREP Prolyl endopeptidase 
CMBL Carboxymethylenebutenolidase homolog  PRSS1 Trypsin 
CPVL Carboxypeptidase - vitellogenic-like PRSS59.1 Protease serine 59 tandem duplicate 1 
CTRB1 Chymotrypsinogen B1 PSMB5 Proteasome subunit beta type 
CTRL Chymotrypsin-like RBBP9 Retinoblastoma-binding protein 9 
CTSA Cathepsin A SCPEP1 Carboxypeptidase 
DPP4 Dipeptidyl-peptidase 4 SERHL Serine hydrolase-like protein 
DPP9 Dipeptidyl-peptidase 9 si:ch211-122f10.4 * Serine-type carboxypeptidase activity 
ESD S-formylglutathione hydrolase si:ch211-71n6.4 * Carboxylic ester hydrolase activity 
FAAH Fatty acid amide hydrolase si:ch211-93f2.1 * Carboxylic ester hydrolase activity 
FAAH2A Fatty-acid amide hydrolase 2a si:ch73-89b15.3 * Carboxylic ester hydrolase activity 
FAAH2B Fatty-acid amide hydrolase 2b si:dkey-21e2.16 * Serine-type endopeptidase activity 
FAP Fibroblast activation protein α SIAE Sialic acid acetylesterase 
LCAT Lecithin-cholesterol acyltransferase TRY Trypsin 
LIPF Lipase member F zgc:100868 * Serine-type endopeptidase activity 
LIPH Lipase member H zgc:112160 
* Serine-type endopeptidase activity 
* Chymotrypsinogen B1 like protein 
LOC562139 Chymotrypsinogen B1 like protein zgc:112285 * Serine-type endopeptidase activity 
LYPLA1 Lysophospholipase I zgc:154142 * Serine-type endopeptidase activity 
LYPLA2 Lysophospholipase II zgc:92041 * Serine-type endopeptidase activity 




Figure S1 (1/2) | Chemical proteomics analysis of (serine) hydrolases during zebrafish development. 











































































































































































































































































































































































































































































































































































































































Figure S1 (2/2) | Chemical proteomics analysis of (serine) hydrolases during zebrafish development. Zebrafish 
whole lysates from different development stages (0-5 dpf, 5 larvae/sample) were treated with MB108 and 
FP-biotin (10 µM each, 30 min, 28 °C), followed by chemical proteomics analysis. Samples boiled (1% SDS, 5 min, 
95 °C) prior to probe incubation served as negative control for each time point. Cut-offs for target selection: 
ratio positive over negative control ≥ 2, unique peptides ≥ 1, identified peptides ≥ 2 for at least one time point. 
Targets must be part of hydrolase target list and/or containing a GXSXG serine hydrolase motif. Data is 
expressed as absolute abundance (mean ± SEM and individual data points) for samples (black fill, n=6) or boiled 
controls (grey fill, n=4). Outliers as determined with a ROUT outlier test (5%) are depicted with open circles for 
non-boiled samples only. Undetected proteins in individual samples are not included in plots or calculations.  
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Table S2 | Identified kinase targets in zebrafish. Abbreviations and descriptions as annotated on uniprot.org. 
Protein  Description Protein Description 
AKT2 v-akt murine thymoma viral oncogene homolog 2 MINK1 Misshapen-like kinase 1 
AKT3A v-akt murine thymoma viral oncogene homolog 3a MYLKB Myosin light chain kinase b 
CAMK2D2 
Calcium/calmodulin-dependent protein kinase  
type II delta 2 chain 
NME2B.2 
NME/NM23 nucleoside diphosphate kinase 2b 
tandem duplicate 2  
CAMK2G1 
Calcium/calmodulin-dependent protein kinase 
(CaM kinase) II gamma 1 
PAK2A P21 protein (Cdc42/Rac)-activated kinase 2a 
CDK1 Cell division control protein 2 PAK2B p21 protein (Cdc42/Rac)-activated kinase 2b 
CDK2 Cyclin-dependent kinase 2 PGK1 Phosphoglycerate kinase (Fragment) 
CDK5 Cyclin-dependent kinase 5 PKMB Pyruvate kinase 
CDK9 Cyclin-dependent kinase 9 PRKAA1 Non-specific serine/threonine protein kinase 
CKBB Brain-subtype creatine kinase PRKACBA Protein kinase cAMP-dependent catalytic β a 
CKMA Creatine kinase, muscle a PRKACBB Protein kinase cAMP-dependent catalytic β b 
CKMB Ckmb protein RPS6KA1 Ribosomal protein S6 kinase 
GRK7A Rhodopsin kinase 1 RPS6KA2 Ribosomal protein S6 kinase 
GSK3AB Glycogen synthase kinase 3 alpha b RPS6KA3A Ribosomal protein S6 kinase 
GSK3B Glycogen synthase kinase 3 RPS6KB1B Ribosomal protein S6 kinase 
HCK Tyrosine-protein kinase SRC Proto-oncogene tyrosine-protein kinase Src 
MAK Male germ-cell associated kinase STK24B Serine/threonine kinase 24b  
MAP2K1 Mitogen-activated protein kinase kinase 1 STK25A Serine/threonine kinase 25a 
MAP2K2A Mitogen-activated protein kinase kinase 2 STK25B Serine/threonine kinase 25b  
MAP2K4A Mitogen-activated protein kinase kinase 4A STK26 Serine/threonine protein kinase 26 
MAP4K4 
Mitogen-activated protein kinase kinase  
kinase kinase 4 
STK3 Serine/threonine-protein kinase 3 
MAPK1 Mitogen-activated protein kinase STK38A Serine/threonine kinase 38a 
MAPK3 Mitogen-activated protein kinase STK38L Serine/threonine kinase 38-like 
MAPK9 Mitogen-activated protein kinase TBK1 TANK-binding kinase 1 
MAPK14 Mitogen-activated protein kinase TNIKB TRAF2 and NCK-interacting kinase b 
MAST1B Microtubule-associated serine/threonine kinase 1b YES1 Tyrosine-protein kinase yes 








Figure S2 (1/2) | Chemical proteomics analysis of kinases during zebrafish development. 

















































































































































































































































































































































































































































































































































































































































Figure S2 (2/2) | Chemical proteomics analysis of kinases during zebrafish development. Zebrafish whole lysates 
from different development stages (0-5 dpf, 5 larvae/sample) were treated with XO44 (10 µM, 30 min, 28 °C) 
and subsequently conjugated to biotin-azide (40 µM, 60 min, 28 °C), followed by chemical proteomics analysis. 
Vehicle treated sample served as negative control for each time point. Cut-offs for target selection: ratio 
positive over negative control ≥ 2, unique peptides ≥ 1, identified peptides ≥ 2 for at least one time point. 
Targets must be annotated as kinase in the Uniprot database. Data is expressed as absolute abundance (mean 
± SEM and individual data points) for samples (black fill,  n=6) or vehicle treated controls (grey fill, n=4). Outliers 
as determined with a ROUT outlier test (5%) are depicted as open circles for non-boiled samples only. 
Undetected proteins in individual samples are not included in plots or calculations.  
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target proteins of FAAH 
inhibitor BIA 10-2474 
ABSTRACT | A recent phase I trial of the fatty acid amide 
hydrolase (FAAH) inhibitor BIA 10-2474 led to the death 
of one volunteer and produced mild-to-severe 
neurological symptoms in four others. Although the cause 
of the clinical neurotoxicity is unknown, it has been 
postulated that, given the clinical safety profile of other 
tested FAAH inhibitors, off-target activities of BIA 10-2474 
may have played a role. The BIA 10-2474 interaction 
landscape was determined by activity-based proteomics 
and revealed that the drug inhibits several lipases that are 
not targeted by PF04457845, a highly selective and 
clinically tested FAAH inhibitor. BIA 10-2474, but not 
PF04457845, produced substantial alterations in lipid 
networks in human cortical neurons, suggesting that 
promiscuous lipase inhibitors have the potential to cause 







Severe adverse effects of drug candidates are rarely observed in phase I clinical trials, 
due to extensive preclinical toxicological profiling in animals and precautions taken into 
account in the design of first-in-human studies. However, in January 2016, a first-in-
human study of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474 led to the 
death of one volunteer and the hospitalization of four others1–4. All patients manifested 
mild-to-severe neurological symptoms3. In rodents, no obvious toxicological results 
were found with BIA 10-2474 that could predict the observed human clinical 
neurotoxicity. In a study on dogs treated for 13 weeks with BIA 10-2474, a dose-
dependent pulmonary toxicity was observed and two dogs from the subgroup receiving 
the highest dose were sacrificed4. An initial toxicology study in primates showed that 
the highest administered dose led to axonal dystrophy in the spinal bulb. A follow-up 
primate study led to the death of one animal and the sacrifice of several others for 
undisclosed ethical reasons4. However, these findings were not considered to be 
sufficiently concerning to abandon the first-in-human studies due to the large 
therapeutic window in preclinical studies of BIA 10-2474. 
 
Figure 1 | Chemical structures of FAAH inhibitor BIA 10-2474, its metabolite BIA 10-2639, and clinically safe FAAH 
inhibitor PF04457845. 
The BIA 10-2474 target enzyme FAAH is a membrane-bound serine hydrolase that 
degrades the endocannabinoid anandamide and related amidated lipids5–8. Three 
explanations for the clinical neurotoxicity of BIA 10-2474 have been proposed: (I) errors 
may have occurred in the clinical trial itself, either in the manufacturing or handling of 
the compound or in the conduct of the trial; (II) through its inhibitory effects on FAAH, 
BIA 10-2474 may have produced high levels of long-chain fatty acid amides (e.g. 
anandamide) and their oxygenated metabolites, which could potentially overstimulate 
cannabinoid CB1R8, TRPV19, and/or NMDA receptors10; or (III) BIA 10-2474 and/or its 
metabolites might have off-target activities. The first hypothesis was dismissed by the 
French authorities4. The second hypothesis is considered unlikely because other FAAH 
inhibitors, such as PF04457845, have exhibited favorable safety profiles in phase I and II 
clinical trials11,12. The third hypothesis has not been directly evaluated, because little or 
no information was available regarding the protein interaction profile of BIA 10-24741. 
BIA 10-2474 (Figure 1) contains an electrophilic imidazole urea that may react with 
the nucleophilic serine of FAAH and other serine hydrolases to form covalent and 
irreversible adducts. Based on previously developed chemical proteomic methods to 
map the interaction landscapes of (ir)reversible serine hydrolase inhibitors13–15, it was 
anticipated that the serine hydrolase targets of BIA 10-2474 could be identified and 
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compared to the selectivity profiles of clinical FAAH inhibitor PF04457845 (Figure 1), 
which has progressed to phase II trials without any serious adverse events16. 
BIA 10-2639, a confirmed metabolite in which the N-oxide is reduced to a pyridine 
(Figure 1)4 was investigated to compare inhibitor and metabolite activity. 
The interaction landscape of BIA 10-2474 was investigated by activity-based protein 
profiling (ABPP), a chemical proteomic method that employs active site-directed 
chemical probes to record the functional state of entire enzyme classes directly in native 
biological systems13–15. When coupled to fluorescent reporter groups, activity-based 
probes (ABPs) enable convenient visualization of enzyme activities in complex 
proteomes by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) 
and in-gel fluorescence scanning. When coupled to a biotin reporter group, ABPs enable 
affinity enrichment and identification of enzyme activities by mass spectrometry 
(MS)-based proteomics. In either format, ABPP serves as a versatile method to assess 
target engagement and proteome-wide selectivity for small-molecule inhibitors as 
pre-incubation of the proteome with an inhibitor will reduce the ABP labeling of proteins 
targeted by the inhibitor. 
Results  
BIA 10-2474 is a weak irreversible inhibitor of FAAH and ABHD6 in vitro 
Competitive and comparative gel-based ABPP was performed using two different 
probes: the broad spectrum serine hydrolase-directed fluorophosphonate-rhodamine 
(FP-TAMRA) and the tailored β-lactone probe MB064 that preferentially reacts with 
endocannabinoid related hydrolases diacylglycerol lipase α (DAGLα), α/β hydrolase 
domain containing protein 6 (ABHD6) and 12 (ABHD12), along with a handful of other 
enzymes14. Together, FP-TAMRA and MB064 provided a target engagement assay for 
FAAH and a broad array (>50) of other brain serine hydrolases. 
Human frontal cortex (GFi3) and cerebellum samples were acquired from three male 
donors (aged 49, 50, and 80 years old with a post-mortem delay of 4-8 h) without any 
history of neuropsychiatric illness or postmortem evidence of neuropathology. ABPP 
studies revealed that the membrane and soluble serine hydrolase content were 
overlapping but varied between these brain regions (Supplementary Figure S1). The 
identity of FAAH and other endocannabinoid hydrolases including DAGLα and ABHD6 
was confirmed with reference inhibitors by competitive ABPP (Supplementary Figure 
S2). In total, 49 and 56 fluorescent bands corresponding to putative serine hydrolases 





Figure 2 | Identification of FAAH and ABHD6 as in vitro targets of BIA 10-2474 by competitive ABPP on serine 
hydrolases. (A-F, H) Gel-based ABPP analysis of human cortex (GFi3) proteome incubated in vitro with vehicle 
or inhibitor BIA 10-2474, BIA 10-2639 or PF04457845 (10/50 µM, 30 min, 37 °C) and subsequently labeled with 
MB064 (250 nM) (A, B) or FP-TAMRA (500 nM) (B, D) (20 min, rt). The serine hydrolase activities were quantified, 
normalized for protein loading and expressed relative to control. Heat-map summary of all 49 quantified bands 
(E) and bar-graph depiction of BIA 10-2474 (off-)targets FAAH (F) and ABHD6 (H). (G) FAAH activity relative to 
vehicle treated control after incubation with BIA 10-2474, BIA 10-2639 or PF04457845 (1/10/50 µM,15 min, rt) 
as measured in a radiometric [14C]-anandamide assay on purified recombinant FAAH. (I) Dose response curve 
of BIA 10-2474 and PF04457845 on recombinant ABHD6, as measured in a natural substrate assay. (J-L) 
Chemical proteomics analysis of human cortex (GFi3 proteome), treated with BIA 10-2474 (J), BIA 10-2639 (K), 
or PF04457845 (L) (50 µM, 30 min, 37 °C) using probes MB108 or FP-biotin (10 µM, 60 min, rt). Data is expressed 
as a H/L ratio as compared to vehicle treated sample. (E-L) Data is expressed as mean ± SEM (E-H, J-L: n=3, K: 
n=4) with * p < 0.05, ** p < 0.01, *** p < 0.001 (two-tailed t-test). 
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The clinical trial subjects who developed neurological symptoms were exposed to a 
dosage of BIA 10-2474 that was 10 to 50 times higher than that required for blockade of 
FAAH activity in the clinical trial participants4. Inhibitor activity against FAAH and other 
serine hydrolases was therefore evaluated at two high concentrations (10 and 50 µM) 
in human brain soluble and membrane proteomes by gel-based competitive ABPP. 
Representative gel-based ABPP data are shown (Figure 2A-D, Figure 2A-D) alongside a 
heat map that summarizes the inhibitor-serine hydrolase interaction landscape (Figure 
2E, Supplementary Figure S3E).  
BIA 10-2474, BIA 10-2639, and PF04457845 all inhibited FAAH, with BIA 10-2474 
showing the weakest inhibitory effect (Figure 2F). In a radioactive substrate assay using 
[14C]-anandamide, the weak inhibitory activity of BIA 10-2474 and BIA 10-2639 was 
confirmed with IC50 values > 1 µM as compared to ± 0.01 µM for PF04457845 (Figure 
2G). Notably, BIA 10-2474 as well as its metabolite exhibited distinct off-target activity 
towards ABHD6 in the gel-based assay (Figure 2H), which was not observed for 
PF04457845. Moreover, BIA 10-2474 and its metabolite did not reduce the labeling of 
endocannabinoid hydrolases monoacylglycerol lipase (MGLL) and DAGLα (Figure 2E, 
Supplementary Figure S3E).  
The brain off-target profiles of FAAH inhibitors were confirmed and extended by 
performing ABPP coupled to high-resolution quantitative mass spectrometry (MS). This 
methodology allows for a more accurate quantification by avoiding the band overlap 
observed with the gel-based assays and enables screening of the inhibitors over a 
broader range of serine hydrolases. Quantitative MS confirmed complete inhibition of 
FAAH and validated ABHD6 as an off-target of BIA 10-2474 and its metabolite, but not 
of PF04457845 (Figure 2J-L). PPME1 was identified as a potential off-target of 
PF04457845 with a heavy/light ratio < 0.5 (Figure 2L). 
To confirm that the off-target ABHD6 identified by ABPP was inhibited in its catalytic 
activity, its activity was measured in a real-time fluorescence-based natural substrate 
assay17. BIA 10-2474 inhibited recombinant ABHD6-mediated hydrolysis of 2-AG with an 
IC50 of 22 ± 4 µM (n=4), whereas PF04457845 was inactive (IC50 > 100 µM) (Figure 2I). 
Notably, BIA 10-2474, BIA 10-2639 and PF04457845 did not cross-react with other 
proteins of the endocannabinoid system including DAGLα, DAGLβ, MGLL and N-acyl 
phosphatidylethanolamine phospholipase D (NAPE-PLD), nor with the 
endocannabinoid-binding TRP ion channels (Supplementary Tables S1, S2). 
The BIA 10-2474 interaction profiling was extended with three compounds in which 
an alkyne functionality was introduced at different positions in the molecule (AJ167, 
AJ179, AJ198) (Supplementary Figure S4A)18. The alkyne group serves as a ligation 
handle to introduce fluorescent reporter groups via copper(I)-catalyzed azide-alkyne 
cycloaddicition (“click”) chemistry19. Few additional labeled proteins were detected in 
human cortical and cerebellar proteomes (Supplementary Figure S4E-G) for which no 
competition was observed upon pre-incubation with BIA 10-2474, indicating limited 
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cross-reactivity of BIA 10-2474 with non-serine hydrolases in the brain proteome. 
Importantly, these experiments definitively prove covalent binding of AJ179 and AJ198 
to FAAH (Supplementary Figure S4B-C, E-F), which was maintained even under 
denaturing SDS-PAGE conditions, thereby supporting an irreversible reaction 
mechanism for BIA 10-2474. 
BIA 10-2474 inhibitory potency is drastically improved in situ 
As noted above, in the biochemical substrate assay using recombinant FAAH and 
gel-based ABPP experiments with human brain lysates, BIA 10-2474 exhibited weaker in 
vitro potency for FAAH compared to PF04457845. Notably, this difference was 
attenuated in situ, as our gel-based ABPP experiments revealed that BIA 10-2474 
inhibited FAAH, as well as other serine hydrolases (e.g., ABHD6 and FAAH2, which is a 
human-specific orthologue of FAAH20) with substantially increased potency in human 
cells (Figure 3). The reason for the increased cellular activity of BIA 10-2474 is at present 
unclear, but it was consistently observed in multiple cell types (data not shown) and with 
multiple protein targets of the compound, which may suggest that cellular accumulation 
of the compound results in greater than expected inhibitory activity against FAAH and 
other serine hydrolases. Previous chemical proteomic studies have uncovered similar 
effects for covalent kinase inhibitors21. 
 
Figure 3 | BIA 10-2474 inhibitory potency towards FAAH, FAAH2, and ABHD6 is increased in situ. (A-C) Dose 
response curves of BIA 10-2474 against FAAH, ABHD6 and FAAH2 in vitro and in situ. HEK293-T cells transiently 
overexpressing FAAH (A) or FAAH2 (B), or endogenously expressing ABHD6 (C) were treated in situ with vehicle 
or BIA 10-2474 (0.1 nM – 50 µM, 2 h, 37 °C), harvested and subsequently prepped as whole lysates (in situ 
samples, blue). Alternatively, membrane fractions from HEK293-T cells overexpressing recombinant FAAH and 
FAAH2 were mixed and in vitro incubated with vehicle of BIA 10-2474 (0.1 nM – 50 µM, 30 min, 37 °C) (in vitro 
samples, green). Subsequently, all samples were labeled with activity-based probe FP-TAMRA (500 nM, 20 min, 
RT). Remaining probe labeling was quantified, normalized for protein loading and expressed relative to vehicle 
treated sample. Data is expressed as mean ± SEM (Vehicle: n=6, BIA: n=3) and pIC50+ ± SD.  
BIA 10-2474 disrupts the neural lipid network by targeting multiple 
hydrolases 
In light of the increased in situ potency of BIA 10-2474, its off-target profile was 
investigated in human cortical neurons using gel-based ABPP studies. Apart from FAAH 
and ABHD6, three additional targets were identified with molecular weights of 
approximately 150, 62 and 47 kDa respectively (Figure 4A). Using chemical proteomics, 
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these off-targets were confirmed and identified as patatin-like phospholipase domain 
containing protein 6 (PNPLA6, also known as neuropathy target esterase (NTE)), 
carboxyl esterase 2 (CES2) and phospholipase 2 group XV (PLA2G15, also known as 
phospholipase A2 (LPLA2)) with a heavy/light ratio < 0.5 (Figure 4B).  
 
Figure 4 | In situ treatment of human neuronal cultures with BIA 10-2474 reveals additional off-targets and results 
in disruption of lipid homeostasis. (A-B) Human neuronal cultures were treated in situ with vehicle or BIA 10-
2474 (50 µM, 24 h, 37 °C). Lysates were labeled with activity-based probes MB064 (2 µM) or FP-TAMRA (500 
nM) (20 min, rt) for gel-based ABPP (A) or with MB108 or FP-biotin (10 µM, 60 min, rt) for chemical proteomics 
(B). (C-D) Dose response curves of BIA 10-2474 against CES2, PLA2G15 or PNPLA6 in situ. HEK293-T cells 
transiently overexpressing CES2, PLA2G15, or PNPLA6 were treated in situ with vehicle, BIA 10-2474 (0.1-100 
µM) (C), or PF04457845 (0.1 – 50 µM) (D) (24 h, 37 °C). Whole lysates were labeled with activity-based probe 
FP-TAMRA (500 nM, 20 min, rt). Remaining probe labeling was quantified, normalized for protein loading and 
expressed relative to vehicle treated sample. Data is expressed as mean ± SEM (vehicle: n=6, treated: n=3) and 
pIC50 ± SD. (E-F) Volcano plot of lipidomics analysis of human neurons treated in situ with vehicle, BIA 10-2474 
(50 μM) (E), or PF04457845 (1 µM) (F) (48 h, 37 °C). Lipids with a fold change (FC) threshold of ≥1.20 or ≤0.80 
and Benjamini–Hochberg false discovery rate (FDR) ≤ 25% are represented by colored circles distinguished by 
lipid class (n=3). 
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Most of the interaction partners of BIA 10-2474 identified in this study are known to 
be involved in cellular lipid metabolism22,23. To confirm the interaction of BIA 10-2474 
with its lipolytic serine hydrolase off-targets, these proteins were transiently 
overexpressed in HEK293-T cells and concentration-dependent in situ inhibition was 
assessed using gel-based ABPP (Figure 4C-D). BIA 10-2474, but not PF04457845, inhibits 
PNPLA6, CES2 and PLA2G15 with IC50-values of 11, 16 and 38 µM respectively. 
Based on the off-target profile of BIA 10-2474 it was postulated that prolonged 
exposure to BIA 10-2474 might result in alterations of human neuronal lipid metabolism. 
This hypothesis was tested by targeted lipidomics analysis of human cortical neurons 
treated with vehicle or BIA 10-2474. In total, 161 lipid species were quantified from 
which significant changes in several lipid classes were observed. Levels of 
N-acylethanolamines, triglycerides, monoacylglycerols, and (lyso)phophatidylcholines 
were increased in BIA 10-2474-treated cells, while those of free fatty acids and 
plasmalogens were reduced, consistent with the inhibition of FAAH, FAAH2, ABHD6, 
CES2, PLA2G15, and PNPLA6 activities (Figure 4E). Prolonged treatment with 
PF04457845 only affected lipid levels of a lysophosphatidylcholine and increased several 
N-acylethanolamines, consistent with FAAH and FAAH2 inhibition (Figure 4F). 
Discussion 
No information had previously been available regarding the protein interaction profile 
of BIA 10-2474 that could help in defining the cause of its clinical toxicity, and in 
particular to directly evaluate the possibility that the observed clinical neurotoxicity 
might have resulted from off-target activity1. Aided by chemical proteomic methods for 
mapping the interaction landscapes of serine hydrolase inhibitors13–15,24,25, the serine 
hydrolase target selectivity of BIA 10-2474 was compared to that of PF04457845, a 
widely used clinically safe FAAH inhibitor. Here, BIA 10-2474 was shown to be an 
irreversible, potent FAAH and FAAH2 inhibitor in situ, that increases cellular levels of 
long-chain fatty acid ethanolamines. Using human brain tissue lysates and cultured 
human cortical neurons and cell lines, multiple lipase off-targets of BIA 10-2474 
(including ABHD6, CES2, PLA2G15 and PNPLA6) were discovered that were not targeted 
by PF04457845. By targeting these lipases, BIA 10-2474 disrupted the neural lipid 
metabolism, resulting in increased levels of N-acylethanolamines, monoacylglycerols, 
triglycerides, (lyso)phosphatidylcholines, and reductions in free fatty acids and 
plasmalogens. When considering the basis for BIA 10 2474’s broader interaction profile 
with serine hydrolases compared to PF04457845, the greater intrinsic reactivity of 
BIA 10-2474, which is reflected in a much faster rate of methanolysis (data not shown), 
may have been a contributing factor. 
FAAH2 is a human orthologue of FAAH, which also degrades long-chain fatty acid 
amides20. However, little is known about the neurobiological function of FAAH2. CES2 is 
a serine esterase involved in the hydrolysis of ester and amide bonds of xenobiotics and 
prodrugs, but also of endogenous lipids. It is highly expressed in the liver and in 
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endothelial cells. Hepatic CES2 is required for triglyceride homeostasis by modulating 
lipolysis, ER stress and lipogenesis26. PLA2G15 is a lysosomal phospholipase highly 
expressed in alveolar macrophages and microglial cells. Inhibition of PLA2G15 leads to 
accumulation of phosphatidylcholines and phosphatidylethanolamines, and has 
previously been implicated in drug-induced phospholipidosis27. 
ABHD6 has a minor role in endocannabinoid 2-arachidonoylglycerol (2-AG) 
metabolism28, degrades bis(monoacylglycerol)phosphate29, and acts as a 
lysophosphatidyl hydrolase22,28. Independent of its catalytic function, ABHD6 exhibits a 
scaffolding function. Recently, proteomic experiments revealed that ABHD6 physically 
interacts with the C-terminal tail of the GluR1 subunit of the α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPAR), one of the major postsynaptic 
ionotropic glutamate receptors mediating excitatory synaptic neurotransmission in the 
central nervous system. Two independent groups have shown that ABDH6 is a potent 
negative regulator of cell surface trafficking of GluR1-containing AMPARs30,31. Some 
enzyme inhibitors are known to act as chemical chaperones increasing cellular protein 
levels by reducing proteolysis or enhancing protein biosynthesis and folding32. 
BIA 10-2474 might also act as a chemical chaperone to modulate ABHD6 protein levels, 
thereby possibly affecting AMPAR signaling in neuronal tissue. 
PNPLA6 has previously been linked to neurodegeneration in humans resulting from 
organophosphate-based pesticides23,33. PNPLA6 is a (lyso)phospholipase that uses 
(lyso)phosphatidylcholine as a substrate and is highly expressed in endothelial cells, 
astrocytes, and neurons. Proper neuronal phosphatidylcholine homeostasis mediated 
by PNPLA6 is required for axonal maintenance34. PNPLA6 inhibition leads to 
neurodegeneration following an age-dependent neuropathy of increasing severity in 
older age. Notably, PNPLA6-mediated neurotoxicity following acute organophosphate 
exposure is species dependent, with less pronounced effects in rodents than humans. 
Mice with a homozygous germline deletion of PNPLA6 have embryonic lethality due to 
placental and vasculature defects, however, brain-specific deletion of PNPLA6 results in 
prominent neuronal pathology35. A threshold of > 70% PNPLA6 inhibition has been 
determined as responsible for developing neurodegeneration upon organophosphate 
exposure in chicken23,33. It is remarkable that many clinical symptoms arising from 
PNPLA6-mediated neurological sequelae following organophosphate exposure 
resemble the neuropathology observed in the clinical trial participants3 who received a 
cumulative dose of 250-300 mg of BIA 10-2474, including precedent for human 
neurotoxicity, brain region sensitivity, age dependency, species selectivity, dosing 
threshold and time course of neuropathology. Additional experimental evidence and 
more detailed information from the Rennes’ clinical trial will be required to firmly 
establish the relative causality of the identified BIA 10-2474 off-targets. Importantly, 
based on this work it cannot be excluded that non-covalent interactions of BIA 10-2474 




Taken together, this study shows that BIA 10-2474 is a covalent irreversible and 
non-selective serine hydrolase inhibitor and highlights the disruption of cellular lipid 
networks as an important potential mediator of the observed neurotoxicity. The 
described data do not reveal whether inhibition of one or more of the identified 
BIA 10-2474’s off-target proteins (including FAAH2, ABHD6, PNPLA6, PLA2G15 and CES2) 
are responsible for the clinical neurotoxicity caused by this drug. However, the study 
does emphasize the general utility of ABPP as a versatile chemical proteomic method to 
assess on-target engagement and off-target activity of covalent drugs to guide 
therapeutic development. In retrospect, it appears likely that the implementation of a 
method such as ABPP might have permitted a safer clinical trial design for BIA 10-2474 
by establishing a dose range in which FAAH was inhibited, but still below the threshold 
for engaging off-target interactions.  
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Experimental procedures 
Materials, probes and inhibitors 
Activity-based probe TAMRA-fluorophosphonate (FP-TAMRA) was purchased from ThermoFisher, 
MB064 and MB108 were synthesized in-house as previously described24. PF04457845 was 
synthesized in house, as well as purchased from Sigma Aldrich. Inhibitors BIA 10-2474, BIA 10-
2639 and activity-based probes AJ167, AJ179, AJ198 were synthesized in-house as previously 
described18. All synthesized compounds were at least 95% pure and were analyzed by LC-MS, NMR 
and HRMS. Other chemicals, reagents, and primers were purchased from Sigma Aldrich unless 
indicated otherwise. 
Cloning 
Full-length human cDNA of ABHD6, FAAH, PNPLA6, PLA2G15, CES2 (Source Bioscience) and FAAH2 
(BioCat) was cloned into mammalian expression vector pcDNA3.1, containing genes for ampicillin 
and neomycin resistance. The inserts were cloned in frame with a C-terminal FLAG-tag and site-
directed mutagenesis was used to remove restriction sites by silent point mutations. Plasmids 
were isolated from transformed XL-10 Z-competent cells (Maxi Prep kit: Qiagen) and sequenced 




HEK293-T (human embryonic kidney) cells were cultured at 37 °C under 7% CO2 in DMEM 
containing phenol red, stable glutamine, 10% (v/v) new born calf serum (Thermo Fisher), and 
penicillin and streptomycin (200 µg/mL each; Duchefa). Medium was refreshed every 2-3 days and 
cells were passaged twice a week at 80-90% confluency by resuspension in fresh medium. Cell 
lines were purchased from ATCC and were regularly tested for mycoplasma contamination. 
Cultures were discarded after 2-3 months of use. 
Human neural cell culture 
Human iPSC-derived neural progenitor cells (NPCs) (Axol Biosciences, line ax0015) were plated on 
sterile coverslips in 12-well plates, coated with poly-L-ornithin/laminin (Sigma-Aldrich), in neural 
differentiation medium (Neurobasal medium, 1% N2 supplement, 2% B27-RA supplement, 1% 
MEM-NEAA, 20 ng/mL BDNF (ProSpec Bio)), 20 ng/mL GDNF (ProSpec Bio), 1 µM db-cAMP (Sigma-
Aldrich), 200 µM ascorbic acid (Sigma-Aldrich), 2 µg/mL laminin, and 1% P/S), resulting in neural 
networks composed of neurons and glia. Cells were refreshed with neural differentiation medium 
3 times per week. During weeks 1-4, medium was fully refreshed. After 4 weeks of neural 
differentiation, only half of the volume of medium per well was refreshed.  
Transient Transfection 
One day prior to transfection HEK293-T cells were seeded to 15 cm dishes or 12 wells plates 
(~62.500 cells/cm2). Prior to transfection, culture medium was aspirated and a minimal amount 
of medium was added. A 3:1 (m/m) mixture of polyethylenimine (PEI) (60 μg/dish or 
1.875 μg/well) and plasmid DNA (20 µg/dish or 0.625 µg/well) was prepared in serum free culture 
medium and incubated (15 min, rt). Transfection was performed by dropwise addition of the 
PEI/DNA mixture to the cells. Transfection with the empty pcDNA3.1 vector was used to generate 
control samples. After 24 h, medium was refreshed. Medium was aspirated 48 or 72 h 
post-transfection and cells were harvested by resuspension in PBS. Cells were pelleted by 
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centrifugation (5 min, 1,000 g) and the pellet was washed with PBS. Supernatant was discarded 
and cell pellets were frozen in liquid nitrogen and stored at -80 °C until sample preparation. 
In situ treatment 
In situ treatment was initiated 24 h (for 24-48 h treatment) or 48 h (for 2 h treatment) 
post-transfection in 12 wells plates. Medium was aspirated and medium containing inhibitor or 
DMSO as vehicle was added (0.1 - 1.0% DMSO, DMSO concentration constant within each 
experiment). Final concentrations for inhibitors are indicated in the main text and figure legends. 
After 2, 4, 24, or 48 h exposure to treatment medium, medium was aspirated and cells were 
harvested and stored as described above until sample preparation (whole cell lysate). 
Sample preparation 
Whole cell lysate 
Cell pellets were thawed on ice, resuspended in cold lysis buffer (20 mM HEPES pH 7.2, 2 mM DTT, 
250 mM sucrose, 1 mM MgCl2, 2.5 U/mL benzonase) and incubated on ice (15 min). The cell lysate 
was used for membrane preparation (below) or was diluted to appropriate concentration in cold 
storage buffer (20 mM Hepes, pH 7.2, 2 mM DTT) for use as whole lysate (HEK293-T: 2.0 mg/mL, 
neuronal cultures: 1.5 mg/mL). Protein concentrations were determined by a Quick Start™ 
Bradford Protein Assay (Bio-Rad) and diluted samples were flash frozen in liquid nitrogen and 
stored at -80 °C until further use. 
Tissue lysate 
Human Brain Tissue was supplied by the Netherlands Brain Bank and stored at - 80 °C until use. 
Tissues were thawed on ice, dounce homogenized in cold lysis buffer (20 mM HEPES pH 7.2, 2 mM 
DTT, 250 mM sucrose, 1 mM MgCl2, 2.5 U/mL benzonase) and incubated on ice (15 min), followed 
by two low-speed spins (3 min, 2500 g, 4 °C) to remove debris. The supernatant fraction was used 
for separation of the cytosolic and membrane fractions. 
Membrane preparation from lysate 
The membrane and cytosolic fractions of cell or tissue lysates were separated by 
ultracentrifugation (93,000 g, 45 min, 4 °C). The supernatant was collected (cytosolic fraction) and 
the membrane pellet was resuspended in cold storage buffer by thorough pipetting and passage 
through an insulin needle. Protein concentrations were determined by a Quick Start™ Bradford 
Protein Assay (Bio-Rad) and samples were diluted to 2.0 mg/mL with cold buffer (20 mM Hepes 
pH 7.2, 2 mM DTT), flash frozen in liquid nitrogen and stored at -80 °C until further use. FAAH and 
FAAH2 overexpression membranes were mixed in an appropriate ratio for ABPP (0.1 mg/mL : 1.0 
mg/mL). 
Activity-based protein profiling  
Direct activity-based probes 
Gel-based ABPP was performed and analyzed with minor adaptations on previously reported 
procedures24. In brief, for in vitro inhibition, human brain proteome or cell lysate was incubated 
with vehicle (2.5% DMSO) or inhibitor (final concentrations indicated in figure legends) (30 min, 
37 °C), followed by an incubation with the activity-based probe MB064 (250 nM, 2 µM) or FP-
TAMRA (500 nM) (20 min, rt). Lysates from in situ treated cells were directly incubated with 
activity-based probes. Reactions were quenched with Laemlli buffer (30 min, rt) and proteins 
(brain: 20 µg, HEK293-T: 10 µg, neurons: 7.5 µg) were resolved by SDS-PAGE (10% acrylamide gel, 
180 V, 75-80 min). In-gel fluorescence was scanned using Cy3 and Cy5 multichannel settings 
(605/50 and 695/55 filters, respectively) on a ChemiDoc imaging system (Bio-Rad) and stained 
with coomassie after scanning. Fluorescence was normalized to coomassie staining and quantified 
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with ImageLabTM software (Bio-Rad). Data was processed in Excel (Microsoft) and graphs and IC50 
fits were prepared with Graphpad Prism 7 (Graphpad). 
Two-step activity-based probes  
The two-step labeling was adapted from previously developed methods36. In brief, human brain 
proteome (80 µg in 40 µL, cytosol or membrane fraction) was pre-incubated with vehicle or 
inhibitor (50 μM, 30 min, 37 °C), followed by an incubation with the alkyne probe (50 μM, 30 min, 
37 °C) and subsequent conjugation to Cyanine-5-azide (Cy5-N3) by addition of 5 µL freshly 
prepared click mix (40 mM CuSO4·(H2O)5, 240 mM sodium ascorbate, 0.3 mM THPTA, 35 µM 
Cy5-N3) (60 min, rt). Proteins were precipitated by adding methanol (50 µL), chloroform (15 µL) 
and water (15 µL), mixed by brief vortexing and pelleted by centrifugation (10 min, 4000 rpm). 
The supernatant was removed and the pellet was washed twice with methanol (50 µL). The pellet 
was redissolved in Laemmli buffer (40 µL, 95 °C, 5 min) and 20 μg protein was resolved by SDS-
PAGE (10% acrylamide gel, 180 V, 75-80 min). In-gel fluorescence was scanned using Cy3- and Cy5- 
multichannel settings (605/50 and 695/55 filters, respectively) on a ChemiDoc imaging system 
(Bio-Rad) and stained with coomassie after scanning. 
Activity-based proteomics  
Activity-based proteomics was based on previously described procedures14. In summary, human 
GFi3 proteome (250 μg protein from cytosolic or membrane fraction) or human neurons (90 μg 
protein from whole lysate, in situ vehicle or inhibitor treated) was incubated with vehicle (2% 
DMSO) or inhibitor (BIA 10-2474 or PF04457845, 50 μM, 30 min, 37 °C). The proteome was labeled 
with MB108 or FP-Biotin (10 μM, 60 min, rt). The labeling reaction was quenched and after a 
chloroform/methanol precipitation, the precipitated proteome was resuspended in 6 M Urea / 
25 mM ammonium bicarbonate (15 min, rt). The proteome was reduced (10 µM DTT, 15 min, 
65 °C), alkylated (iodoacetamide, 40 mM, 30 min, rt), and subsequently heated with SDS (0.2%, 
5 min, 65 °C). Avidin-Agarose beads (50 µL of a 50% slurry / sample) were washed with PBS and 
incubated with the proteome (3 h, rt, shaking). Beads were isolated by centrifugation (2500 g, 
2 min) and washed with SDS-PBS (0.5% w/v) once and three times with PBS. After transfer to a 
low-binding Eppendorf tube, proteins were digested with sequencing grade trypsin (Promega) 
(500 ng per sample) in 250 µL OB-Dig buffer (100 mM Tris pH 8.0, 100 mM NaCl, 1 mM CaCl2, 2% 
acetonitrile) (37 °C, O/N, 900 rpm). The pH was adjusted with formic acid to pH 3 and beads were 
removed by filtration. Peptides were isotopically labeled by on stage-tip dimethyl labeling, with 
subsequent addition of 20, 20, 30, 30, and 40 µL of light (vehicle, L) or medium (inhibitor, H) 
reagent to the stage-tips. The centrifugation speed during labeling was adjusted to have a flow 
through time of approximately 5 min (400 - 1000 g) per labeling step. 
Targeted lipidomics 
Sample extraction 
Lipids were extracted from in situ treated human neurons (48 h, 50 μM BIA 10-2474, 1 µM 
PF04457845 or vehicle (0.25% DMSO)). The sample extraction was performed on ice. In brief, cell 
pellets with 1 million cells were transferred to 1.5 mL Eppendorf tubes, spiked with 10 µL each of 
deuterated internal standard mix for endocannabinoids (N-arachidonoylethanolamide (AEA)-d8, 
N-arachidonoyldopamine (NADA)-d8, N-docosahexaenoylethanolamide (DHEA)-d4, 
2-arachidonoylglycerol (2-AG)-d8, N-stearoylethanolamine (SEA)-d3, N-palmitoylethanolamine 
(PEA)-d4, N-linoleoylethanolamine (LEA)-d3 and N-oleoylethanolamine (OEA)-d4), positive apolar 
lipids (lysophosphatidylcholines (LPC)17:0, phosphatidylethanolamines (PE)17:0/17:0, 
phosphatidylcholines (PC)17:0/17:0, sphingomyelins (SM) d18:1/17:0, triglycerides (TG) 
17:0/17:0/17:0, ceramides (Cer) d18:1/17:0) and negative polar lipids (fatty acid (FA)17:0-d33), 
followed by the addition of ammonium acetate buffer (100 µL, 0.1 M, pH 4). After addition of 
methyl tert-butyl ether (1 mL), the tubes were thoroughly mixed for 4 min using a bullet blender 
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at medium speed (Next Advance), followed by a centrifugation step (5000 g, 12 min, 4 °C). Then 
925 μL of the upper methyl tert-butyl ether layer was transferred into clean 1.5 mL Eppendorf 
tubes. Samples were dried in a speed-vac followed by reconstitution in acetonitrile/water (50 μL, 
90/10, v/v). The reconstituted samples were centrifuged (14000 g, 3 min, 4 °C) before transferring 
into LC-MS vials. Each sample was injected on three different lipidomics platforms: 
endocannabinoids (5 µL), positive apolar lipids (2 µL) and for negative polar lipids (8 µL).  
LC-MS/MS Analysis for endocannabinoids 
A targeted analysis of 21 endocannabinoids and related N-acylethanolamines were measured 
using an Acquity UPLC I class Binary solvent manager pump (Waters) in conjugation with AB SCIEX 
6500 quadrupole-ion trap (QTRAP) (AB Sciex). Separation was performed with Acquity HSS T3 
column (1.2 x 100 mm, 1.8 µm) maintained at 45 °C. The aqueous mobile phase A consisted of 
2 mM ammonium formate and 10 mM formic acid, and the organic mobile phase B was 
acetonitrile. The flow rate was set to 0.4 mL/min; initial gradient conditions were 55% B held for 
2 min and linearly ramped to 100% B over 6 min and held for 2 min; after 10 s the system returned 
to initial conditions and held 2 min before next injection. Electrospray ionization-MS was operated 
in positive mode for measurement of 21 endocannabinoids and NAEs, and a selective Multiple 
Reaction Mode (sMRM) was used for quantification. 
LC-MS/MS analysis for positive apolar and negative polar lipids 
Both lipidomics methods are adapted and modified from previously published work37. In brief, 
these methods are measured on an Acquity UPLC Binary solvent manager pump (Waters) coupled 
to an Agilent 6530 electrospray ionization quadrupole time-of-flight (ESI-Q-TOF, Agilent, Jose, CA, 
USA) high resolution mass spectrometer using reference mass correction. The chromatographic 
separation was achieved on an Acquity HSS T3 column (1.2 x 100 mm, 1.8 µm) maintained at 40 °C 
for both methods. The positive polar lipids that include targets from different lipid classes 
including (lyso)phosphatidylcholines, triglycerides, ceramides. (Lyso)phosphatidylethanolamines 
and sphingomyelins were separated using a flow of 0.4 mL/min over a 16 min gradient. In positive 
mode, the aqueous mobile phase A consisted of 60/40 (v/v) acetonitrile/H2O with 10 mM 
ammonium formate, and the organic mobile phase B consisted of 10/90 (v/v) 
acetonitrile/isopropanol with 10 mM ammonium formate. The negative apolar lipids that 
constitute mainly free fatty acids and (lyso)phosphatidylcholines were separated with a flow of 
0.4 mL/min over 15 min gradient. In negative mode, the aqueous mobile phase A consisted of 
5/95 (v/v) acetonitrile/H2O with 10 mM ammonium formate, and the organic mobile phase B 
consisted of 99% (v/v) methanol with 10 mM Ammonium formate. The targets in both lipid 
methods were detected full scan (100-1000 m/z) in their respective ion charge mode. 
Activity assays 
Radiolabeled natural substrate assay FAAH 
The radiolabeled natural substrate based assay for human FAAH was performed as reported 
previously38. Anandamide (AEA) (Sigma Chemical) was purchased from Sigma Chemical Co., 
purified FAAH was obtained from Cayman Chemical, [14C-ethanolamine]-anandamide 
(60 Ci/mmol) was purchased from ARC. FAAH (2.5 μg per test) was pre-incubated with each 
compound (15 min, rt) and subsequently incubated with [14C-ethanolamine]anandamide (10 µM, 
15 min, 37 °C, in 500 μL of 50 mM Tris–HCl pH 9). The reaction was stopped by the addition of 
0.6 mL of ice-cold methanol/chloroform (2:1, v/v). The mixture was centrifuged (3000 g, 5 min), 
the upper aqueous layer was put in a vial containing liquid scintillation cocktail (Ultima Gold XR, 
Perkin Elmer Life Sciences) and radioactivity was quantified in a β-counter. 
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Natural substrate-based fluorescence assay ABHD6 
The natural substrate ABHD6 assay was performed as previously published39. 
Natural substrate-based fluorescence assay DAGLα/β  
The natural DAG substrate assay was performed as reported previously17. Standard assay 
conditions: 0.2 U/mL glycerol kinase (GK), glycerol-3-phosphate oxidase (GPO) and horseradish 
peroxidase (HRP), 0.125 mM ATP, 10 μM Amplifu™Red, 5% DMSO in a total volume of 200 μL. The 
assay additionally contained 5 μg/mL MGLL-overexpressing membranes, 100 μM SAG and 
0.0075% (w/v) Triton X-100, with a final protein concentration of 50 μg/mL. The mDAGLβ assay 
was performed as the hDAGLα assay, but assay buffer was supplemented with 5 mM CaCl2 and 
the SAG concentration was 75 μM. 
Natural substrate-based fluorescence assay MGLL 
The natural substrate MGLL assay was performed as previously published17. 
Surrogate substrate assay NAPE-PLD 
The surrogate substrate assay was based on a previously reported method40. The membrane 
protein fraction of HEK293-T cells transiently overexpressing NAPE-PLD was diluted to 0.4 mg/mL 
in assay buffer (50 mM Tris-HCl pH 7.5, 0.02% Triton X-100, 150 mM NaCl). The substrate PED6 
(10 mM, Invitrogen) was consecutively diluted in DMSO (25x) and in assay buffer (10x). The assay 
was performed in a dark Greiner 96 wells plate, end volume 100 μL. The membrane protein lysate 
(final concentration 0.04 mg/mL) was incubated with inhibitor or vehicle (30 min, 37 °C). A sample 
without membrane protein lysate was incorporated for background subtraction. Subsequently, 
substrate was added (PED6, final concentration: 1 μM) and the measurement is started 
immediately on a TECAN infinite M1000 pro (37 °C, scanning at 2 min intervals for 1 h: excitation 
485 nm, emission 535 nm). 
Radioligand displacement assays for cannabinoid receptors 
[3H]CP55940 displacement assays to determine the affinity for the CB1R and CB2R were 
performed as previously described25,41, with the following changes. Ligands of interest were 
incubated (25 °C, 2 h) with membrane aliquots containing 1.5 μg (CHOK1hCB2_bgal) membrane 
protein in 100 μL assay buffer (50 mM Tris–HCl, 5 mM MgCl2, 0.1% BSA, pH 7.4) with ~1.5 nM 
[3H]CP55940 per assay point. Non-specific binding was determined in the presence of 10 μM 
AM630. Filtration was performed on 96-well GF/C filters, each well presoaked for 30 min with 
25 μL 0.25% PEI, using a 96-wells Filtermate harvester (PerkinElmer). Filter-bound radioactivity 
was determined by scintillation spectrometry using a Microbeta® 2450 microplate counter 
(PerkinElmer). 
Fluorescent Ca2+ assays for TRP ion channels 
HEK293 (human embryonic kidney) cells stably overexpressing recombinant human TRPV1 or rat 
TRPA1, TRPV2, TRPV3, TRPV4, or TRPM8 were grown in 10 cm Petri dishes as mono-layers in 
minimum essential medium (MEM) supplemented with non-essential amino acids, 10% fetal 
bovine serum, 2 mM glutamine, and maintained at 5% CO2 at 37 °C. Quantitative real time analysis 
was carried out to measure TRP gene over-expression in transfected-cells (data not shown). On 
the day of the experiment, cells were loaded with the methyl ester Fluo-4 AM in MEM (4 μM in 
DMSO containing 0.02% Pluronic F-127, Invitrogen (dark, 1 h, rt) washed twice with Tyrode’s 
buffer (145 mM NaCl, 2.5 mM KCl, 1.5 mM CaCl2, 1.2 mM MgCl2, 10 mM d-glucose, and 10 mM 
HEPES, pH 7.4), resuspended in the same buffer and transferred (about 100,000 cells) to the 
quartz cuvette of the spectrofluorimeter (PerkinElmer LS50B equipped with PTP-1 Fluorescence 
Peltier System; PerkinElmer Life and Analytical Sciences) under continuous stirring. The effects on 
intracellular Ca2+ concentration ([Ca2+]i) before and after the addition of various concentrations of 
test compounds was measured by cell fluorescence (excitation: 488 nm, emission: 516 nm, 25 °C). 
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The effects of compounds were normalized against the response to ionomycin (4 µM) in each 
experiment. The increases in fluorescence in wildtype HEK293 cells were used as baseline and 
subtracted from the values obtained from transfected cells. Efficacy was defined as the maximum 
response elicited by the compounds tested and was determined by comparing their effect with 
the analogous effect observed with 4 µM ionomycin (Cayman), while the potency of the 
compounds (EC50) was determined as the concentration required to produce half-maximal 
increases in [Ca2+]i. Curve fitting (sigmoidal dose–response variable slope) and parameter 
estimation were performed with GraphPad Prism 6 (GraphPad). 
Antagonist/desensitizing behavior was evaluated by adding the test compounds in the quartz 
cuvette 5 min before stimulation of cells with agonists. In the case of human TRPV1-expressing 
HEK293 cells the agonist used was capsaicin (0.1 μM, in the case of SR141716A 10 nM was also 
used), which was able of elevating intracellular Ca2+ with a potency of EC50 = 5.3 ± 0.4 nM and 
efficacy = 78.6 ± 0.6%.  
For TRPV2, the rat TRPV2-HEK293 cells exhibited a sharp increase in [Ca2+]i upon application 
of lysophosphatidylcholine (LPC, 3 μM). The concentration for half-maximal activation was 3.40 ± 
0.02 μM and efficacy was 91.7 ± 0.5%. For TRPV3, rat TRPV3-expressing HEK293 cells were first 
sensitized with the non-selective agonist 2-aminoethoxydiphenyl borate (100 µM). 
Antagonist/desensitizing behavior was evaluated against thymol (100 μM), which showed an 
efficacy of 34.7 ± 0.2% and a potency of EC50 = 84.1 ± 1.6 µM. For TRPV4, the rat TRPV4-expressing 
HEK293 cells the agonist used was N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-
hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide 
(GSK1016790A), (10 nM), which was able of elevating intracellular Ca2+ with a potency of EC50 = 
0.46 ± 0.07 µM, and an efficacy of 51.9 ± 1.7%. For TRPM8, the rat TRPM8-expressing HEK293 
cells, antagonist/desensitizing behavior was evaluated against icilin at 0.25 μM and 0.10 μM. For 
icilin, efficacy was 75.1 ± 1.1 and potency EC50 = 0.11 ± 0.01 µM. For HEK293 cells stably 
overexpressing recombinant rat TRPA1, the effects of TRPA1 agonists are expressed as a 
percentage of the effect obtained with 100 μM allyl isothiocyanate (AITC), which showed a 
potency of EC50 = 1.41 ± 0.04 µM and an efficacy of 65.9 ± 0.5. 
The effect on [Ca2+]i exerted by agonist alone was taken as 100%. Data are expressed as the 
concentration exerting a half-maximal inhibition of agonist-induced [Ca2+]i elevation (IC50), which 
was calculated again using GraphPad Prism 6 (Graphpad). All determinations were performed at 
least in triplicate. Statistical analysis of the data was performed by analysis of variance at each 
point using ANOVA followed by the Bonferroni’s test. 
Statistical methods 
All statistical measures and methods are included in the respective figure or table captions. In 
brief: all data are shown as the mean ± SEM where applicable. A Student’s t-test (unpaired, two-
tailed) was used to determine differences between two groups. All statistical analyses were 
conducted using Excel (Microsoft) or GraphPad Prism 6 (Graphpad), and a p-value < 0.05 was 
considered significant throughout unless indicated otherwise. For the lipid profiling study 
(Figure 4E-F), a Benjamini-Hochberg correction (25% false discovery rate) was applied. 
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Supplementary data 
Table S1 | Remaining enzyme activities of endocannabinoid related enzymes. DAGLα, DAGLβ, MGLL, ABHD6 and 
NAPE-PLD relative to DMSO as vehicle and [3H]CP55940 displacement at overexpressing CB1R- and CB2R 
membranes (prefix h: human, prefix m: mouse). 
Inhibitor Remaining activity 
(% ± SD) 
Radioligand displacement 
(% ± SEM) 










 10 μM 102.7 ± 9.3 94.1 ± 4.3 117.9 ± 3.0 83.9 ± 8.2 96.9 ± 11.9 29.8 ± 1.5 6.0 ± 5.4 
30 μM 113.4 ± 4.0 102.9 ± 1.9 - 31.2 ± 13.2 - - - 










 10 μM 107.6 ± 2.6 94.5 ± 1.7 - 111.2 ± 8.3 89.0 ± 7.2 36.8 ± 4.1 13.4 ± 8.0 
30 μM 110.2 ± 3.2 102.1 ± 4.2 - 90.3 ± 11.2 - - - 










 10 μM 99.2 ± 8.7 105.5 ± 0.5 - 108.3 ± 21.6 98.6 ± 6.7 59.9 ± 2.5 51.5 ± 4.6 
30 μM 83.0 ± 8.4 106.2 ± 1.5 - 97.5 ± 26.7 - - - 
50 μM - - - - 70.2 ± 6.8 103.8 ± 4.6 86.4 ± 1.3 
Table S2 | Efficacy and affinity of compounds for TRPV-, TRPA1- and TRPM8-channels. 
 TRPV1 TRPV2 TRPV3 














BIA 10-474 < 10 > 20 μM < 10 > 20 μM < 10 > 20 μM 
PF04457845 < 10 > 20 μM < 10 > 20 μM < 10 > 20 μM 
BIA 10-2639 < 10 > 20 μM < 10 > 20 μM < 10 > 20 μM 
 TRPV4 TRPA1 TRPM8 












BIA 10-2474 < 10 > 20 μM < 10 > 20 μM > 20 μM 
PF04457845 < 10 > 20 μM < 10 > 20 μM > 20 μM 
BIA 10-2639 < 10 > 20 μM < 10 > 20 μM > 20 μM 
Table S3 | Lipids significantly altered by in situ BIA 10-2474 treatment of human cortical neurons. Lipids identified 
as significant based on t-test (with a post-hoc false discovery rate (FDR) correction applied using Benjamini-
Hochberg procedure) and fold changes are divided into their different classes together with their trend. All 
lipids had an FDR rate less than 25%. 
Lipid class Metabolites identified as significant due to treatment Effect 
Phosphatidylcholines (PC) C38:2, C38:6, C38:7, C40:6, C40:6, C40:7, C40:8 Increased 
Lysophosphatidylcholines 
(LPC) 
sn1&2: C14:0, C22:6, C16:0, C16:1, C18:0, C18:1, C18:2, C20:4 
Increased sn1: C18:2, C20:1, C20:2 C20:4, C22:6, C20:3 (ω3ω6) 
sn2: C14:0, C18:2, C20:4, C22:6, C20:3 (ω3ω6) 
Fatty acids C20:4 (ω6), C20:5 (ω3), C22:4, C25:5 (ω3ω6) Decreased 
Plasmalogen 
phosphatidylcholines (pPC) 
C36:4, C36:6, C38:4, C38:5, C38:7, C40:6 Decreased 
Triglycerides C46:1, C48:1, C48:2, C48:3, C50:1, C52:1, C54:1 Increased 
N-Acylethanolamines C20:4, C22:6, C18:1, C16:0, C16:1, C18:0 Increased 
Mono&di-acylglycerols sn1:C18:1, C18:2 & sn2: C18:1, C18:2 Increased 




Figure S1 | Serine hydrolase profiling in human brain proteome by comparative ABPP. (A-B) Labeling comparison 
between human cerebellum and cortex, membrane (M) and cytosol (C) fractions of three independent donors. 
Human proteome was labeled with MB064 (250 nM) (A) or FP-TAMRA (500 nM) (B) (20 min, rt).  
 
Figure S2 | Band identification in human brain proteome by competitive ABPP. (A-B) Human proteome 
(cerebellum and cortex, membrane fraction) was incubated with vehicle or reference inhibitors LEI10514, 
DH37625, JZL18442, JZL1958, WWL7043 (10 µM, 30 min, 37 °C) and subsequently labeled with MB064 (250 nM) 
(A) or FP-TAMRA (500 nM) (B) (20 min, rt). Inhibitor targets and identified bands are indicated in the figure. 
 
Probe MB064 (250 M)
Donor #1 #2 #3
Tissue Cerebellum Cortex Cerebellum Cortex Cerebellum Cortex








Probe FP-TAMRA (500 nM)
Donor #1 #2 #3
Tissue Cerebellum Cortex Cerebellum Cortex Cerebellum Cortex








- MGLL (M) 
- MGLL (M) 
- FAAH (M) 
- ABHD6 (M) 
- DAGLα (M) 
A B      
CoomassieCoomassie
Probe MB064 (250 nM)

























ABHD6 (38 kDa) x x x x x x
DAGLα (115 kDa) x x x x
DAGLβ (73 kDa) x x
FAAH (63 kDa) x x




















Probe FP-TAMRA (500 nM)

























ABHD6 (38 kDa) x x x x x x
DAGLα (115 kDa) x x x x
DAGLβ (73 kDa) x x
FAAH (63 kDa) x x
MGLL (33 kDa) x x x x
A B       
ABPP REVEALS OFF-TARGET PROTEINS OF FAAH INHIBITOR BIA 10-2474 
 77 
 
Figure S3 | Identification of FAAH and ABHD6 as in vitro targets of BIA 10-2474 by competitive ABPP on serine 
hydrolases. Gel-based ABPP analysis of human cerebellum proteome incubated in vitro with vehicle or inhibitor 
BIA 10-2474, BIA 10-2639 or PF04457845 (10/50 µM, 30 min, 37 °C) and subsequently labeled with MB064 
(250 nM) (A,-B) or FP-TAMRA (500 nM) (B, D) (20 min, rt). (E) Heat-map summary of all 56 quantified bands, 
normalized for protein loading and expressed relative to control (n=3). 
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Figure S4 | BIA 10-2474 interaction profiling by two-step labeling of human cortex and cerebellum with BIA-
derived two-step probes. (A) Chemical structures of BIA 10-2474 derived two-step probes AJ167, AJ179, and 
AJ198. (B, E) Two-step probe validation by competitive ABPP with BIA 10-2474 and AJ167, AJ179, AJ198. Human 
cortex (B) or cerebellum (E) membranes were incubated with vehicle, BIA 10-2474, or two-step probe (50 µM, 
30 min, 37 °C) and subsequently labeled with MB064 (250 nM) or FP-TAMRA (500 nM) (20 min, rt). (C-D, F-G) 
Competitive two-step ABPP with BIA 10-2474 and two-step probes. Human cortex (C-D) or cerebellum (F-G) 
proteome was incubated in vitro with vehicle or BIA 10-2474 (50 µM, 30 min, 37 °C) and subsequently labeled 
with two step probe (AJ167, AJ179 or AJ198) (50 µM, 30 min, 37 °C). Cy5-azide was conjugated to the bound 
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Identification of ABHD6 
as a diacylglycerol lipase 
ABSTRACT | The endocannabinoid 2-arachidonoyl-
glycerol (2-AG) is an important signaling lipid, which is 
involved in neuronal differentiation. This study aimed to 
identify the biosynthetic enzymes responsible for 2-AG 
production during retinoic acid (RA)-induced neurite 
outgrowth of Neuro-2a cells, a widely used cellular model 
for neuronal differentiation. First, it was confirmed that 
RA stimulation of Neuro-2a cells led to 2-AG production 
and neurite outgrowth. The diacylglycerol lipase (DAGL) 
inhibitor DH376 abolished 2-AG levels and delayed 
neuronal differentiation. Surprisingly, CRISPR/Cas9-
mediated knockdown of the 2-AG producing enzymes 
DAGLα and DAGLβ in Neuro-2a cells did not reduce 
cellular 2-AG levels, suggesting there are other enzymes 
capable of producing 2-AG in this cell line. Chemical 
proteomics revealed DAGLβ and β−hydrolase domain 
containing protein (ABHD6) as the only targets of DH376 
in Neuro-2a cells. Biochemical, genetic and lipidomic 
studies demonstrated that ABHD6 possesses 
diacylglycerol lipase activity in conjunction with its 
previously reported role as monoacylglycerol lipase. RA 
treatment of Neuro-2a cells resulted in a three-fold 
increase in ABHD6 activity, whereas DAGLβ activity was 
decreased. Thus, these data extend the role of ABHD6 as 
a MAG lipase to a DAG lipase and suggest it is involved in 







The endocannabinoid 2-archidonoylglycerol (2-AG) is an important signaling lipid in the 
central nervous system (CNS). It acts as a retrograde messenger that activates the 
presynaptic cannabinoid receptor type 1 (CB1R), thereby regulating neurotransmitter 
release. 2-AG is involved in a variety of physiological processes, including modulation of 
memory, energy balance and emotional states, such as stress and anxiety1. Biochemical, 
pharmacological and genetic studies have established diacylglycerol lipases α and β 
(DAGLα, DAGLβ) as the main biosynthetic enzymes that produce 2-AG in the brain by 
catalyzing the sn-1-specific hydrolysis of diacylglycerol (DAG) to generate 2-AG2 (Figure 
1). For example, congenital deletion of DAGLα or DAGLβ resulted in 80% and 50% 
reduction, respectively, of brain 2-AG levels in knockout (KO) mice as compared to 
wildtype (WT) littermates3. Pharmacological studies with covalent, irreversible, dual 
DAGL inhibitors, such as DH376 and DO34, showed that acute blockade of 2-AG 
biosynthesis in the mouse brain reduced neuroinflammatory responses4, reversed 
LPS-induced anapyrexia4, reduced food intake5 and modulated cocaine-seeking 
behavior6 and stress responses7.  
The life span of 2-AG signaling at the synapse is tightly controlled. Monoacylglycerol 
lipase (MGLL)8 and α,β-hydrolase domain containing protein 6 and 12 (ABHD6, ABHD12) 
have been identified as the key enzymes terminating the physiological role of 2-AG. They 
hydrolyze the ester bond in 2-AG, thereby generating glycerol and arachidonic acid 
(AA)9,10 (Figure 1). MGLL is the predominant lipase in the brain covering over 85% of 2-AG 
hydrolysis, whereas ABHD6 and ABHD12 account for 4 and 9%, respectively11.   
 
Figure 1 | Schematic overview of 2-AG signaling and metabolism. CB1R: Cannabinoid receptor type 1, DAGL: 
diacylglycerol lipase, MGLL: monoacylglycerol lipase, ABHD: α,β-hydrolase domain containing protein, DAG: 
diacylglycerol, 2-AG: 2-arachidonoyl glycerol, AA: arachidonic acid. 
2-AG signaling is not only important in the adult brain, but multiple studies have also 
provided evidence of a functional role of 2-AG during neural developmental processes12, 
including axonal growth and guidance2,13–15, differentiation16, and neurogenesis3,17. In 
adult mice, DAGLα is mainly restricted to postsynaptic sites on neurons, whereas DAGLβ 
is expressed in microglial cells, but during neuronal development their expression 
pattern is different. Both DAGLα and DAGLβ were found in neurons at developing axonal 
tracts2,14,17,18. Jung and colleagues have investigated the role of DAGLs in neuronal 
differentiation using retinoic acid (RA)-induced neurite outgrowth in murine 
neuroblastoma cell line Neuro-2a16. They found that RA elevated cellular 2-AG levels in 
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increased neurite outgrowth, whereas silencing the expression of DAGLs using shRNAs 
reduced the number of cells with neurites16. The contribution of the endogenously 
expressed DAGL enzymes to 2-AG biosynthesis in these cells is, however, less clear. 
Here, we sought to revisit this question and aimed to dissect the role of the two 
DAGL isoforms in 2-AG biosynthesis in Neuro-2a using pharmacological and genetic 
methods. Surprisingly, CRISPR/Cas9-mediated knockdown (KD) of DAGLα and/or DAGLβ 
did not reduce 2-AG levels in Neuro-2a, suggesting that other enzymes contribute to 
2-AG biosynthesis in these cells. Interestingly, treatment of the cells with the DAGL 
inhibitor DH376 almost completely abolished cellular 2-AG levels. Chemical proteomics 
of DH376-treated Neuro-2a revealed ABHD6 as the only other target of DH376. 
Additional biochemical, genetic and lipidomics studies showed that ABHD6 possesses 
diacylglycerol lipase activity, next to its previously reported role as monoacylglycerol 
(MAG) lipase. The identification of ABHD6 as a general lipase using both DAGs and MAGs 
as substrates, may have important implications for its proposed role in the 
endocannabinoid system. 
Results & Discussion 
To investigate the role of DAGL in neuronal differentiation, Neuro-2a cells were 
incubated with RA, which induced a time-dependent outgrowth of neurites (Figure 
2A-B). This was accompanied by increased cellular 2-AG levels as determined by liquid 
chromatography-mass spectrometry (LC-MS) (Figure 2C). These findings confirm the 
results of Jung et al.16. Of note, anandamide (AEA) and arachidonic acid (AA) levels were 
also significantly increased (Figure 2C). To check whether endogenously expressed 
DAGLs are responsible for the 2-AG production during differentiation, the cells were 
incubated with the dual DAGL inhibitor DH376. Cellular 2-AG and AA, but not AEA, levels 
were strongly reduced by DH376 (Figure 2D). The inhibitor also induced a significant 
delay in the differentiation of Neuro-2a cells, expressed as the fraction of neurite 
bearing cells after 24, 48, and 72 h of RA stimulation (Figure 2B). This suggested that 
DAGL-dependent 2-AG and/or AA production plays a role in the differentiation process, 
which is in line with the previous observations by Jung et al.16. 
To investigate which DAGL isoform is responsible for 2-AG production in Neuro-2a 
cells a genetic approach was used, because there are currently no subtype-specific DAGL 
inhibitors available. Of note, single cell heterogeneity (in 2-AG production and neurite 
outgrowth) prevented the unequivocal analysis of single cell clone knockouts 
(Supplementary Figure S1). Therefore, disruption of DAGL and DAGLβ  genes was 
performed by three sequential rounds of transfection of Cas9 and single guide RNA’s 
(sgRNA) in Neuro-2a cell populations (Supplementary Figure S2A-C). This yielded three 
different Neuro-2a knockdown (KD) populations: DAGLα KD, DAGLβ KD and 
DAGLα−β KD. DAGLα and DAGLβ activity in these cell populations was measured using 
activity-based protein profiling (ABPP) to determine the efficiency of the genetic 




fluorophosphonates (FP) or β-lactones) to assess the functional state of DAGLα and 
DAGLβ (and other serine hydrolases) in native biological systems. When coupled to 
fluorescent reporter groups, activity-based probes (ABPs) enable visualization of 
enzymatic activity in complex proteomes by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and in-gel fluorescence scanning. When coupled to a biotin 
reporter group, ABPs enable affinity enrichment and identification of enzyme activities 
by mass spectrometry (MS)-based proteomics. Gel-based ABPP with a fluorescent 
FP-probe (FP-TAMRA) and β-lactone probe MB064 showed a strong reduction (> 70%) 
of DAGLβ activity in the DAGLβ KD and DAGLα−β KD populations (Figure 3A-B), whereas 
other serine hydrolase activities were not affected. LC-MS-based chemical proteomics 
confirmed these findings (Figure 3C). Of note, no DAGLα activity was observed in either 
of the populations, including WT Neuro-2a (Figure 3A-B). The residual DAGLβ activity 
can be explained by a transfection efficiency below 100% and by insertion or deletion of 
a full codon upon Cas9-mediated DNA modification, thus preventing the frameshift that 
generally results in an early STOP-codon.  
 
Figure 2 | RA-induced differentiation increased cellular 2-AG levels and is delayed by DH376 treatment. (A-C) 
Neuro-2a cells were differentiated with RA (50 μM, 2% serum, 24-72 h) in the presence or absence of inhibitor 
DH376 (100 nM). (A) Phase contrast microscopy of representative differentiated and non-differentiated 
Neuro-2a cultures (72 h incubation). Scale bar: 50 µm. (B) Neuro-2a differentiation was quantified as the 
percentage of neurite bearing cells (mean ± SEM (n=3), t-test: *** p < 0.001 vehicle versus RA, # p < 0.05, ## p 
< 0.01 RA versus RA-DH376). (C) Lipidomics analysis on vehicle and RA-stimulated cells (72 h). Lipid abundance 
was normalized to the number of cells. Data is expressed as % of vehicle (mean ± SEM (n=5), t-test: 
*** p < 0.001). (D) Lipidomics analysis on in situ DH376-treated Neuro-2a (100 nM, 2 h). Lipid abundance was 
normalized for the amount of protein. Data is expressed as % of vehicle (mean ± SEM (Veh: n=8, DH376: n=4), 
t-test: * p < 0.05, *** p < 0.001). 
Next, the cellular 2-AG levels of these genetically modified Neuro-2a populations 
were determined using LC-MS. Surprisingly, despite having > 70% reduction in DAGLβ 
activity and no detectable DAGLα activity, the 2-AG levels in the DAGLα KD, DAGLβ KD 
or double DAGLα-β KD populations were not significantly different from WT populations 
(Figure 3C). To test whether the 2-AG production in the KD populations was still sensitive 
to DH376 treatment, the cells were incubated in situ with DH376 (100 nM, 2 h). 
Lipidomics analysis on these samples revealed that DH376 again abolished cellular 2-AG 
levels and reduced AA by 50% in all cell types (Figure 3C). Of note, a small but significant 
increase in AEA levels in the double DAGLα-β KD populations was observed (Figure 3C), 
which might be the result of increased ABHD4 activity (Figure 3D). Taken together, these 















































h             h             h
A                       B                                                 C                                         D











































































IDENTIFICATION OF ABHD6 AS A DAG LIPASE 
 
87 
which seems unlikely, or that an alternative, unidentified enzyme, which is sensitive to 
DH376, contributes to 2-AG biosynthesis in Neuro-2a cells.  
 
Figure 3 | DAGL KD did not alter 2-AG levels in Neuro-2a, whereas 2-AG was abolished by DAGL inhibitor DH376. 
(A-B) DAGL KD populations were analyzed by gel-based ABPP using probes MB064 (2 μM) and FP-TAMRA 
(500 nM) (20 min, rt). Coomassie served as protein loading control. (B) Probe labeling of DAGLβ was quantified 
and normalized for protein loading. Data is expressed as % of vehicle (mean ± SEM (WT: n=9, KD: n=3), t-test: 
*** p < 0.001). (C) Lipidomics analysis on WT and DAGL KD Neuro-2a populations treated in situ with vehicle or 
DH376 (100 nM, serum-free, 2 h). Lipid abundance was normalized for the amount of protein. Data is expressed 
as % of vehicle (mean ± SEM (WT: n=8, KD: n=4/2), t-test: * p < 0.05, ** p < 0.01, *** p < 0.001). (D) DAGL KD 
efficiency was assessed by chemical proteomics on WT and KD Neuro-2a cells using probes MB108 and FP-biotin 
(10 μM each, 30 min, 37 °C). Data is expressed as % of WT-vehicle (mean ± SEM (n=4), t-test with Holm-Sidak 
multiple comparison correction: * p < 0.05, ** p < 0.01, *** p < 0.001).  
To identify all 2-AG producing enzymes targeted by DH376 in Neuro-2a, a chemical 
proteomics strategy was employed. The alkyne moiety of DH376 served as a ligation 
handle to introduce a reporter group via a copper(I)-catalyzed azide-alkyne 
cycloaddition (“click” chemistry)19. Neuro-2a cells were incubated with DH376, lysed and 
the covalently bound inhibitor-targets were conjugated to Cy5-azide, resolved by 
SDS-PAGE and visualized by in-gel fluorescence scanning (Figure 4A-B). Apart from 
DAGLβ, one other fluorescent band with a molecular weight of ~ 35 kDa was observed. 
Competitive ABPP using MB064 and FP-TAMRA suggested that this fluorescent band 
could be ABHD6, which was previously also reported as an off-target of DH3764,20. To 
confirm the identity of this protein in Neuro-2a cells, chemical proteomics was 
employed (Figure 4C). DAGLβ and ABHD6 were identified as the only targets of DH376 
in Neuro-2a cells (Figure 4D). Thus, combined these data suggested that ABHD6 could 
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Figure 4 | DH376 targets DAGLβ and ABHD6 in Neuro-2a. Neuro-2a cells were treated in situ with vehicle or 
DH376 (100 nM, serum-free, 2 h) to investigate the DH376 interaction profile. (A, B) In situ DH376 targets were 
visualized by gel-based ABPP after conjugation of DH376 to Cy5-azide (5 μM, 60 min, rt) or with probe MB064 
(2 μM, 20 min, rt). Coomassie served as a protein loading control. (B) Probe labeling was quantified and 
normalized for protein loading. Data is expressed as % of vehicle (mean ± SEM (Veh n=9, DH376 n=3), t-test: 
*** p < 0.001). (C) Chemical proteomics enabled DH376 target identification. Lysates of in situ DH376-treated 
Neuro-2a cells were conjugated to biotin-azide (40 μM, 60 min, 37 °C). Vehicle treated samples served as a 
negative control. Data is expressed as absolute abundance (mean ± SEM (n=4), t-test: *** p < 0.001). (D) 
Competitive proteomics validated ABHD6 and DAGLβ as DH376 targets in in situ treated Neuro-2a cells, using 
probes MB108 and FP-biotin (10 μM each, 30 min, 37 °C). Data is expressed as % of WT-Vehicle (mean ± SEM 
(n=4), t-test with Holm-Sidak multiple comparison correction: *** p < 0.001). 
ABHD6 has previously been reported as a promiscuous lipase that not only uses 
2-AG, but also various lysophosphatidyl species21 and bis(monoacylglycero)phosphate22 
as substrates. Therefore, to confirm that ABHD6 can act also as a general lipase using 
DAG as a substrate, a DAG hydrolysis assay was developed based on fluorescent 
1-nitrobenzoxadiazole-decanoyl-2-decanoyl-sn-glycerol (NBD-DAG) substrate. Lysates 
from human embryonic kidney 293-T (HEK293-T) cells overexpressing recombinant 
human ABHD6 (Figure 5A) or its catalytically inactive mutant (ABHD6S148A) as a negative 
control, were incubated with NBD-DAG and analyzed by high performance thin layer 
chromatography (HPTLC). Lysates from HEK293-T cells expressing DAGLα or its 
catalytically inactive mutant (DAGLαS472A) served as positive and negative controls 
respectively (Supplementary Figure S3A). Both DAGLα and ABHD6 exhibited DAG-lipase 
activity as their overexpression resulted in the hydrolysis of NBD-DAG, whereas their 
mutants did not (Figure 5B-C, Supplementary Figure S3C-D), thereby showing that 
ABHD6 is able to hydrolyze the sn-1 ester bond of an sn-1-acyl-2-decanoyl-glycerol. Of 
note, the NBD-DAG hydrolysis observed in HEK293-T cells expressing GFP reflects 
conversion of the substrate by endogenous hydrolases, including ABHD6 and to a lesser 
extent DAGLβ. 
Click MB064 Merge
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Figure 5 | Recombinant ABHD6 possesses DAG-lipase activity in vitro and in situ. HEK293-T cells were transiently 
transfected with GFP, ABHD6, or its catalytically inactive serine mutant (S148A) and treated in situ with vehicle 
or DH376 (DH, 1 µM, 2 h, serum-free). (A) Protein activity and expression was confirmed by gel-based ABPP and 
western blot. Samples were subsequently incubated with probes MB064 (red; 500 nM, 10 min, rt), FP-BODIPY 
(green; 500 nM, 10 min, rt), and Cy5-azide click mix (blue; 2.5 μM, 30 min, rt). Coomassie served as a protein 
loading control. Western blot with mouse-anti-FLAG (1:2500, 45 min, rt) verified expression of the catalytically 
inactive protein. (B-C) Whole cell lysates were incubated with DAG-NBD (5 μM, 30 min, 37 °C), lipids were 
extracted and analyzed by HPTLC. (C) DAG hydrolysis was quantified and expressed as % of GFP (mean ± SEM 
(n=3), t-test: *** p < 0.001). (D) Lipid abundance of transfected and in situ treated cells was measured and 
normalized to the amount of protein. Data is expressed as % of GFP-Vehicle (mean ± SEM (n=4), t-test: 
* p < 0.05, ** p < 0.01). 
Next, it was determined whether ABHD6 could utilize endogenous DAGs in a cellular 
context. To this end, recombinant ABHD6 was overexpressed in HEK293-T cells (DAGLα 
as positive control and the catalytically inactive mutants as negative controls) and 
endogenous DAG (16:0, 20:4) levels were determined by targeted lipidomics (Figure 5D, 
Supplementary Figure S3D). Both ABHD6 and DAGLα overexpression reduced the levels 
of DAG (16:0, 20:4), whereas overexpression of the catalytically inactive mutants had no 
effect on the DAG-levels. DH376 treatment of the transfected cells prevented the 
reduction in DAG levels and even led to an increase in this lipid species, indicating that 
this DAG species serves also as an endogenous substrate for DAGLα/ABHD6. 
Overexpression of ABHD6 did not significantly affect 2-AG levels, in line with the dual 
MAG/DAG-lipase character of ABHD6, whereas its final product AA was increased 
(Figure 5D). In summary, these data indicate that ABHD6 is able to act as a DAG/MAG-
lipase using DAG (16:0, 20:4) as an endogenous substrate. 
To check whether endogenous cellular levels of 2-AG and AA are under control of 
ABHD6, a Neuro-2a ABHD6 KD population and a triple DAGLα-β-ABHD6 KD population 
were generated (Figure 6A, Supplementary Figure S2D-F). ABHD6 KD had no effects on 
2-AG or AA levels (Figure 6C), which suggests that DAGLβ and ABHD6 can compensate 
for each other. The KD efficiency at the protein level was reduced in the triple DAGLα-
DAGLβ-ABHD6 KD as compared to the single KDs as determined by gel-based ABPP 
(Figure 6A-B) and chemical proteomics (Figure 6D). It was estimated that approximately 
40-50% of ABHD6 activity was remaining, as well as 30-40% DAGLβ activity. In line with 
the reduced ABHD6 and DAGL activity in the triple KD, both 2-AG and AA levels were 
reduced by approximately 30%. 
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Figure 6 | Neuro-2a DAGLα-β-ABHD6 triple KD populations have decreased 2-AG levels. (A-B) ABHD6 and 
DAGLα-β-ABHD6 KD populations were analyzed by gel-based ABPP using probes MB064 (2 μM) and FP-TAMRA 
(500 nM) (20 min, rt). Coomassie served as a protein loading control. (B) Probe labeling was normalized for 
protein loading. Data is expressed as % of vehicle (mean ± SEM (WT: n=9, KD: n=3), t-test: *** p < 0.001). (C) 
Lipidomics analysis on WT and ABHD6 KD Neuro-2a populations treated in situ with vehicle or DH376 (100 nM, 
serum-free, 2 h). Lipid abundance was normalized for the amount of protein. Data is expressed as % of vehicle 
(mean ± SEM (WT: n=8, KD: n=4/2), t-test: * p < 0.05, ** p < 0.01, *** p < 0.001). (D) DAGL and ABHD6 KD 
efficiency was assessed by chemical proteomics on WT and KD Neuro-2a populations using probes MB108 and 
FP-biotin (10 μM each, 30 min, 37 °C). Data is expressed as % of WT-vehicle (mean ± SEM (n=4), t-test with 
Holm-Sidak multiple comparison correction: ** p < 0.01, *** p < 0.001). 
Finally, in light of the finding that ABHD6 can act as a DAG lipase, the DAGLβ and 
ABHD6 activity in Neuro-2a cells during RA-induced differentiation was mapped by 
gel-based ABPP (Figure 7A). A threefold increase in ABHD6 activity was observed in 
differentiated Neuro-2a cells, whereas DAGLβ activity was decreased (Figure 7B). These 
data indicate that the RA-induced 2-AG and AA production (Figure 1B) in Neuro-2a cells 
is due to increased ABHD6 activity.  
 
Figure 7 | DAGLβ activity decreased, while ABHD6 activity increased during RA-induced differentiation of 
Neuro-2a. Neuro-2a cells were stimulated by in situ treatment with retinoic acid (RA, 50 μM, 2% serum, 72 h). 
(A) Whole lysates of vehicle or RA stimulated cells were analyzed by gel-based ABPP using activity-based probes 
MB064 (2 μM) or FP-TAMRA (500 nM) (20 min, rt). Coomassie served as a protein loading control. (B) Probe 
labeling was normalized to loading control. Data is expressed as % of vehicle (mean ± SEM (n=3), t-test, 
*** p < 0.001). 
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DAGL-dependent endocannabinoid signaling is required for axonal growth and guidance 
in the developing brain. DAGLα and DAGLβ are reported as the main enzymes that 
produce the endocannabinoid 2-AG. It has been estimated that 10-20% of the 2-AG pool 
in mouse brain may result from alternative biosynthetic pathways. Here, ABHD6 is 
identified as an additional DAG lipase, which is supported by several lines of 
biochemical, genetic, and pharmacological evidence. First, genetic knockdown of both 
DAGL and DAGLβ in Neuro-2a cells had no effect on cellular 2-AG levels. Second, the 
dual DAGL/ABHD6 inhibitor DH376 completely abolished cellular 2-AG levels. Third, 
ABHD6 catalyzed the degradation of a fluorescent DAG substrate. Fourth, 
overexpression of ABHD6, but not its catalytically inactive mutant, reduced endogenous 
DAG (16:0, 20:4) levels, which was inhibited by DH376. Fifth, cellular 2-AG levels 
decreased upon triple KD of DAGLα-β-ABHD6 in Neuro-2a. These data thus extend the 
role of ABHD6 from a MAG lipase to a DAG lipase and suggest a role for ABHD6 in 





Materials, probes, and inhibitors  
Fluorophosphonate-rhodamine (FP-TAMRA) was purchased from Thermo Fisher, as well as 
synthesized in-house as previously described23. FP-Biotin was purchased from Santa Cruz 
Biotechnology. Fluorophosphonate-BODIPY (FP-BODIPY)23, MB06424, MB10824, and DH3764 were 
synthesized as previously described. All synthesized compounds were at least 95% pure and were 
analyzed by LC-MS, NMR, and HRMS. Primers were ordered from Sigma Aldrich or Integrated DNA 
Technologies. Other chemicals, reagents were purchased from Sigma Aldrich, unless indicated 
otherwise.  
Cloning general  
Full-length human DAGLα and ABHD6 cDNA (Source Bioscience) was cloned into the mammalian 
expression vector pcDNA3.1, containing ampicillin and neomycin resistance genes. The inserts 
were cloned in frame with a C-terminal FLAG-tag and site-directed mutagenesis was used to 
generate the catalytically inactive DAGLαS472A and ABHD6S148A mutants. pcDNA3.1 containing the 
gene for eGFP was used as a transfection control. Plasmids were isolated from transformed XL-10 
Z-competent cells (Midi/Maxi Prep, Qiagen) and sequenced at the Leiden Genome Technology 
Center. Sequences were analyzed and verified (CLC Main Workbench).  
Cell culture  
General  
Neuro-2a (murine neuroblastoma) and HEK293-T (human embryonic kidney) cells were cultured 
at 37 °C under 7% CO2 in DMEM containing phenol red, stable glutamine, newborn bovine serum 
(10% v/v; Thermo Fisher), and penicillin and streptomycin (200 μg/mL each; Duchefa). Medium 
was refreshed every 2-3 days and cells were passaged twice a week at ~ 90% confluence by 
resuspension in fresh medium. Cell lines were purchased from ATCC and were regularly tested for 
mycoplasma contamination. Cultures were discarded after 2-3 months of use.  
Single cell clone generation  
Single cell clones of Neuro-2a cells were generated by seeding cells at a density of 0.5, 1, 2, or 4 
cells per well in 96-wells plates. After several days, wells plates were screened for growth of single 
cell clones by phase-contrast microscopy (EVOS Auto FL2). Single cell clones were selected and 
expanded to full cultures.  
Transient transfections (HEK293-T)  
One day prior to transfection, HEK293-T cells were seeded at 1*106 cells/well in 6-wells plates or 
at 0.3*106 cells/well in 12-wells plates. Prior to transfection, culture medium was aspirated and a 
minimal amount of complete medium was added. A 3:1 (m/m) mixture of polyethyleneimine (PEI) 
and plasmid DNA (1.25 μg per 6-well, 0.625 μg per 12-well) was prepared in serum-free culture 
medium and incubated for 15 min at rt. Transfection was performed by dropwise addition of the 
PEI/DNA mixture to the cells. Transfection with pcDNA3.1 encoding GFP was used to generate 
control samples. 24 h Post-transfection culture medium was refreshed. In situ treatments were 
initiated 48 h post-transfection. Transfection efficiency was checked by fluorescence microscopy 
on eGFP transfected samples (EVOS FL2 Auto, GFP-channel).  
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In situ treatments  
Neuro-2a cells were seeded at appropriate density (0.3*106 cells/well in 12-wells plates, 2.5*106 
cells/dish in 6 cm dishes) 48 h prior to treatment. Alternatively, HEK293-T cells from transient 
transfections were used at 24-48 h post-transfection. Culture medium was aspirated and after a 
careful PBS wash, treatment medium (serum-free DMEM) containing vehicle (0.1% DMSO) or 
DH376 (100 nM – 1 µM, as indicated in figure legends) was added. After incubation for 2 h at 37 °C 
and 7% CO2, treatment medium was aspirated and cells were carefully washed with PBS. 
Subsequently cells were harvested by resuspension in PBS and spun down (1000 g, 3 min, rt). Cell 
pellets were flash frozen in liquid nitrogen and stored at -80 °C until further use.  
Retinoic acid stimulation  
Neuro-2a cells were seeded at 1*105 cells/well in 6-well plates or 1*106 cells/ dish in 10 cm dishes. 
One day after seeding, medium was aspirated and retinoic acid stimulation was initiated by adding 
DMEM containing 2% newborn bovine serum and all-trans-retinoic acid (50 μM) or vehicle 
(0.1% DMSO). For Figure 2D, co-treatment was done with vehicle (0.1% DMSO) or DH376 (100 
nM) throughout the entire differentiation process. After 24, 48 or 72 h of stimulation, neurite 
outgrowth was investigated using phase contrast microscopy (Olympus or EVOS FL2 Auto, phase 
contrast, large ring). Neurite outgrowth was quantified by counting the number of cells with a 
minimum of 2 outgrowth processes longer than the cell body, as a percentage of the total number 
of cells (3 dishes, 5 images per dish). Cell count and viability were checked by Trypan blue staining 
and automated cell counting (TC20TM Cell Counter, Bio-Rad).  
CRISPR/Cas9-mediated knockdowns  
Guide design & constructs  
Two sgRNA’s, in early exons, with high efficiency and specificity as predicted by CHOPCHOP v2 
online web tool25 (http://chopchop.cbu.uib.no) were selected. Guides were cloned into the BbsI 
restriction site of plasmid px330-U6-Chimeric_BB-CBh-hSpCas9 (gift from Feng Zhang, Addgene 
plasmid #42230) as previously described26,27. Constructs and primers are annotated in Table 1. 
Knockdown population generation  
Neuro-2a cells were transfected sequentially (3 times within the course of 10 days) to yield 
populations with a high knockdown efficiency. Cells were seeded at day 0, 3, and 6 and transfected 
at day 1, 4, and 7. Samples for T7E1 assays, and ABPP were harvested at day 2, 5, and 11 and after 
several weeks of culturing the cells. One day prior to the first transfection, Neuro-2a cells were 
seeded to a 6-well plate to reach 80% confluence at the time of transfection. Prior to transfection, 
culture medium was aspirated and 2 mL of fresh medium was added. A 5:1 (m/m) mixture of 
polyethyleneimine (PEI) (17.5 μg per well) and plasmid DNA (total 3.5 μg per well) was prepared 
in serum-free culture medium (250 μL each) and incubated (15 min, rt). Transfection was 
performed by dropwise addition of the PEI/DNA mixture to the cells. 24 h Post-transfection the 
culture medium was refreshed, a small amount of cells was harvested for analysis by T7E1 assay 
and ABPP, while the remainder was kept in culture under standard conditions for following 
transfections. After three transfection rounds, the cells were cultured according to standard 
protocol. Ampoules of knockdown populations were prepared (complete DMEM, 10% DMSO) and 
stored at -150 °C. Efficiency of knockdown was checked over time. Cells were discarded after 
3 months of culture.  
T7E1 assay  
Genomic DNA was obtained by mixing 50 μL QuickExtractTM (Epicentre) with cell pellet (~ 10% of 
a well from a 6-well plate). The samples were incubated at 65 °C for 6 min, mixed by vortexing and 
then incubated at 98 °C for 2 min. Genomic DNA extracts were diluted in sterile water and directly 




extract using Phusion High-Fidelity DNA Polymerase (Thermo Fisher) in Phusion HF buffer Green 
(Thermo Fisher) in a final volume of 20 μL, for primers see Table 1.  
For the T7E1 assay, genomic PCR products were denatured and reannealed in a thermocycler 
using the following program: 5 min at 95 °C, 95 to 85 °C using a ramp rate of -2 °C/s, 85 °C to 25 °C 
using a ramp rate of -0.2 °C/s. Annealed PCR product (8.5 μL) was mixed with NEB2 buffer (1 μL) 
and T7 endonuclease I (5 U, 0.5 μL; New England Biolabs), followed by a 30 min incubation at 
37 °C. Digested PCR products were analyzed using agarose gel electrophoresis with ethidium 
bromide staining. A sample without T7 endonuclease I was taken along as control. Agarose gels 
were analyzed using ImageLabTM Software (Bio-Rad) and DNA modification efficiency was 
expressed as percentage T7E cleavage (volume integral of digested bands / volume integral all 
bands * 100%). 
Table 1 | sgRNA targets, sgRNA oligos (top, bottom) and T7E1 primers (forward, reverse). Constructs indicated 
with an asterisk (*) were used to generate double and triple knockdowns.  
sgRNA Target Construct Primer Sequences 
Dagla – Exon 2 447* 
Top:      CACCGAGGATTACAAACCTGCAGAG 
Bottom: AAACCTCTGCAGGTTTGTAATCCTC 
Forward: GAACTTGGGGTCTTTTTGTCTG 
Reverse:  CAAGGAAGAACAGGTAACCAGG 
             – Exon 3 485 
Top:      CACCGCATGGCTGGCAGCTCTGGG 
Bottom: AAACCCCAGAGCTGCCAGCCATGC 
Forward: GGTAGTAGTTACTGCCGATGCC 
Reverse:  CTCTTCAGGGCTGACTCAGTTT 
Daglb – Exon 1 449* 
Top:      CACCGTGGGAGGTGCGCCATGCCG 
Bottom: AAACCGGCATGGCGCACCTCCCAC 
Forward: TTAAACAGAAATGACCACACCG 
Reverse:  CCTGGTTTCTATGAATTGCTCC 
             – Exon 2 450 
Top:      CACCGTGTATCTCACGCACAGAAGG 
Bottom: AAACCCTTCTGTGCGTGAGATACAC 
Forward:  CTCCTACATCTCTTGCTTGCCT 
Reverse:  ACACAAATGGTAGCGCAGTATG 
Abhd6 – Exon 2 724 
Top:      CACCGGTTAACATGTTTGTGATTG 
Bottom: AAACCAATCACAAACATGTTAACC 
Forward: GATCCATGGTATACCCCTAACCACTGAGTCATCTC 
Reverse:  TGACTCGAGATTGGAATGGCGATATGGTTACACT 
             – Exon 3 725* 




Whole lysate preparation  
Cells were harvested in PBS and pelleted by centrifugation (1000 g, 3-5 min, rt). Cell pellets were 
snap-frozen and stored at -80 °C until further use. Cell pellets were thawed on ice, resuspended 
in cold lysis buffer (20 mM HEPES pH 7.2, 2 mM DTT, 250 mM sucrose, 1 mM MgCl2, 2.5 U/mL 
benzonase) and incubated on ice (15-30 min). Protein concentrations were determined by a Quick 
StartTM Bradford Protein Assay (Bio-Rad). After dilution to 2 mg/mL in sucrose lysis buffer or 
storage buffer (20 mM HEPES pH 7.2, 2 mM DTT), samples were used or flash frozen in liquid 
nitrogen and stored at -80 °C until further use. DTT was left out of all buffers for samples intended 
for click-chemistry.  
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Activity-based protein profiling  
Gel-based ABPP: Single probe  
Whole lysate (2 mg/mL) was incubated with activity-based probes MB064 (250 nM - 2 μM, 20 min, 
rt) or FP-TAMRA (500 nM, 20 min, rt). The reaction was quenched with Laemmli buffer (30 min, rt) 
and 20 μg protein was resolved by SDS-PAGE (10% acrylamide gel) along with protein marker 
(PageRulerTM Plus, Thermo Fisher). In-gel fluorescence was detected in the Cy3- and Cy5-channel 
on a ChemiDocTM MP imaging system (Bio-Rad) and gels were stained with coomassie after 
scanning. Fluorescence was quantified and normalized to coomassie staining using ImageLabTM 
software (Bio-Rad) and data was processed in Excel (Microsoft) and GraphPad Prism 7 (GraphPad). 
Gel-based ABPP: Probe mixture  
Whole lysates (DTT-free, 2 mg/mL) were incubated with activity-based probe MB064 (2 μM, 10 
min, rt), followed by incubation with FP-TAMRA (500 nM, 10 min, rt) and a subsequent 
conjugation to Cy5-azide by incubation with click-mix (2.5/10 μM Cy5-N3, 67 mM sodium 
ascorbate, 4 mM CuSO4·(H2O)5, 1.3 mM THPTA; 30 min, rt). The reaction was quenched with 
Laemmli buffer (30 min, rt) and 15 μg protein was resolved by SDS-PAGE (10% acrylamide gel) 
along with protein marker (PageRulerTM Plus, Thermo Fisher). In-gel fluorescence was detected in 
the Cy3- and Cy5-channel on a ChemiDocTM MP imaging system (Bio-Rad) and gels were stained 
with coomassie after scanning. Fluorescence was quantified and normalized to coomassie staining 
using ImageLabTM software (Bio-Rad) and data was processed in Excel (Microsoft) and GraphPad 
Prism 7 (GraphPad).  
Chemical proteomics with label-free quantification  
The chemical proteomics workflow was modified from a previously published protocol20. In short, 
for general profiling of the serine hydrolases the whole lysates (250 µg protein, n=4) were 
incubated with serine hydrolase probe cocktail (10 µM MB108, 10 µM FP-Biotin, 30 min, 37 °C, 
300 rpm). A denatured protein sample (1% SDS, 5 min, 100 ˚C) was taken along as a negative 
control. For DH376 target identification, the whole lysates of DH376 treated cells (250 µg protein, 
n=4) were conjugated to biotin-azide by the addition of 10x concentrated click mix (final: 1 mM 
CuSO4(H2O)5, 0.56 mM sodium ascorbate, 0.2 mM THPTA, 0.04 mM biotin-azide in MilliQ) and 
subsequent incubation (60 min, 37 °C, 300 rpm). A vehicle treated sample was taken along as a 
negative control. Precipitation, alkylation, avidin enrichment, on-bead digestion and sample 
preparation was performed according to protocol20. Dried peptides were stored at -20 °C until 
LC-MS analysis. Prior to measurement, samples were reconstituted in 50 µL LC-MS solution and 
transferred to LC-MS vials. Analysis was performed using Progenesis QIP (Waters) as published, 
using the following cut-offs: ≥ 2-fold enrichment compared to negative control, ≥ 2 peptides, ≥ 1 
unique peptide, peptide ion correlations ≥ 0.7. 
Lipidomics  
Sample preparation: Neuro-2a retinoic acid stimulation  
Neuro-2a cells were seeded at 0.75*106 cells/dish in a 10 cm dish. One day after seeding, medium 
was aspirated and retinoic acid stimulation was initiated by adding DMEM containing 2% serum 
and retinoic acid (50 μM) or vehicle (0.1% DMSO). After 72 h neurite outgrowth was investigated 
using phase contrast microscopy (Olympus). Cells were carefully washed with PBS and harvested 
by resuspension in PBS (for retinoic acid stimulated cells, 5 dishes were combined to yield 
sufficient cells). Cells were pelleted (200 g, 10 min, rt) and resuspended in 1 mL PBS. Cell count 
and viability were checked by Trypan blue staining and automated cell counting (TC20TM Cell 
Counter, Bio-Rad) and 2*106 cells were pelleted (1000 g, 3 min, rt). Pellets were flash frozen in 




Sample preparation: Neuro-2a single cell clones  
Neuro-2a cells were seeded at 1.25*106 cells/ dish in a 10 cm dish. One day after seeding, medium 
was aspirated and cells were cultured in 2% serum and vehicle (0.1% DMSO). After 48 h cells were 
carefully washed with PBS and harvested by resuspension in. Cells were pelleted (200 g, 5 min, rt) 
and resuspended in PBS. Cell count and viability were checked by Trypan blue staining and 
automated cell counting (TC20TM Cell Counter, Bio-Rad) and 1*106 cells were pelleted (1000 g, 
3 min, rt). Pellets were flash frozen in liquid nitrogen and stored at -80 °C until lipid extraction.  
Sample preparation: Neuro-2a knockdown populations  
Neuro-2a cells were seeded at 2.5*106 cells/dish in a 6 cm dish 48 h prior to treatment. 
Alternatively, HEK293-T cells from transient transfections were used at 48 h post-transfection 
(6-wells format). Culture medium was aspirated and after a careful PBS wash, treatment medium 
(serum-free DMEM) containing vehicle (0.1% DMSO) or DH376 (100 nM) was added. After 
incubation for 2 h at 37 °C and 7% CO2, treatment medium was aspirated and cells were carefully 
washed with PBS. Subsequently cells were harvested by resuspension in 1250 μL PBS. Cell count 
and viability were checked by Trypan blue staining and automated cell counting (TC20TM Cell 
Counter, Bio-Rad). Cells from 1000 μL suspension were spun down (1000 g, 3 min, rt) in a low 
binding Eppendorf tube. Pellets were flash frozen in liquid nitrogen and stored at -80 °C until lipid 
extraction. The remaining cell suspension (~ 200 μL) was flash frozen and used to determine the 
protein concentration of each sample. The suspension was thawed on ice and cells were lysed by 
sonication using a probe sonicator (Heidolph; 5 s per sample, 10% amplitude). Protein 
concentrations (~ 1 mg/mL) were determined by a Quick StartTM Bradford Protein Assay (Bio-Rad) 
and were used for normalization of the lipid abundance. 
Lipid extraction  
Lipid extraction was performed as previously described28 with minor adaptations. In brief, cell 
pellets were transferred into 1.5 mL Eppendorf tubes, spiked with 10 μL of deuterated internal 
standard mix (Table 2), followed by addition of 200 µL of ammonium acetate buffer (0.1 M, pH 4) 
was added. After addition of 1000 μL methyl tert-butyl ether (MTBE), the tubes were thoroughly 
mixed for 5 min using a bullet blender (Next Advance) at medium speed, followed by a 
centrifugation step (16,000 g, 5 min, 4 °C). Then 850 μL of the upper MTBE layer was transferred 
to clean 1.5 mL Eppendorf tubes. Samples were dried in a SpeedVac (Eppendorf) followed by 
reconstitution in 50 μL of acetonitrile:water (90:10, v/v). The reconstituted samples were 
centrifuged (16,000 g, 3 min, 4 °C) before transferring into LC-MS vials. 5 μL of each sample was 
injected into the LC-MS/MS system. 
General LC-MS/MS Analysis  
LC-MS/MS analysis was performed as previously described28 with minor adaptations. A targeted 
analysis of 31 compounds, including endocannabinoids and related N-acylethanolamines 
(NAEs) and free fatty acids (Table 2), was measured using an Acquity UPLC I class Binary solvent 
manager pump (Waters) in conjugation with AB SCIEX 6500 quadrupole-ion trap (AB Sciex). The 
separation was performed with an Acquity HSS T3 column (2.1 × 100 mm, 1.8 μm) maintained at 
45 °C. The aqueous mobile phase A consisted of 2 mM ammonium formate and 10 mM formic 
acid, and the organic mobile phase B was acetonitrile. The flow rate was set to 0.55 mL/min; initial 
gradient conditions were 55% B held for 2 min and linearly ramped to 100% B over 6 min and held 
for 2 min; after 10 s the system returned to initial conditions and held 2 min before next injection. 
Electrospray ionization-MS and a selective Multiple Reaction Mode (sMRM) was used for 
endocannabinoid quantification. Individually optimized MRM transitions using their synthetic 
standards for target compounds and internal standards are described in Table 2. 
 




LC-MS/MS analysis of DAG (16:0, 20:4) was performed as described in the above section with the 
following adaptations. The mobile phase A was 10 mM ammonium formate and 10 mM formic 
acid in 60:40 (v/v%) acetonitrile:water, the mobile phase B was 10 mM ammonium formate and 
10 mM formic acid in 10:90 (v/v%) acetonitrile:isopropanol. The flow rate was set to 0.4 mL/min; 
initial gradient conditions were 50% B for 0.5 min and linearly ramped to 60% B at 2 min, then 
ramped to 90% B at 6 min; after 6 seconds the system returned to initial conditions and held 
1.4 min before next injection. 
Table 2 | LC-MS Standards and internal standards for lipidomics analysis. 
Standards 
Abbreviation Metabolite Q1 Q3 Polarity 
DAG (16:0, 20:4) 1-Palmitoyl-2-arachidonoyl-sn-glycerol 634 313 + 
1&2-AG 2&1-Arachidonoylglycerol (20:4) 379 287 + 
AEA Anandamide (20:4) 348 62 + 
DHEA N-Docosahexaenoylethanolamide (22:6) 372 62 + 
LEA  N-Linoleoylethanolamide (18:2) 324 62 + 
NADA N-Arachidonoyl dopamine (28:4) 440 137 + 
OEA N-Oleoylethanolamide (18:1) 326 62 + 
PEA N-Palmitoylethanolamide (16:0) 300 62 + 
SEA N-Stearoylethanolamide (18:0) 328 62 + 
2-AGE 2-Arachidonyl glycerol ether (20:4) 365 273 + 
DEA N-Docosatetraenoylethanolamide (22:4) 376 62 + 
DGLEA  Dihomo-γ-Linolenoyl Ethanolamide (18:3) 350 62 + 
O-AEA O-Arachidonoyl ethanolamine (20:4) 348 62 + 
2-LG    2-Linoleoyl glycerol (18:2) 355 263 + 
1-LG     1-Linoleoyl glycerol (18:2) 355 263 + 
2-OG     2-Oleoyl glycerol (18:1) 357 265 + 
EPEA Eicosapentaenoyl ethanolamide (20:5) 346 62 + 
POEA  N-Palmitoleoylethanolamide (16:1) 298 62 + 
ETAEA Eicosatrienoic acid ethanolamide (20:3) 350 62 + 
PDEA   N-Pentadecanoylethanolamide (15:0) 286 62 + 
α-LEA  N-α-Linolenylethanolamide (18:2) 322 62 + 
OA Oleic acid (18:1) 281 263 - 
LA Linoleic acid (18:2-ω6) 279 261 - 
α-LA α-Linolenic acid (18:3-ω3) 277 233 - 
γ-LA γ-Linolenic acid (18:3-ω6) 277 233 - 
DGLA Dihomo-γ-linolenic acid (20:3-ω6) 305 261 - 
MA Mead acid (20:3-ω9) 305 261 - 
AA Arachidonic Acid (20:4-ω6) 303 259 - 
EPA Eicosapentaenoic acid (20:5-ω3) 301 257 - 
DTA Docosatetraenoic acid (22:4-ω6) 332 288 - 
DHA Docosahexaenoic acid (22:6-ω3) 327 283 - 
Internal standards 
Abbreviation Metabolite  Q1 Q3 Polarity 
DAG  (34:0) 1-Margaroyl-2-margaroyl-sn-glycerol 614 327 + 
2-AG  (20:4)-d8 2-Arachidonoylglycerol-d8 387 294 + 
PEA    (16:0)-d4 Palmitoyl ethanolamide-d4 304 62 + 
SEA    (18:0)-d3 Stearoyl ethanolamide-d3 331 62 + 
OEA   (18:1)-d4 Oleoyl ethanolamide-d4 330 66 + 
LEA    (18:2)-d4 Linoleoyl ethanolamide-d4 328 66 + 
AEA   (20:4)-d8 Arachidonoyl ethanolamide-d8 356 62 + 
DHEA (22:6)-d4 Docosahexaenoyl ethanolamide-d4 376 66 + 





NBD-HPTLC assay  
Whole lysates of HEK293-T transiently expressing eGFP (control), DAGLα, ABHD6 or their 
catalytically inactive serine mutants were prepared as described above. Lysate (100 μg protein) 
was mixed with 5 μM DAG-NBD (Cayman Chemical; 2 mM stock in EtOH) in HEPES buffer (20 mM 
HEPES pH7.2, 2 mM DTT) and incubated (30 min, 37 °C, 600 rpm, dark). As a control, a sample 
without protein was taken along. After incubation, lipids were extracted by a Bligh and Dyer 
extraction. In short, 800 μL chloroform:methanol (1:1, v/v) and 110 uL MilliQ were added to the 
sample. Phases were separated by centrifugation (5 min, 13,000 g) and the bottom layer was 
transferred to a dark Eppendorf tube. The upper layer was extracted once more by adding 400 μL 
chloroform. The lipid extract was dried in a speedvac (Eppendorf) (45 min, 45 °C). Lipids were 
reconstituted in 40 μL methanol, and lipids (2 μL, n=3) were separated by thin layer 
chromatography on HPTLC Silica gel 60 plates (Merck) using chloroform:methanol (80:20, v/v) as 
eluent. NBD-labeled lipids were detected using a Typhoon Imaging system (GE Heatlhcare 
Bio-Science) (Alexa488 channel, 250V). Fluorescence was quantified using ImageLabTM software 
(Bio-Rad). Excel (Microsoft) and GraphPad Prism 7 (GraphPad) were used for further analysis. 
DAG-NBD was expressed as fraction of the total NBD intensity in each lane and normalized to eGFP 
samples.  
Western blot  
Cell lysates were denatured with Laemmli buffer (30 min, rt) and 20 μg lysate was resolved on a 
10% acrylamide SDS-PAGE gel along with PageRulerTM Plus Protein Marker (Thermo Scientific). 
Proteins were transferred to 0.2 μm polyvinylidene difluoride membranes by Trans-Blot Turbo™ 
Transfer system (Bio-Rad). Membranes were washed with TBS (50 mM Tris, 150 mM NaCl) and 
blocked with 5% milk in TBS-T (50 mM Tris, 150 mM NaCl, 0.05% Tween 20) (1 h, rt). Membranes 
were then incubated with primary antibody mouse-anti-FLAG (F3156, Sigma Aldrich; 1:2500 in 5% 
milk in TBS-T, 45 min, rt) washed with TBS-T, incubated with secondary donkey-anti-mouse-
Alexa647 (A-31571, Thermo Fisher; 1:10000 in 5% milk TBS-T, 45 min, rt), and washed with TBS-T 
and TBS. Fluorescence was detected on the ChemiDocTM MP imaging system (Bio-Rad) in the 
Alexa647 channel, and Cy3/Cy5 channels for the protein marker. Signal was normalized to 
coomassie staining using ImageLabTM software (Bio-Rad) and data was processed in Excel 
(Microsoft) and GraphPad Prism 7 (GraphPad). 
Statistical methods 
All statistical measures and methods are included in the respective figure or table captions. In 
brief: all data are shown as the mean ± SEM, unless indicated otherwise. A Student’s t-test 
(two-tailed, unpaired) was used to determine statistical significance, with a Holm-Sidak 
multi-comparison correction for proteomics data using GraphPad Prism 7 (GraphPad). Samples 
were compared to WT/Vehicle/GFP controls and statistical significance is indicated as * p < 0.05, 
** p < 0.01, *** p < 0.001. 
 
  





Figure S1 | Neuro-2a single cell clones have diverging phenotypes and lipid profiles. (A) Neuro-2a and Neuro-2a 
single cell clones (SCCs) show a diverging extent of neurite outgrowth upon treatment with retinoic acid (50 μM, 
0.1% DMSO, 2% serum, 48 h). -/±/+ indicate the state of neurite outgrowth as compared to the mixed culture 
under the same conditions. Scale bar: 50 μm. (B) WT Neuro-2a and six different WT Neuro-2a single cell clones 
(SCCs) were analyzed by gel-based ABPP using probes MB064 (250 nM) and FP-TAMRA (500 nM) (20 min, rt). 
Coomassie served as a protein loading control. (C) Heat map summary of lipidomics performed on Neuro-2a 
and Neuro-2a SCCs revealed variation in lipid abundance between clones. Lipid abundance was normalized to 
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Figure S2 | Efficiency of CRISPR/Cas9-mediated knockdown in Neuro-2a. Knockdown populations were generated 
by three sequential transfections (T1-T3) with Cas9 and two different separate guides for each target. Most 
efficient guides were used to generate double and triple knockdowns. (A-B, D-E) Knockdown efficiency is 
determined by a T7E1 assay on genomic DNA was analyzed after each round of transfection and quantified for 
DAGL (A-B) and ABHD6 (D-E) knockdowns. (C, F) ABPP analysis of knockdown efficiency. After each transfection, 
whole lysates were incubated with MB064 (2 μM, 20 min, rt) and analyzed by SDS-PAGE.  
 
Figure S3 | Recombinant DAGLα possesses DAG-lipase activity in vitro and in situ. HEK293-T cells were transiently 
transfected with GFP, DAGLα or its catalytically inactive serine mutants (S472A) and treated in situ with vehicle 
or DH376 (DH, 1 µM, 2 h, serum-free). (A) Protein activity and expression were confirmed by gel-based ABPP 
and western blot. Samples were subsequently incubated with probes MB064 (500 nM, 10 min, rt), FP-BODIPY 
(500 nM, 10 min, rt), and Cy5-azide click mix (2.5 μM, 30 min, rt). Coomassie served as a protein loading control. 
Western blot with mouse-anti-FLAG (1:2500, 45 min, rt) verified expression of the catalytically inactive protein. 
(B-C) Whole lysates were incubated with DAG-NBD (5 μM, 30 min, 37 °C, 600 rpm). Lipids were extracted and 
analyzed by HPTLC (n=3). DAG hydrolysis was quantified and expressed as % of GFP (mean ± SEM (n=3), t-test: 
*** p < 0.001). (D) Lipid abundance of transfected and in situ treated cells was measured and normalized to the 
amount of protein (n=4). Data is expressed as % of GFP-Vehicle (mean ± SEM (n=4), t-test: * p < 0.05, ** p < 
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The aim of this thesis was to explore activity-based protein 
profiling (ABPP) as a tool in drug discovery and cell biology.  
Chapter 1 discussed the different phases of the drug 
discovery process, such as target discovery and hit 
identification. ABPP is introduced as a versatile chemical 
tool, which may aid in addressing these challenges. ABPP 
employs active site-directed probes to assess the functional 
state of an entire enzyme class (e.g. serine hydrolases and 
kinases) in complex protein samples. Fluorescently labeled 
activity-based probes (ABPs) allow rapid analysis of the 
functional state of the enzymes by in-gel fluorescence 
scanning, whereas probes with affinity tags enable target 
enrichment and identification by mass spectrometry 
(MS)1,2. The ABPP methodology can be used in a 
comparative setup to map the activity landscape of 
different biological samples (e.g. healthy versus diseased) 
(Figure 1A). Alternatively, a competitive setup with 
inhibitors can be used for target engagement studies or 
selectivity profiling (Figure 1B).  
The serine hydrolases play a central role in the research 
performed in this thesis. They represent a large protein 
family (~ 1% of the mammalian proteome) and are involved 
in a broad spectrum of physiological processes, including 
signaling and metabolism2. In the described work, a special 
focus was set on the serine hydrolases of the 
endocannabinoid system (ECS), which were also introduced 
in Chapter 1.  




The ECS regulates a broad spectrum of physiological and pathological processes, 
including memory, pain, anxiety, appetite, metabolism and inflammation. The versatile 
role of the ECS in physiology makes the ECS interesting for therapeutic exploitation3,4. 
The ECS is comprised of the cannabinoid receptor type 1 and 2 (CB1R, CB2R), their 
endogenous ligands, the endocannabinoids 2-arachidonoylglycerol (2-AG) and 
anandamide (AEA), and their metabolic enzymes5. Diacylglycerol lipase α and β (DAGLα, 
DAGLβ) are the two main 2-AG biosynthetic enzymes6. Monoacylglycerol lipase (MGLL) 
and α,β-hydrolase domain containing protein 6 and 12 (ABHD6, ABHD12) can terminate 
2-AG signaling by its hydrolysis to arachidonic acid (AA) and glycerol7–10. There are 
multiple AEA biosynthetic pathways, but hydrolysis of N-acylphosphatidyl-
ethanolamines (NAPEs) to N-acylethanolamines (NAEs, including AEA), by NAPE 
phospholipase D (NAPE-PLD) is considered to be the canonical pathway11. Fatty acid 
amide hydrolase (FAAH) hydrolyzes the NAEs to ethanolamines and free fatty acids12,13. 
With the exception of NAPE-PLD, all endocannabinoid metabolic enzymes are part of 
the serine hydrolase family.  
 
Figure 1 | Schematic representation of competitive (A) and comparative (B) ABPP. 
Chapter 2 demonstrated comparative ABPP as a tool for rapid mapping of the serine 
hydrolase activity profile in ischemic cardiac tissue. The endocannabinoids and their 
receptors have emerged as important modulators of the cardiovascular system, 
especially under diseased conditions14–16. The role of endocannabinoid metabolizing 
enzymes, however, has been investigated less extensively. Cardiac tissues from patients 
with terminal-stage heart failure (due to previous ischemic pathology) and non-failing 
control hearts were used to determine the endocannabinoid levels and the activity of 
the endocannabinoid hydrolases. mRNA expression of DAGLβ, MGLL, ABHD6 and 
NAPEPLD was decreased in the ischemic tissues. Two subgroups were identified within 
the ischemic group by lipidomics and ABPP analysis; the first similar to control hearts 
and the second with reduced levels of the endocannabinoid 2-AG and drastically 
increased levels of AEA, NAEs and free fatty acids. The aberrations in the lipid profile 
were accompanied by decreased activity of 13 hydrolases, including the 2-AG hydrolytic 
enzyme MGLL. The distinct profiles of the two ischemic subgroups indicate the existence 
A   B
Purification
and/or analysis







X      Y
SUMMARY & FUTURE PROSPECTS 
 
105 
of differential biological states and may be related to more severe cardiac damage in the 
second subgroup, based on the significant reduction in cardiac output and the increase 
in systemic vascular resistance within this patient group.  
In a similar setup as described in Chapter 2, comparative ABPP has contributed to 
the discovery of novel therapeutic targets or biomarkers for a variety of clinical 
indications. For example, in cancer research, the strength of the technique was 
demonstrated by the identification of enhanced MGLL activity in aggressive human 
cancer cells and primary tumors. Overexpression of MGLL in non-aggressive cancer cells 
increased their pathogenicity and the effects could be reversed with a MGLL inhibitor17. 
Similarly, elevated levels of KIAA1363 activity were detected in aggressive cancer cells. 
Inhibition of this hydrolase disrupted lipid metabolism in cancerous cells, thereby 
impairing cell migration and tumor growth in vivo18. Upon further investigation, MGLL 
and KIAA1363 may serve as biomarkers for tumor malignancy and as therapeutic targets 
for the treatment of certain aggressive tumors.  
In Chapter 3, the ABPP methodology was extended to an in vivo model system. 
Recently, the zebrafish (Danio rerio) has emerged as a model system for embryonic 
development.19,20 Furthermore, zebrafish larvae are increasingly used as a pre-clinical 
vertebrate model in drug discovery21,22 and toxicological screening23–25. Thus far, most 
biochemical studies were limited to protein26,27 and gene expression28,29 profiles, 
whereas the protein activity component was often not taken into account. This 
limitation was addressed in Chapter 3, which described the development of an ABPP 
method for broad-spectrum profiling of serine hydrolase and kinase activity in zebrafish 
larvae. ABPP coupled to MS-analysis enabled the identification and mapping of 45 
hydrolases (including ECS-related MGLL, ABHD6a, ABHD12 and FAAH2a) and 51 kinases 
throughout early zebrafish development (0-5 days post fertilization). The number of 
detected hydrolases and kinases increased during development and could be correlated 
to specific developmental processes. Chapter 3 also showcased how zebrafish larvae can 
be used as pre-clinical animal model for in vivo target engagement and selectivity 
screening. FAAH inhibitor PF04457845 was used in a competitive ABPP setup and was 
found to be a highly selective compound. Inhibitor uptake and downstream effects on 
the lipid profile were confirmed using MS-based methods.  
Phenotypic screening in intact animals, rather than in a single cell type, takes the 
complexity of the complete organism into account. For example, dorsomorphin, an 
inhibitor of the bone morphogenetic protein (BMP) (ALK8 in zebrafish, ALK2 in humans), 
was discovered in a phenotypic screen, because it triggered dorsalization in early 
zebrafish embryogenesis. Its target was identified based on phenotypic similarity to 
larvae carrying a genetic Alk8 mutation21,30. The large collection of zebrafish phenotypes 
associated with specific genetic mutations has been an effective tool for target 
identification in the past21. Nevertheless, without a phenotypic match target 




simultaneous modulation of multiple targets. In such cases, competitive ABPP can serve 
as a valuable tool for target identification and selectivity profiling, complementary to 
existing methods. In addition, in vivo treatment of the larvae can provide a rapid readout 
for basic toxicological studies during hit/lead identification and optimization, while 
monitoring inhibitor selectivity by competitive ABPP. Likewise, comparative ABPP may 
aid in target discovery by identifying altered enzyme activities in zebrafish disease 
models. 
In Chapter 4, competitive ABPP was used to investigate the interaction landscape of 
FAAH inhibitor BIA 10-2474. A recent phase I clinical trial with this inhibitor resulted in 
the death of one volunteer and hospitalization of four others with mild-to-severe 
neurological symptoms31–34. Considering the clinical safety profile of other FAAH 
inhibitors, it was postulated that off-target activities of BIA 10-2474 may have played a 
role. In a competitive ABPP assay with human brain lysates, BIA 10-2474 was a poorly 
potent, but apparently selective FAAH inhibitor with ABHD6 as the only off-target. 
However, BIA 10-2474’s inhibitory potency towards recombinant FAAH, FAAH2 (a 
human FAAH orthologue) and ABHD6 improved drastically in a cellular system. In this 
light, the in situ interaction landscape of BIA 10-2474 was investigated in human cortical 
neurons and three additional off-targets were identified; patatin-like phospholipase 
domain containing protein 6 (PNPLA6), carboxyl esterase 2 (CES2) and phospholipase 2 
group XV (PLA2G15). Importantly these lipases, except for FAAH and FAAH2, were not 
targeted by PF04457845, a highly selective and clinically safe FAAH inhibitor35,36. 
Prolonged BIA 10-2474, but not PF04457845, exposure produced substantial alterations 
in the lipid network of primary neurons, in accordance with the role of the BIA 10-2474 
targets in cellular lipid metabolism. BIA 10-2474 thus acts a promiscuous lipase inhibitor, 
with the potential to cause metabolic dysregulation in the nervous system, which in turn 
may have contributed to the observed clinical neurotoxicity. The relative causality of the 
identified BIA 10-2474 off-targets, however, could not be established in this study, 
because clinical samples of the patients were not available. Integration of chemical 
proteomics in the drug discovery workflow as a tool to assess on-target engagement and 
off-target activity may guide therapeutic development and will hopefully contribute to 
the safety of clinical trials. 
Remarkably, prolonged in situ BIA 10-2474 treatment (48 h) of HEK293-T cells 
recombinantly expressing ABHD6 or FAAH resulted in accumulation of inhibited ABHD6 
protein, but not of inhibited FAAH protein (Figure 2A). This effect was mimicked using 
ABHD6 inhibitor KT19537 (Figure 2A) and similar increases in ABHD6 levels were obtained 
in a second human cell line (U2-OS) as well as in the murine cell line Neuro-2a 
(Figure 2B). No other BIA 10-2474 targets accumulated upon inhibition (Figure 2C). 
These data suggest that the increase in ABHD6 protein levels is not due to general 
interference with protein metabolism or biosynthesis, but rather suggests that ABHD6 
proteostasis is modulated specifically upon its inhibition. Some enzyme inhibitors are 
known to act as chemical chaperones increasing cellular protein levels by reducing 
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proteolysis or by enhancing protein biosynthesis and folding38, and BIA 10-2474 and 
KT195 may function as such. Of note, no suitable antibodies were available to study the 
effect of ABHD6 inhibition on endogenous protein levels. Alternatively, BIA 10-2474 
analogs AJ167, AJ179, and AJ198 (described in Chapter 4) containing a bio-orthogonal 
ligation handle, were used to enable target visualization using two-step ABPP. However, 
these analogs did not inhibit ABHD6 substantially (Figure 2D).  
 
Figure 2 | ABHD6, but no other BIA 10-2474 targets, accumulates upon BIA 10-2474 inhibition. (A-B) HEK293-T 
(A), U2-OS, and Neuro-2a (B) cells were transiently transfected with FLAG-tagged ABHD6 (A, B) or FAAH (A). 
Cells were treated in situ with vehicle, BIA 10-2474 (10 µM), PF04457845 (1 µM), or KT 195 (10 µM) for 48 h. 
Protein activity and expression was analyzed by gel-based ABPP with FP-TAMRA (500 nM) (A) or MB064 (250 
nM) (20 min, rt) (B) and western blot against the FLAG-tag. Coomassie staining served as a protein loading 
control. Labeling was quantified and normalized for protein loading and is expressed as % of vehicle (mean ± 
SEM (n=3), t-test with Holm-Sidak multiple comparison correction: * p < 0.05, ** p < 0.01, *** p < 0.001). (C) 
HEK293-T cells were transiently transfected with FLAG-tagged PNPLA6, PLA2G15 or CES2 and were treated in 
situ with vehicle or BIA 10-2474 (1, 10, 100 µM) for 48 h. Protein activity and expression was analyzed by gel-
based ABPP with FP-TAMRA (500 nM, 20 min, rt) and western blot against the FLAG-tag. Coomassie staining 
served as a protein loading control. (D) HEK293-T cells were transiently transfected with ABHD6 and treated in 
situ with vehicle, BIA 10-2474, AJ167, AJ179, or AJ198 (10 µM, 48 h). ABHD6 activity is visualized by gel-based 
ABPP with probe MB064 (250 nM, 20 min, rt) (n=2). 
The accumulation of inhibited ABHD6 is especially relevant considering the 
scaffolding function of ABHD6, which is independent of its catalytic function. ABHD6 acts 
as a potent negative regulator of cell surface trafficking of GluR1-subunit of the α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), one of the major 
postsynaptic ionotropic glutamate receptors mediating excitatory synaptic 
neurotransmission in the central nervous system. Provided that endogenous ABHD6 also 
accumulates upon inhibition, BIA 10-2474 may cause aberrations in AMPAR-mediated 
glutamatergic signaling as a result of ABHD6 accumulation, which in turn may contribute 
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assessing the effects of BIA 10-2474 and ABHD6 inhibition on glutamatergic signaling 
and thus on excitotoxicity.  
In Chapter 5 ABPP is employed to identify the enzymes involved in neuronal 
differentiation. Retinoic acid (RA)-stimulation of Neuro-2a cells was previously shown to 
induce neurite outgrowth and to increase cellular 2-AG levels39. The contribution of 
endogenously expressed DAGLα and DAGLβ was investigated using pharmacological, 
genetic, and chemical proteomic methods. DAGL inhibitor DH376 completely abolished 
cellular 2-AG levels and delayed RA-induced neuronal differentiation. Surprisingly, 
CRISPR/Cas9-mediated knockdown (KD) of the 2-AG biosynthetic DAGLα and DAGLβ in 
Neuro-2a cells did not affect cellular 2-AG levels, suggesting the presence of other 
enzymes capable of 2-AG biosynthesis. A bio-orthogonal ligation handle in DH376 
enabled target identification by chemical proteomics. DAGLβ and ABHD6 were identified 
as the only DH376-targets in Neuro-2a cells. ABHD6 has been reported as a promiscuous 
lipase that uses 2-AG, as well as various lysophosphatidyl species40 and 
bis(monoacylglycero)phosphate41 as substrates. Biochemical, genetic and lipidomic 
studies revealed that ABHD6 possesses diacylglycerol (DAG) lipase activity in 
conjunction with its previously reported role as a monoacylglycerol (MAG) lipase. During 
RA-induced differentiation an elevation of ABHD6 activity was observed along with a 
reduction in DAGLβ activity, suggesting a physiological role of ABHD6 in 2-AG signaling.  
The exact physiological role of ABHD6 in 2-AG metabolism, however, is difficult to 
assess due to its dual MAG and DAG lipase activities. It is likely that the reactions are 
driven by the relative substrate and product concentrations. This could be further 
studied using radiolabeled substrates. Triple DAGL and ABHD6 KO mice may also provide 
information on the physiological role of ABHD6 in 2-AG signaling. In a dual DAGLα and 
DAGLβ knockout mouse model, brain 2-AG levels were not completely abolished42 and 
it is tempting to speculate that ABHD6 may account for the remainder of the 2-AG 
content. 
In the study by Jung and colleagues, RA-induced differentiation was mediated by 
CB1R39. Notably, in Chapter 5 both 2-AG and AEA levels increased during RA-induced 
differentiation, suggesting that either endocannabinoid may be responsible for the 
CB1R-mediated effects in differentiating Neuro-2a cells. Remarkably, also other NAE 
levels increased during differentiation, ranging from a 2- to a 15-fold increase (Figure 3). 
These pronounced alterations propose a role of the NAEs in neuronal differentiation. 
The NAE N-docosahexaenoylethanolamine (DHEA, synaptamide) has already been 
described as a potent neurogenic metabolite. A biotinylated DHEA analog enabled 
affinity purification of the DHEA interaction partners and resulted in the identification 
of G-protein coupled receptor 110 (GPR110) as the synaptamide receptor mediating the 
neurogenic effects of DHEA43. Similar approaches could enable identification of the 
interaction partners of other NAEs and may thereby contribute to understanding their 
role in neuronal differentiation.  




Figure 3 | NAE levels increase during RA-induced differentiation of Neuro-2a. Neuro-2a cells were stimulated by 
in situ treatment with retinoic acid (RA, 50 μM, 2 % serum, 72 h). Lipids were extracted and analyzed by 
LC-MS/MS. Lipid abundance was normalized to the number of cells. Data is expressed as a fraction of vehicle 
(mean ± SEM (n=5)). Vehicle and RA-treatment are statistically significant with p < 0.001 for all NAE’s (t-test 
with Holm-Sidak multiple comparison correction). 
To investigate the role of AEA and the NAE’s in differentiation, NAPE-PLD and FAAH 
KD populations were generated (Figure 4). Over 90% KD efficiency was reached based 
on western blot analysis (Figure 4A, C). Upon NAPE-PLD KD, most NAEs were strongly 
reduced, including AEA (Figure 4B). KD of FAAH resulted in elevated levels of a few NAE 
species, but not of AEA (Figure 4D), suggesting the existence of other AEA metabolic 
pathways in these cells. Automation of the neurite outgrowth analysis, e.g. with 
applications like NeuriteTracer44, is required to properly assess the differentiation 
process over time. Fluorescence imaging instead of phase contrast imaging, which was 
used in Chapter 5, would significantly aid these types of studies. Comparison of 
Neuro-2a WT and KD populations during differentiation, as well as the effects of spiking 
endocannabinoids and NAEs to the differentiation medium may help establish the role 
of these lipids in RA-induced differentiation in Neuro-2a.  
 
Figure 4 | NAE levels are altered in Neuro-2a NAPE-PLD and FAAH KD populations. (A-D) Neuro-2a KD populations 
of NAPE-PLD (A-B) and FAAH (C-D) were generated by three sequential transfections with Cas9 and two separate 
guides for each target (NAPE-PLD: 729, 730; FAAH: 731, 732). (A, C) Western blot showed a high KD efficiency 
of NAPE-PLD and FAAH using antibodies against each target. FAAH activity was strongly decreased in FAAH KD 
populations, based on gel-based ABPP using FP-TAMRA (500 nM, 20 min, rt). Labeling was quantified and is 
expressed as % of vehicle (mean ± SEM, n=3). (B, D) Lipids were extracted from WT and KD cells and analyzed 
by LC-MS/MS. Lipid abundance was normalized for the amount of protein. Data is expressed as a fraction of 
vehicle (mean ± SEM (n=4), t-test with Holm-Sidak multiple comparison correction: * p < 0.05, ** p < 0.01, *** 




























































































































































































































































































































































































































Opportunities and challenges in ABPP 
The continuous development of the ABPP methodology contributes to its maturation 
and further extend on its already versatile character. Novel broad-spectrum probes 
targeting other protein classes will increase the biological reach of the technique, 
whereas highly specific probes enable alternative experimental approaches, e.g. 
imaging enzyme activity in living cells, assessing subcellular localization of active protein 
using correlative light and electron microscopy (CLEM)45, or visualizing activity in vivo 
using ABPs containing a positron emission tomography (PET) radiotracer46. The 
development of new analytical platforms and analysis methods can improve the 
experimental throughput and provide new experimental approaches to biological 
questions. For example, the recently developed label-free quantification method for 
chemical proteomics47 enables comparison of multiple sample types within one 
experiment. This analysis method circumvents the previously required sample pairing, 
which could lead to distortions due to divergence between biological replicates. 
Technical advances in MS-analysis will contribute to further exploitation of ABPP as a 
tool in cellular biology, for example by facilitating the characterization of post-
translational modifications (PTMs)48 in intact proteins (top-down proteomics)49.  
Further integration of competitive ABPP in the drug discovery process is a promising 
perspective for this method. In target-based drug discovery, activity assays with purified 
enzyme often serve as the primary screening method50. By taking the proteins out of 
their biological context, external factors such as protein-protein interactions cannot be 
accounted for. This may result in limited in vitro to in situ/in vivo translatability. For now, 
high-throughput screening (HTS)-compatible ABPP assays, such as fluorescence 
polarization51 and EnPlex52 still require the use of purified protein. However, these 
techniques do have major advantages as they do not require prior knowledge on the 
enzyme’s substrate and (with limited modifications) the same assay can be used for 
other targets of the same ABP. After hit identification, gel- and MS-based ABPP can guide 
the lead optimization and preclinical phases, by enabling rapid assessment of potency 
and selectivity within the native proteome and in biologically relevant systems. Patient-
derived inducible pluripotent stem cells (iPSCs) may provide particularly promising 
disease models and may proof valuable in competitive ABPP approaches for phenotype- 
and target-based drug discovery. 
Even though the competitive ABPP method provides a lot of information on the 
inhibitor interaction profile, it is still limited to the enzymes that react with the probe. 
In the case of covalent inhibitors, a ligation handle can aid identification of covalent 
targets (e.g. DH376 in Chapter 5). However, incorporation of a ligation handle may 
change the inhibitor reactivity and selectivity, as was observed for the BIA 10-2474 
alkyne derivatives in Figure 2. Non-covalent targets may be identified using a 
photoactivatable group, which interacts covalently with the associated proteins after 
UV-irradiation. In a similar fashion, non-enzymatic proteins, e.g. receptors, can be 
targeted using these so called photoaffinity probes53.  




Taken together, this thesis described several ABPP strategies and applications in drug 
discovery and cell biology (Figure 5). In a comparative setup, ABPP enabled rapid 
assessment of clinical samples to identify molecular role players in disease, which may 
lead to the discovery of novel therapeutic targets or biomarkers. Competitive ABPP, on 
the other hand, provides information on the drug interaction landscape. It enabled 
target engagement studies and inhibitor selectivity profiling, as demonstrated with 
BIA 10-2474, an inhibitor that caused severe neurological symptoms in a phase I clinical 
trial. Integration of competitive ABPP in preclinical testing will provide better insight in 
drug selectivity and drug safety. In zebrafish larvae the comparative ABPP methodology 
served as a tool to map the kinase and serine hydrolase landscape throughout 
embryonic development, thereby providing new activity-based insights in embryonic 
development. In addition, competitive ABPP in these larvae enabled in vivo target 
engagement and selectivity profiling. Lastly, a combined approach of ABPP, 
CRISPR/Cas9-mediated genetic modification, biochemistry and lipidomics resulted in 
the identification of ABHD6 as a 2-AG biosynthetic diacylglycerol lipase in retinoic 
acid-induced differentiation of Neuro-2a.  
 
Figure 5 | Visual summary of ABPP strategies and their applications described in this thesis. 
To conclude, activity-based protein profiling is a versatile and powerful chemical tool 
and its integration in cell biology and drug discovery research is anticipated to bring 


















Materials, probes, and inhibitors  
Fluorophosphonate-TAMRA (FP-TAMRA) was purchased from Thermo Fisher. MB064, 
BIA 10-2474, AJ167, AJ179, AJ198 were synthesized as previously described54,55. All synthesized 
compounds were at least 95% pure and were analyzed by LC/MS, NMR, and HRMS. Primers were 
ordered from Sigma Aldrich or Integrated DNA Technologies. Other chemicals and reagents were 
purchased from Sigma Aldrich, unless indicated otherwise.  
Cloning  
Full-length human cDNA of ABHD6, FAAH, PNPLA6, PLA2G15, CES2 (Source Bioscience) was cloned 
into mammalian expression vector pcDNA3.1, containing genes for ampicillin and neomycin 
resistance. The inserts were cloned in frame with a C-terminal FLAG-tag and site-directed 
mutagenesis was used to remove restriction sites by silent point mutations. pcDNA3.1 containing 
the gene for eGFP was used as a transfection control. Plasmids were isolated from transformed 
XL-10 Z-competent cells (Maxi Prep kit: Qiagen) and sequenced at the Leiden Genome Technology 
Center. Sequences were analyzed and verified (CLC Main Workbench). 
Cell Culture  
General  
HEK293-T (human embryonic kidney), U2-OS (human osteosarcoma) and Neuro-2a (murine 
neuroblastoma) cells were cultured at 37 °C under 7% CO2 in DMEM containing phenol red, stable 
glutamine, newborn bovine serum (10%, v/v; Thermo Fisher), and penicillin and streptomycin 
(200 μg/mL each; Duchefa). Medium was refreshed every 2-3 days and cells were passaged twice 
a week at ~ 90% confluence by resuspension in fresh medium (HEK293-T, Neuro-2a) or 
trypsinization (U2-OS). Cell lines were purchased from ATCC and were regularly tested for 
mycoplasma contamination. Cultures were discarded after 2-3 months of use.  
Transient transfections  
One day prior to transfection, cells were seeded at 0.3*106 cells/well in a 12-wells plate. Prior to 
transfection, culture medium was aspirated and a minimal amount of complete medium was 
added. A mixture (HEK293-T, U2-OS: 3:1 (m/m); Neuro-2a: 5:1 (m/m)) of polyethyleneimine (PEI) 
and plasmid DNA (0.625 μg/well) was prepared in serum-free culture medium and incubated 
(15 min, rt). Transfection was performed by dropwise addition of the PEI/DNA mixture to the cells. 
Transfection with pcDNA3.1 encoding GFP or empty pcDNA3.1 vector was used to generate 
control samples. 24 h Post-transfection culture medium was refreshed. Transfection efficiency 
was checked by fluorescence microscopy on eGFP-transfected samples (EVOS FL2 Auto, 
GFP-channel).  
In situ treatments  
Cells from transient transfections were used at 24h post-transfection. Culture medium was 
aspirated and after a careful PBS wash treatment medium containing vehicle (0.1% DMSO) or 
inhibitor (1-100 µM as indicated in figure legends) was added. After incubation for 48 h at 37 °C 
and 7% CO2, treatment medium was aspirated and cells were carefully washed with PBS. 
Subsequently cells were harvested by resuspension or scraping in PBS and were spun down 
(1000 g, 3-5 min, rt). Cell pellets were flash frozen in liquid nitrogen and stored at -80 °C until 
further use.  
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CRISPR/Cas9 knockdowns  
Guide design & constructs  
Two sgRNA’s, in early exons, with high efficiency and specificity as predicted by CHOPCHOP v2 
online web tool56 (http://chopchop.cbu.uib.no) were selected. Guides were cloned into the BbsI 
restriction site of plasmid px330-U6-Chimeric_BB-CBh-hSpCas9 (gift from Feng Zhang, Addgene 
plasmid #42230) as previously described57,58. Constructs and primers are annotated in Table 1. 
Knockdown population generation  
Neuro-2a cells were transfected sequentially to yield populations with a high knockdown 
efficiency. The full experimental procedure is provided in Chapter 5. After three transfection 
rounds, the cells were cultured according to standard protocol. Knockdown efficiency was 
determined by T7E assay, gel-based ABPP and western blot. Ampoules of knockdown populations 
were prepared (complete DMEM, 10% DMSO) and stored at -150 °C. Cells were discarded after 3 
months of culture.  
Table 1 | sgRNA targets, sgRNA oligos (top, bottom) and T7E1 primers (forward, reverse).  
sgRNA Target Construct Primer Sequences 
Nape-pld – Exon 2 729 
Top:      CACCGATAGCTTGGCGCTGGAGAC 
Bottom: AAACGTCTCCAGCGCCAAGCTATC 
                 – Exon 3 730 
Top:      CACCAGTTCGCTTATTGTACACGG 
Bottom: AAACCCGTGTACAATAAGCGAACT 
Faah        – Exon 1 731 
Top:      CACCGCGCTGCACCGCCTTGTCCA 
Bottom: AAACTGGACAAGGCGGTGCAGCGC 
                 – Exon 2 732 
Top:      CACCGAATCCAGGTCAGGATTCTG 
Bottom: AAACCAGAATCCTGACCTGGATTC 
Whole lysate preparation  
Cell pellets were thawed on ice, resuspended in cold lysis buffer (20 mM HEPES pH 7.2, 2 mM DTT, 
250 mM sucrose, 1 mM MgCl2, 2.5 U/mL benzonase) and incubated on ice (15 min). Protein 
concentrations were determined by a Quick StartTM Bradford Protein Assay (Bio-Rad). After 
dilution to 2 mg/mL in sucrose lysis buffer or storage buffer (20 mM HEPES pH 7.2, 2 mM DTT), 
samples were used or flash frozen in liquid nitrogen and stored at -80 ⁰C until further use. DTT 
was left out of all buffers for samples intended for click-chemistry.  
Activity-based protein profiling  
Whole lysate (2 mg/mL) was incubated with activity-based probes MB064 (250 nM, 20 min, rt) or 
FP-TAMRA (500 nM, 20 min, rt). The reaction was quenched with Laemmli buffer (30 min, rt) and 
20 μg protein was resolved by SDS-PAGE (10% acrylamide gel) along with protein marker 
PageRulerTM Plus (Thermo Fisher). In-gel fluorescence was detected in the Cy3- and Cy5-channel 
on a ChemiDocTM MP imaging system (Bio-Rad) and gels were stained with coomassie after 
scanning. Fluorescence was quantified and normalized to coomassie staining using ImageLabTM 
software (Bio-Rad) and data was processed in Excel (Microsoft) and GraphPad Prism 7 (GraphPad). 
Western blot  
Cell lysates were denatured with Laemmli buffer (30 min, rt) and 20 μg lysate was resolved on a 
10% acrylamide SDS-PAGE gel along with PageRulerTM Plus Protein Marker (Thermo Scientific). 
Proteins were transferred to 0.2 μm polyvinylidene difluoride membranes by Trans-Blot Turbo™ 
Transfer system (Bio-Rad). Membranes were washed with TBS (50 mM Tris, 150 mM NaCl) and 




were subsequently incubated with primary antibody mouse-anti-FLAG (F3156, Sigma Aldrich; 
1:5000 in 5% milk in TBS-T, 45 min at rt or O/N at 4 °C), rabbit-anti-NAPE-PLD (ab95397, Abcam; 
1:200 in TBS-T, O/N, 4 °C), or mouse-anti-FAAH (CST2942, Cell Signaling Technologies; 1:1000 in 
5% milk in TBS-T, O/N, 4 °C). After incubation membranes were washed with TBS-T and incubated 
with secondary goat-anti-mouse-HRP or goat-anti-rabbit-HRP (sc-2005, sc-2004, Santa Cruz 
Biotechnologies; 1:5000 in 5% milk TBS-T, 45 min, rt) and washed with TBS-T and TBS. 
Chemilumescence (developed with ECL) was detected on the ChemiDocTM MP (Bio-Rad) in the 
chemiluminessence channel, and colorimetric channel for the protein marker. Signal was 
normalized to coomassie staining using ImageLabTM software (Bio-Rad) and data was processed in 
Excel (Microsoft) and GraphPad Prism 7 (GraphPad). 
Lipidomics  
Sample preparation: Neuro-2a retinoic acid stimulation  
Neuro-2a cells were seeded at 0.75*106 cells/dish in a 10 cm dish. One day after seeding, medium 
was aspirated and retinoic acid stimulation was initiated by adding DMEM containing 2% serum 
and retinoic acid (50 μM) or vehicle (0.1% DMSO). After 72 h neurite outgrowth was investigated 
using phase contrast microscopy (Olympus). Cells were carefully washed with PBS and harvested 
by resuspension in PBS (for retinoic acid stimulated cells, 5 dishes were combined to yield 
sufficient cells). Cells were pelleted (200 g, 10 min, rt) and resuspended in 1 mL PBS. Cell count 
and viability were checked by Trypan blue staining and automated cell counting (TC20TM Cell 
Counter, Bio-Rad) and 2*106 cells were pelleted (1000 g, 3 min, rt). Pellets were flash frozen in 
liquid nitrogen and stored at -80 °C until lipid extraction.  
Sample preparation: Neuro-2a knockdown populations  
Neuro-2a cells (WT or KD) were seeded at 2*106 cells/dish in a 10 cm dish. Cells were harvested 
when confluence was reached. Culture medium was aspirated and cells were resuspended in 
DMEM. Cell count and viability were checked by Trypan blue staining and automated cell counting 
(TC20TM Cell Counter, Bio-Rad) and 2*106 cells were pelleted (1000 g, 3 min, rt) (n=3 pellets). 
Pellets were washed twice with PBS (5 min, 1000 g), flash frozen in liquid nitrogen and stored 
at -80 °C until lipid extraction. 
Lipid extraction & LC-MS/MS Analysis 
Lipid extraction was performed as previously described55 with minor adaptations. The full 
experimental procedure is provided in Chapter 5. 
Statistical methods 
Experiments were performed in an appropriate number of replicates, as indicated in figure 
legends. A t-test was used to determine statistical significance, with Holm-Sidak multi-comparison 
correction using GraphPad Prism 7 (GraphPad). Samples were compared to vehicle or wildtype 
controls and statistical significance is indicated as * p < 0.05, ** p < 0.01, *** p < 0.001. 
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Het doel van het onderzoek beschreven in dit proefschrift is 
het verkennen van de toepasbaarheid van activiteit 
gebaseerde eiwitprofilering in medicijnontwikkeling. 
De zoektocht naar behandelmethoden voor ziekten en 
voor symptoomverlichting gaat enkele duizenden jaren 
terug. Ondanks grote ontwikkelingen in de medische 
wetenschap is medicijnontwikkeling nog steeds een 
ingewikkeld en uitdagend proces. Hoofdstuk 1 beschrijft de 
gang van zaken in de moderne medicijnontwikkeling. Deze 
baseert zich met name op het concept dat een verstoring 
van de biologische balans een bepaald ziektebeeld met zich 
meebrengt. Door eiwitten die deze onbalans veroorzaken te 
moduleren met behulp van chemische stoffen, kan een 
ziektebeeld (deels) verholpen worden. De identificatie en 
validatie van een eiwit als therapeutisch aangrijpingspunt 
vormt vaak het begin van het medicijnontwikkelingsproces. 
In de daaropvolgende fases worden chemische 
modulatoren van het doeleiwit geïdentificeerd, 
geoptimaliseerd en uitvoerig getest in preklinische 
modellen, waarna het kandidaat geneesmiddel uiteindelijk 
ook in de kliniek wordt getest. De gemiddelde doorlooptijd 
van de ontwikkeling van één nieuw medicijn is 12 tot 14 jaar 
en de kosten lopen op tot ruim 2,5 miljard dollar. 
Belangrijke redenen voor de lange duur en hoge kosten van 
de ontwikkeling zijn onverwachte toxiciteit en onvoldoende 
werkzaamheid van het kandidaat geneesmiddel in late 
testfases.  
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Om het medicijnontwikkelingsproces te verbeteren, worden voortdurend nieuwe 
technieken en strategieën ontwikkeld. In de laatste jaren is activiteit gebaseerde 
eiwitprofilering (activity-based protein profiling, ABPP) een krachtige techniek gebleken 
in de ontwikkeling van nieuwe geneesmiddelen (Figuur 1). ABPP maakt het mogelijk om 
het enzymatisch actieve deel van bepaalde eiwitklassen te bestuderen in complexe 
eiwitmonsters. De methode maakt gebruikt van chemische sensoren (activity-based 
probes) die covalent met actieve enzymen reageren. Een label aan de sensor maakt het 
mogelijk de doeleiwitten in kaart te brengen, bijvoorbeeld door fluorescente labels voor 
directe visualisatie met behulp van gel-analyse (SDS-PAGE) of een affiniteitslabel voor 
zuivering en identificatie met behulp van massaspectrometrie (MS). ABPP maakt het 
mogelijk om het activiteitsprofiel van verschillende biologische toestanden te 
vergelijken (comparatieve ABPP), zoals ziek en gezond weefsel, wat kan leiden tot de 
ontdekking van nieuwe therapeutische aangrijpingspunten. Tevens kan de techniek 
gebruikt worden om de potentie en de selectiviteit van chemische modulatoren of 
experimentele geneesmiddelen te testen, door bijvoorbeeld levende cellen met het 
medicijn te behandelen en vervolgens het activiteitsprofiel van behandelde en 
onbehandelde cellen te vergelijken (competitieve ABPP).  
In Hoofdstuk 1 wordt tevens het endocannabinoïde systeem (ECS) geïntroduceerd. 
Het ECS medieert de psychoactieve effecten van THC, de actieve stof in Cannabis sativa 
waaraan het systeem haar naam dankt. De cannabinoïde receptoren werden 
oorspronkelijk ontdekt als de doeleiwitten van THC, maar kunnen eveneens geactiveerd 
worden door lichaamseigen liganden, de endocannabinoïden 2-arachidonoylglycerol 
(2-AG) en anandamide. Samen met de enzymen verantwoordelijk voor hun aanmaak en 
afbraak en de receptoren vormen zij het ECS. De brede rol van het ECS in verschillende 
fysiologische en pathologische processen maakt dit systeem een bijzonder interessante 
bron van potentiële therapeutische aangrijpingspunten.  
Het ECS is onder meer betrokken bij diverse cardiovasculaire processen en speelt 
een belangrijke rol in verschillende hart- en vaatziekten. In Hoofdstuk 2 werden de 
endocannabinoïden en de bijbehorende metabole enzymen onderzocht in hartmonsters 
van patiënten met eindstadium ischemisch hartfalen met behulp van ABPP en lipidomics 
(een methode voor de analyse van lipiden met behulp van massaspectrometrie). Lipide-
analyse bracht twee categorieën aan het licht binnen de ischemische hartmonsters; de 
een overeenkomstig met de controleharten, de ander met verlaagde niveaus van 2-AG 
en een sterke toename van anandamide, andere N-acylethanolamines en vrije vetzuren. 
Het afwijkende lipide profiel ging gepaard met een afname in activiteit van 13 van de 31 
gedetecteerde hydrolases, inclusief monoacylglycerol lipase, dat betrokken is bij de 
afbraak van 2-AG. Deze bevindingen suggereren een biologisch verschil tussen de 
ischemische hartmonsters, ondanks het ontbreken van klinisch kenmerken die de 




De ABPP-methodologie werd in Hoofdstuk 3 toegepast in een in vivo modelsysteem. 
Recentelijk heeft de zebravis (Danio rerio) aan populariteit gewonnen als modelsysteem 
voor vroege embryonale ontwikkeling. Bovendien worden de larven steeds vaker 
gebruikt als een preklinisch modelorganisme in medicijnontwikkeling en voor 
toxicologische testen. Met behulp van comparatieve ABPP werd het activiteitsprofiel 
van twee eiwitklassen, de serine hydrolases en de kinases, in kaart gebracht gedurende 
de eerste vijf dagen van de embryonale ontwikkeling. In totaal werden met behulp van 
massaspectrometrie 45 hydrolases en 51 kinases geïdentificeerd. Het aantal 
gedetecteerde hydrolases en kinases nam toe gedurende de ontwikkeling en 
correleerde met specifieke ontwikkelingsprocessen. Daarnaast werd de competitieve 
ABPP-methode toegepast om eenvoudig in vivo selectiviteit van chemische 
modulatoren te kunnen bepalen. PF04457845, een remmer van de serine hydrolase 
fatty acid amide hydrolase (FAAH), werd gebruikt als modelmolecuul en liet een zeer 
schoon interactieprofiel zien. Het effect van FAAH-inhibitie werd bevestigd met behulp 
van lipidomics. 
 
Figuur 1: Visuele samenvatting. Schematische weergave van de toepassingen van ABPP in medicijnontwikkeling 
en celbiologie zoals beschreven in dit proefschrift. 
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In Hoofdstuk 4 werd de competitieve ABPP-methode toegepast om het 
interactieprofiel van het kandidaat geneesmiddel BIA 10-2474, een fatty acid amide 
hydrolase (FAAH) remmer, te onderzoeken. In een recente klinische studie overleed één 
proefpersoon aan de gevolgen van hersenschade na toediening van BIA 10-2474 en 
werden vier anderen opgenomen met milde tot ernstige neurologische klachten. 
Aangezien eerder geteste FAAH-remmers (zoals PF04457845) klinisch veilig waren 
bevonden, werd er verondersteld dat onbedoelde interacties van BIA 10-2474 met 
andere eiwitten een bijdrage leverden aan de neurotoxiciteit van het molecuul. In vitro 
bleek BIA 10-2474 een matig potente, maar vrij selectieve FAAH-remmer met 
α,β-hydrolase domain containing protein 6 (ABHD6) en FAAH2 als enige onbedoeld 
geremde eiwitten (off-targets) in humaan hersenlysaat. In een cellulair systeem bleek 
BIA 10-2474 echter veel potenter en bovendien beduidend minder selectief. In 
behandelde celculturen van humane corticale neuronen werden drie extra off-targets 
van BIA 10-2474 geïdentificeerd, te weten patatin-like phospholipase domain containing 
protein 6, carboxyl esterase 2 en phospholipase 2 group XV. De klinisch veilige 
PF04457845, daarentegen, was selectief en remde enkel FAAH en FAAH2. Alle 
geïdentificeerde interactiepartners van BIA 10-2474 zijn betrokken bij 
lipidestofwisseling. Lipidomics wees uit dat BIA 10-2474 zodoende de lipidehuishouding 
in zenuwcellen verstoorde, wat mogelijk heeft bijgedragen aan de klinische 
neurotoxiciteit van dit experimentele geneesmiddel. De relatieve causaliteit van de 
geïdentificeerde BIA 10-2474 off-targets kon echter niet worden vastgesteld, mede 
doordat klinische monsters van de behandelde vrijwilligers niet beschikbaar waren. 
Hoofdstuk 5 demonstreerde dat ABPP, behalve voor medicijnontwikkelingsstudies, 
ook een zeer waardevolle methode is voor het beantwoorden van celbiologische 
vraagstukken. De endocannabinoïde 2-AG is een belangrijk signaalmolecuul in het 
centraal zenuwstelsel, waar het samen met de cannabinoïde receptor (CB1R) een rol 
speelt in neuronale differentiatie. Biochemische, farmacologische en genetische studies 
hebben aangetoond dat diacylglycerol lipase α en β (DAGLα, DAGLβ) de voornaamste 
enzymen zijn die 2-AG produceren in de hersenen, door het katalyseren van de 
hydrolyse van diacylglycerol (DAG) naar 2-AG. Tijdens retinolzuur-geïnduceerde 
differentiatie van Neuro-2a, een veelgebruikt cellulair model voor neuronale 
differentiatie, namen cellulaire 2-AG-niveaus toe. De relatieve bijdrage van de 2-AG-
producerende enzymen werd in Hoofdstuk 5 onderzocht met behulp van ABPP, 
farmacologische en genetische methoden. Inhibitie van DAGLα en -β met DAGL-inhibitor 
DH376 bracht het cellulaire 2-AG-niveau vrijwel volledig omlaag en vertraagde de 
differentiatie. Genetische inactivatie van DAGLα en/of DAGLβ door middel van 
CRISPR/Cas9-gemedieerde knockdown had echter geen effect op cellulaire 2-AG-
niveaus. Deze data suggereren de aanwezigheid van alternatieve 2-AG producerende 
enzymen, die geïnhibeerd worden door DH376. DAGLβ en ABHD6 werden 
geïdentificeerd als de enige doelenzymen van DH376 in Neuro-2a met behulp van 




hydrolyseerde recombinant ABHD6 een fluorescent DAG-substraat, in een cellulair 
systeem zorgde overexpressie van ABHD6 voor een afname van endogeen DAG en een 
driedubbele knockdown van DAGLα, DAGβ en ABHD6 verlaagde 2-AG-niveaus in 
Neuro-2a. Deze data wijzen erop dat ABHD6 diacylglycerol lipase activiteit bezit, naast 
de eerder gerapporteerde monoacylglycerol lipase activiteit. Ten slotte werd met 
comparatieve ABPP aangetoond dat DAGLβ activiteit verminderde tijdens Neuro-2a 
differentiatie, terwijl ABHD6 activiteit sterk verhoogde, wat een rol voor ABHD6 in 
neuronale differentiatie impliceert. 
In Hoofdstuk 6 werd het uitgevoerde onderzoek samengevat en werden tevens 
enkele startpunten voor vervolgonderzoek aangereikt. In navolging op Hoofdstuk 4, 
werd aangetoond dat inhibitie van ABHD6 door BIA 10-2474 resulteerde in ophoping 
van het inactieve eiwit. Dit is in het bijzonder relevant omdat ABHD6, onafhankelijk van 
de katalytische activiteit, een rol speelt in het transport van receptoren. Mogelijk kan 
inhibitie van ABHD6, met ophoping van het inactieve eiwit als gevolg, op deze manier 
de neuronale signaaltransductie verstoren. Naar aanleiding van Hoofdstuk 5, werden 
ook de niveaus van andere lipiden tijdens de neuronale differentiatie onderzocht. Naast 
2-AG was ook de endocannabinoïde anandamide verhoogd, evenals verschillende 
andere N-acylethanolamines. De rol van deze lipiden in differentiatie van Neuro-2a kan 
in de toekomst verder onderzocht worden met behulp van de CRISPR/Cas9-
gemedieerde knockdowns van de enzymen verantwoordelijk voor de aanmaak en 
afbraak van deze lipiden (respectievelijk N-acylphosphatidyl ethanolamine 
phospholipase D (NAPE-PLD) en FAAH) die in Hoofdstuk 6 omschreven staan. Tot slot 
werden in Hoofdstuk 6 de uitdagingen in de ABPP-methodologie besproken en werd het 
toekomstperspectief van ABPP in medicijnontwikkeling geschetst. 
Tezamen laat het onderzoek dat dit proefschrift beschrijft, zien dat activity-based 
protein profiling een veelzijdige en waardevolle techniek is in medicijnontwikkeling en 
celbiologie. Comparatieve ABPP kan bijdragen aan de ontdekking van nieuwe 
therapeutische aangrijpingspunten door de vergelijking van activiteitsprofielen in 
klinische monsters te faciliteren (Hoofdstuk 2). Competitieve ABPP daarentegen biedt 
een uitkomst voor de identificatie van doelenzymen van chemische modulatoren in 
fenotypische screens, bijvoorbeeld in zebravis embryo’s (Hoofdstuk 3). Bovendien kan 
competitieve ABPP tot nieuwe inzichten leiden door het profileren van nieuwe 
experimentele geneesmiddelen, zowel retrospectief zoals beschreven voor BIA 10-2474 
(Hoofdstuk 4), als prospectief door de ontwikkeling van nieuwe geneesmiddelen te 
sturen. Daarnaast is ABPP een waardevolle toevoeging aan de celbiologische 
gereedschapskist, waar ze bijdraagt aan nieuwe inzichten in biologische processen zoals 
embryonale ontwikkeling (Hoofdstuk 3) en neuronale differentiatie (Hoofdstuk 5). Naar 
verwachting zullen de continue ontwikkelingen in de ABPP-methodologie en verdere 
integratie van de techniek in onderzoek binnen én buiten de academie, belangrijke 
inzichten voortbrengen en een waardevolle bijdrage leveren aan medicijnontwikkeling in 
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